<?xml version='1.0' encoding='UTF-8'?>
<chapter id="ch0147">
    <title>126 Histoplasma, Blastomyces, Coccidioides, Paracoccidioides and Other Dimorphic Fungi Causing Systemic Mycoses</title>
    <sect1 id="ch0147s0001">
      <title>126 Histoplasma, Blastomyces, Coccidioides, Paracoccidioides and Other Dimorphic Fungi Causing Systemic Mycoses</title>
      <anchor id="ch0147s0001a0001"/>
      <anchor id="ch0147s0001a0002"/>
      <para id="ch0147s0001p0001" role="chapterAuthor">GEORGE R. THOMPSON, III AND BEATRIZ L. GOMEZ</para>
    </sect1>
    <sect1 id="ch0147s0002">
      <title>TAXONOMY</title>
      <anchor id="ch0147s0002a0001"/>
      <anchor id="ch0147s0002a0002"/>
      <para id="ch0147s0002p0001">The dimorphic fungi causing systemic disease belong to the class<emphasis>Eurotiomycetes</emphasis>, order <emphasis>Onygenales</emphasis> (<link linkend="ch0147s0055s0001li0001">1</link>). The <emphasis>Onygenales</emphasis> share several general characteristics: their sexual stages (teleomorphs) form rudimentary asci surrounded by a network of hyphae, which may have complex appendages, and their asexual (anamorph) species generally possess one of two forms, either unicellular aleurioconidia or arthroconidia in chains of alternately viable and nonviable cells.</para>
      <para id="ch0147s0002p0002">The order<emphasis>Onygenales</emphasis> contains the families <emphasis>Ajellomycetaceae</emphasis> and <emphasis>Onygenaceae.</emphasis> The <emphasis>Onygenaceae</emphasis> and <emphasis>Ajellomycetaceae</emphasis> are well separated from the <emphasis>Arthrodermataceae</emphasis> (dermatophytes). This chapter covers the dimorphic members of the families <emphasis>Onygenaceae</emphasis> and <emphasis>Ajellomycetaceae.</emphasis> Nonpathogenic species of <emphasis>Chrysosporium, Uncinocarpus</emphasis>, and other related genera are not covered here. It should be noted that dual nomenclature for pleomorphic fungi has been discontinued (<link linkend="ch0147s0055s0001li0002">2</link>), although it is likely that the widely recognized anamorph names for dimorphic fungi will be kept. <emphasis>Ajellomycetaceae</emphasis> contains the species <emphasis>Ajellomyces dermatitidis, A. capsulatum, A. duboisii</emphasis>, and <emphasis>A. crescens</emphasis>, the anamorphs of which have been placed in the genera <emphasis>Blastomyces</emphasis> (<emphasis>Blastomyces dermatitidis, B. gilchristii, B. helicus, B. parvus</emphasis>, and <emphasis>B. silverae</emphasis>) and <emphasis>Histoplasma</emphasis> (<emphasis>Histoplasma capsulatum</emphasis> and <emphasis>H. duboisii</emphasis>). The newer genera <emphasis>Emergomyces</emphasis> (<emphasis>Emergomyces pasteurianus, Es. africanus, Es. crescens, Es. orientalis, Es. canadensis</emphasis>, and <emphasis>Es. europaeus</emphasis>) and <emphasis>Adiaspiromyces</emphasis> (<emphasis>Adiaspiromyces crescens</emphasis> and <emphasis>A. terricola</emphasis>) contain species that have no known teleomorphs (<link linkend="ch0147s0055s0001li0003">3</link>, <link linkend="ch0147s0055s0001li0004">4</link>). DNA sequence data place <emphasis>Paracoccidioides</emphasis> (<emphasis>Paracoccidioides brasiliensis</emphasis> and <emphasis>P. lutzii</emphasis>) in the family <emphasis>Ajellomycetaceae</emphasis> as well (<link linkend="ch0147s0055s0001li0005">5</link>). <emphasis>Onygenaceae</emphasis> contains the species <emphasis>Coccidioides immitis and Coccidioides posadasii.</emphasis> Molecular phylogenetic studies have indicated that species of the <emphasis>Onygenales</emphasis> are divided into several clades (descendants of a common ancestor). In all of these phylogenetic trees, pathogenic organisms are interspersed with nonpathogenic relatives, which suggests that the capacity to infect humans has arisen numerous times during the evolution of the <emphasis>Onygenales</emphasis>.</para>
    </sect1>
    <sect1 id="ch0147s0003">
      <title>Histoplasma capsulatum</title>
      <anchor id="ch0147s0003a0001"/>
      <anchor id="ch0147s0003a0002"/>
      <para id="ch0147s0003p0001">Historically,<emphasis>H. capsulatum</emphasis> was divided into three varieties: <emphasis>H. capsulatum</emphasis> var. <emphasis>capsulatum</emphasis>, a human pathogen found in North and South America; <emphasis>H. capsulatum</emphasis> var. <emphasis>duboisii</emphasis>, a human pathogen found in Africa (<link linkend="ch0147s0055s0001li0006">6</link>); and <emphasis>H. capsulatum</emphasis> var. <emphasis>farciminosum</emphasis>, a pathogen of horses and mules found in parts of northern Africa and the Middle East. Phylogenetic studies defined at least eight clades within <emphasis>H. capsulatum:</emphasis> North American class 1, North American class 2, Latin American group A, Latin American group B, Australian, Netherlands (Indonesian), Eurasian, and African clades (<link linkend="ch0147s0055s0001li0007">7</link>). Seven of these eight clades comprise genetically and geographically distinct populations that can be regarded as phylogenetic species. The single exception, the Eurasian clade, originated from within the Latin American group A clade. <emphasis>H. capsulatum</emphasis> var. <emphasis>farciminosum</emphasis> was placed within the Eurasian clade. In addition to the seven phylogenetic species, another seven lineages represented by single isolates from Latin America were identified (<link linkend="ch0147s0055s0001li0007">7</link>). These may represent additional phylogenetic species. Subsequent studies also using multilocus sequence typing of <emphasis>Histoplasma capsulatum</emphasis> in formalin-fixed paraffin-embedded tissues from cats living in regions where the organism is not endemic revealed a new phylogenetic clade. The <emphasis>H. capsulatum</emphasis> sequences recovered from the cats were most closely related to the North American-1 clade but clustered separately outside this clade, suggesting that the <emphasis>H. capsulatum</emphasis> infecting the animals may represent a separate clade or phylogenetic species (<link linkend="ch0147s0055s0001li0008">8</link>). In 2016, new sequences of <emphasis>Histoplasma</emphasis>, detected using different phylogenetic and population genetics methods, led to a proposal of the new phylogenetic species LAmA1, LAmA2, LAmB1, LAmB2, RJ, and BAC-1, nested within the former Latin American group A clade (<link linkend="ch0147s0055s0001li0009">9</link>). A more recent analysis using genome-wide population genetics and phylogenetic analyses led to partly different groupings and resulted in the proposal of the new species names <emphasis>Histoplasma mississippiense</emphasis> for NAm1, <emphasis>Histoplasma ohiense</emphasis> for NAm2, and <emphasis>Histoplasma suramericanum</emphasis> for LAmA and the restriction of <emphasis>Histoplasma capsulatum sensu stricto</emphasis> to the Panama (H81) lineage (<link linkend="ch0147s0055s0001li0010">10</link>).</para>
      <para id="ch0147s0003p0002">At this time, the disease African histoplasmosis is considered a distinct entity, but the taxonomic placement of<emphasis>H. capsulatum</emphasis> var. <emphasis>duboisii</emphasis> has been called into question by the finding of one <emphasis>H. capsulatum</emphasis> var. <emphasis>capsulatum</emphasis> isolate from South Africa that was placed in the African (<emphasis>H. capsulatum</emphasis> var. <emphasis>duboisii-</emphasis>containing) clade (<link linkend="ch0147s0055s0001li0007">7</link>). The genome of <emphasis>H. capsulatum</emphasis> has an estimated size between 28 and 39 Mbp, and sequence assemblies are available for five strains (<ulink url="https://www.broadinstitute.org/fungal-genome-initiative/histoplasma-genome-project">https://www.broadinstitute.org/fungal-genome-initiative/histoplasma-genome-project</ulink>).</para>
      <anchor id="ch0147s0003a0003"/>
      <beginpage pagenum="2467"/>
    </sect1>
    <sect1 id="ch0147s0004">
      <title>Blastomyces Species</title>
      <anchor id="ch0147s0004a0001"/>
      <anchor id="ch0147s0004a0002"/>
      <para id="ch0147s0004p0001">The genus<emphasis>Blastomyces</emphasis> currently consists of <emphasis>B. dermatitidis</emphasis> and <emphasis>B. gilchristii</emphasis> (<link linkend="ch0147s0055s0001li0011">11</link>). Recently, <emphasis>B. percursus</emphasis> (<link linkend="ch0147s0055s0001li0004">4</link>, <link linkend="ch0147s0055s0001li0012">12</link>), <emphasis>B. parvus</emphasis> (formerly <emphasis>Emmonsia parva</emphasis>), <emphasis>B. helicus</emphasis> (formerly <emphasis>Emmonsia helica</emphasis>) (<link linkend="ch0147s0055s0001li0013">13</link>), <emphasis>B. silverae</emphasis> (<link linkend="ch0147s0055s0001li0014">14</link>), and <emphasis>B. emzantsi</emphasis> (<link linkend="ch0147s0055s0001li0015">15</link>) were proposed. <emphasis>B. silveriae</emphasis> is unusual among this genus in that it is not known to be pathogenic. Genotyping studies of <emphasis>B. dermatitidis</emphasis> have revealed an association between clinical phenotype and genetic groups, suggesting that genotyping of isolates may help to predict patient clinical associations (<link linkend="ch0147s0055s0001li0016">16</link>), although this work had not been validated with newly identified species. Whole-genome sequence assemblies and annotations for <emphasis>B. dermatitidis</emphasis> and <emphasis>B. gilchristii</emphasis> strains, including the highly virulent clinical strain SLH14081 and the relatively avirulent strain ER-3 (<link linkend="ch0147s0055s0001li0017">17</link>), are available via the Broad Institute page (<ulink url="https://www.broadinstitute.org/fungal-genome-initiative/blastomyces-genome-project">https://www.broadinstitute.org/fungal-genome-initiative/blastomyces-genome-project</ulink>).</para>
    </sect1>
    <sect1 id="ch0147s0005">
      <title>Coccidioides Species</title>
      <anchor id="ch0147s0005a0001"/>
      <anchor id="ch0147s0005a0002"/>
      <para id="ch0147s0005p0001">Phylogenetic studies have led to the recognition of two species within the genus<emphasis>Coccidioides.</emphasis> The species name <emphasis>C. immitis</emphasis> is now restricted to isolates from California and Washington state (<link linkend="ch0147s0055s0001li0018">18</link>), while the name <emphasis>C. posadasii</emphasis> has been proposed for all other isolates belonging to this genus. These two taxa were initially thought not to interbreed; however, more recent evidence has shown that genetic exchange between these species has occurred, with evidence of hybridization and genetic introgression (<link linkend="ch0147s0055s0001li0019">19</link>). More recent work using whole-genome sequencing has additionally identified genetically distinct subpopulations associated with specific geographic locales (Tucson, Arizona; Phoenix, Arizona; Texas-Mexico; Guatemala; etc.) (<link linkend="ch0147s0055s0001li0020">20</link>, <link linkend="ch0147s0055s0001li0021">21</link>). Genome sequence assemblies and annotations of <emphasis>Coccidioides immitis</emphasis> and <emphasis>C. posadasii</emphasis> have been completed (<link linkend="ch0147s0055s0001li0022">22</link>) and are now available at <ulink url="https://www.broadinstitute.org/scientific-community/science/projects/fungal-genome-initiative/coccidioides-genomes">https://www.broadinstitute.org/scientific-community/science/projects/fungal-genome-initiative/coccidioides-genomes</ulink> and <ulink url="http://fungidb.org/fungidb/">http://fungidb.org/fungidb/</ulink>.</para>
    </sect1>
    <sect1 id="ch0147s0006">
      <title>Paracoccidioides Species</title>
      <anchor id="ch0147s0006a0001"/>
      <anchor id="ch0147s0006a0002"/>
      <para id="ch0147s0006p0001">Phylogenetic analysis of<emphasis>P. brasiliensis</emphasis> showed that this fungus can be divided into at least three distinct species that appear to be confined to regions of endemicity: S1, PS2, and PS3 (<link linkend="ch0147s0055s0001li0023">23</link>). The highly divergent “Pb01-like” group was named “<emphasis>Paracoccidioides lutzii</emphasis>” (<link linkend="ch0147s0055s0001li0024">24</link>, <link linkend="ch0147s0055s0001li0025">25</link>), and names were recently proposed for PS2 (<emphasis>P. americana</emphasis>), PS3 (name has been proposed as <emphasis>P. restrepiensis</emphasis> or <emphasis>P. restrepoana</emphasis>), and a fifth phylogenetic species restricted to Venezuela, PS4 (<link linkend="ch0147s0055s0001li0026">26</link>, <link linkend="ch0147s0055s0001li0027">27</link>) (<emphasis>P. venezuelensis</emphasis>) (<link linkend="ch0147s0055s0001li0028">28</link>). At present, five phylogenetically diverse <emphasis>P. brasiliensis</emphasis> species (<emphasis>P. brasiliensis, P. americana, P. restrepiensis/P. restrepoana, P. venezuelensis</emphasis>, and <emphasis>P. lutzii</emphasis>) have been recognized as etiologic agents of this mycosis. <emphasis>P. lutzii</emphasis> diverged from the other species around 30 million years ago (MYA); meanwhile, <emphasis>P. venezuelensis</emphasis> and <emphasis>P. restrepiensis/P. restrepoana</emphasis> appeared closely related, with a recent divergence of less than 0.2 MYA (<link linkend="ch0147s0055s0001li0029">29</link>).</para>
      <para id="ch0147s0006p0002">Genomic and morphologic analyses strongly support the existence of a sexual cycle in species of the genus<emphasis>Paracoccidioides</emphasis> (<link linkend="ch0147s0055s0001li0030">30</link>). Comparison of 18S and chitin synthetase sequences has indicated that <emphasis>P. brasiliensis</emphasis> is related to the uncultivable pathogen <emphasis>Paracoccidioides (Lacazia) loboi</emphasis>, the agent of lacaziosis (<link linkend="ch0147s0055s0001li0031">31</link>) (see <ulink url="ch0152#ch0152s0001">chapter 131</ulink>).</para>
      <para id="ch0147s0006p0003">The Broad Institute has completed the sequencing, assembly, and annotation (<link linkend="ch0147s0055s0001li0032">32</link>) as well as a subsequent improved update (<link linkend="ch0147s0055s0001li0033">33</link>) of the genomes of two reference strains of <emphasis>P. brasiliensis</emphasis> (Pb03 and Pb18) and one strain of <emphasis>P. lutzii</emphasis> (Pb01) (<ulink url="https://www.broadinstitute.org/fungal-genome-initiative/paracoccidioides-genome-project">https://www.broadinstitute.org/fungal-genome-initiative/paracoccidioides-genome-project</ulink>). Recently, genome sequences of two additional strains of <emphasis>P. brasiliensis</emphasis> have been released (strain PbCnh, this species’ first assembled genome of mating type α/MAT1-1, and strain Pb300) (<link linkend="ch0147s0055s0001li0034">34</link>).</para>
    </sect1>
    <sect1 id="ch0147s0007">
      <title>Emergomyces and Adiaspiromyces Species</title>
      <anchor id="ch0147s0007a0001"/>
      <anchor id="ch0147s0007a0002"/>
      <para id="ch0147s0007p0001">Significant taxonomic changes have occurred within<emphasis>Ajellomycetaceae</emphasis> and resulted in the genera <emphasis>Adiaspiromyces</emphasis> and <emphasis>Emergomyces. Adiaspiromyces</emphasis> includes the environmental organism <emphasis>Adiaspiromyces terricola</emphasis>, although naming of these organisms has not been univerally accepted. The species formerly known as <emphasis>Adiaspiromyces crescens</emphasis> has recently been renamed <emphasis>Emergomyces crescens</emphasis> (<link linkend="ch0147s0055s0001li0004">4</link>, <link linkend="ch0147s0055s0001li0014">14</link>).</para>
      <para id="ch0147s0007p0002">The newly proposed genus<emphasis>Emergomyces</emphasis> contains <emphasis>Emergomyces pasteurianus</emphasis> (formerly <emphasis>Emmonsia pasteuriana</emphasis>) as the type species and five additional species: <emphasis>Es. africanus</emphasis> (<link linkend="ch0147s0055s0001li0035">35</link>), <emphasis>Es. orientalis</emphasis> (<link linkend="ch0147s0055s0001li0036">36</link>), <emphasis>Es. canadensis</emphasis> (<link linkend="ch0147s0055s0001li0037">37</link>), <emphasis>Es. crescens</emphasis> (<link linkend="ch0147s0055s0001li0004">4</link>, <link linkend="ch0147s0055s0001li0014">14</link>), and <emphasis>Es. europaeus</emphasis> (<link linkend="ch0147s0055s0001li0004">4</link>, <link linkend="ch0147s0055s0001li0014">14</link>). <emphasis>Emergomyces</emphasis> species have been found to cause disseminated disease in immunocompromised patients (<link linkend="ch0147s0055s0001li0038">38</link>), and work to further characterize this newly described genus is ongoing. Whole-genome sequencing of <emphasis>Emergomyces africanus</emphasis> (strain CBS136260) and its sister species <emphasis>Emergomyces pasteurianus</emphasis> (strain CBS 101426) has been completed and shows that both contain the α mating type locus (MAT1-1) (<link linkend="ch0147s0055s0001li0004">4</link>).</para>
      <para id="ch0147s0007p0003">Two former<emphasis>Emmonsia</emphasis> species have been moved to the genus <emphasis>Blastomyces. Emmonsia parva</emphasis> has been renamed <emphasis>Blastomyces parvus. Emmonsia helica</emphasis>, which was recently detected in an HIV-infected man in California (<link linkend="ch0147s0055s0001li0039">39</link>), has been renamed <emphasis>Blastomyces helicus</emphasis>.</para>
      <sect2 id="ch0147s0007s0001">
        <title>DESCRIPTION OF THE AGENTS</title>
        <anchor id="ch0147s0007s0001a0001"/>
        <anchor id="ch0147s0007s0001a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0147s0008">
      <title>Histoplasma capsulatum</title>
      <anchor id="ch0147s0008a0001"/>
      <anchor id="ch0147s0008a0002"/>
      <para id="ch0147s0008p0001"><emphasis>H. capsulatum</emphasis> is a thermally dimorphic fungus, displaying a filamentous mold form in the environment and in culture at temperatures below 35°C and a yeast phase in tissue and at temperatures above 35°C. The mold phase may contain two types of conidia (<anchor id="ch0147s0008a0003"/><link linkend="ch0147s0008a0005">Fig. 1</link>). Macroconidia are thick walled with a diameter of 8 to 15 μm and display characteristic tubercles or projections on their surfaces. Microconidia, smooth walled with a diameter of 2 to 4 μm, are the infectious particles (<link linkend="ch0147s0055s0001li0040">40</link>, <link linkend="ch0147s0055s0001li0041">41</link>). The yeast phase develops as small oval budding cells with a diameter of 2 to 4 μm, often within macrophages (<anchor id="ch0147s0008a0004"/><link linkend="ch0147s0008a0006">Fig. 2</link> and <link linkend="ch0147s0011a0003">3A</link>). The yeast cell found in African histoplasmosis is thick walled and larger, 8 to 15 μm in diameter.</para>
      <para id="ch0147s0008p0002"><emphasis>H. capsulatum</emphasis> is found in soils throughout the world. It grows best in soils with a high nitrogen content, particularly those enriched with bird or bat guano. Birds do not become colonized or infected with <emphasis>H. capsulatum</emphasis> (due to their high body temperatures), and their droppings are primarily a nutrient source. Soil samples from sites where birds have roosted have remained contaminated for at least 10 years after the roost has been cleared (<link linkend="ch0147s0055s0001li0042">42</link>).</para>
      <figure id="ch0147s0008f0001"><title><phrase role="figureLabel"><anchor id="ch0147s0008a0005"/><link linkend="ch0147s0008a0003"><emphasis role="strong">FIGURE 1</emphasis></link></phrase> Mycelial phase of <emphasis>H. capsulatum</emphasis> showing tuberculate macroconidia and microconidia. Lactophenol cotton blue stain. Magnification, ~×245.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0147f10.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <figure id="ch0147s0008f0002"><title><phrase role="figureLabel"><anchor id="ch0147s0008a0006"/><link linkend="ch0147s0008a0004"><emphasis role="strong">FIGURE 2</emphasis></link></phrase> GMS stain showing blastoconidia of <emphasis>H. capsulatum.</emphasis> Magnification, ~×290.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0147f11.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0147s0008p0003">Histoplasmosis is the most common endemic mycosis in North America, but it is also found throughout Central and South America (<link linkend="ch0147s0055s0001li0040">40</link>, <link linkend="ch0147s0055s0001li0043">43</link>). In the United States, the disease is most prevalent in states surrounding the Mississippi and Ohio Rivers, but foci of endemicity exist throughout the eastern half of the continent. Other regions of endemicity include parts of Africa, Australia, and eastern Asia, in particular India and Malaysia (<link linkend="ch0147s0055s0001li0001">1</link>).</para>
      <anchor id="ch0147s0008a0007"/>
      <beginpage pagenum="2468"/>
    </sect1>
    <sect1 id="ch0147s0009">
      <title>Blastomyces Species</title>
      <anchor id="ch0147s0009a0001"/>
      <anchor id="ch0147s0009a0002"/>
      <para id="ch0147s0009p0001"><emphasis>B. dermatitidis, B. gilchristii</emphasis>, and <emphasis>B. percursus</emphasis> are thermally dimorphic, converting from the mold phase to the yeast phase under appropriate conditions of temperature and nutrition. At room temperature, a floccose white mold can be recovered (<anchor id="ch0147s0009a0003"/><link linkend="ch0147s0009a0006">Fig. 4</link>). The microconidia are oval or pyriform (pear shaped) with a diameter of 2 to 10 μm; no macroconidia are produced. Large round thick-walled yeast cells, 5 to 15 μm, with broad-based budding daughter cells are found in tissue and on appropriate media at 37°C (<anchor id="ch0147s0009a0004"/><link linkend="ch0147s0009a0007">Fig. 5</link>). Yeast cells may occur inside or outside macrophages. <emphasis>B. helicus</emphasis> and <emphasis>B. silverae</emphasis> were described only recently and are phenotypically similar to <emphasis>B. dermatitidis</emphasis> (<link linkend="ch0147s0055s0001li0013">13</link>).</para>
      <para id="ch0147s0009p0002">The<emphasis>B. parvus</emphasis> mold phase produces small single-celled conidia (about 4 μm) on the sides of the hyphae or on short side branches. Inside the host, the conidia transform into structures termed adiaspores, which resemble the spherules of <emphasis>Coccidioides</emphasis> species. <emphasis>Blastomyces parvus</emphasis> adiaspores are smaller (10 to 25 μm) than <emphasis>Emergomyces crescens</emphasis> (<emphasis>Adiaspiromyces crescens</emphasis>) and are produced at 40°C (<link linkend="ch0147s0055s0001li0044">44</link>).</para>
      <figure id="ch0147s0009f0001"><title><phrase role="figureLabel"><anchor id="ch0147s0009a0005"/><link linkend="ch0147s0011a0003"><emphasis role="strong">FIGURE 3</emphasis></link></phrase> (A) Calcofluor white wet mount of sputum showing blastoconidia of <emphasis>H. capsulatum.</emphasis> Original magnification, ×475. (Courtesy of the American Society of Clinical Pathology.) (B) Calcofluor white wet mount of sputum showing blastoconidia of <emphasis>P. brasiliensis.</emphasis> Magnification, ~×255.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0147f12.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <figure id="ch0147s0009f0002"><title><phrase role="figureLabel"><anchor id="ch0147s0009a0006"/><link linkend="ch0147s0009a0003"><emphasis role="strong">FIGURE 4</emphasis></link></phrase> Mycelial phase of <emphasis>B. dermatitidis.</emphasis> Magnification, ~×240.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0147f13.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <figure id="ch0147s0009f0003"><title><phrase role="figureLabel"><anchor id="ch0147s0009a0007"/><link linkend="ch0147s0009a0004"><emphasis role="strong">FIGURE 5</emphasis></link></phrase> Blastoconidia of <emphasis>B. dermatitidis.</emphasis> GMS stain. Magnification, ~×290.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0147f14.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0147s0009p0003">The natural habitat of<emphasis>Blastomyces</emphasis> spp. is the soil, particularly near waterways, although the ecology of <emphasis>Blastomyces</emphasis> has not been completely defined due to the difficulty of isolating the organism in nature (<link linkend="ch0147s0055s0001li0045">45</link>). It appears to survive best in moist acidic soils that contain a high nitrogen and organic content. Higher soil temperatures and recent rainfall facilitate growth of the fungus.</para>
      <anchor id="ch0147s0009a0008"/>
      <beginpage pagenum="2469"/>
      <para id="ch0147s0009p0004">The largest number of cases of blastomycosis has been reported from North America, but the disease is also endemic in Africa and parts of Central and South America. In the United States, the organism is most commonly found in states surrounding the Mississippi and Ohio Rivers; in Canada, the disease occurs primarily in the provinces that border the Great Lakes (<link linkend="ch0147s0055s0001li0046">46</link>).</para>
    </sect1>
    <sect1 id="ch0147s0010">
      <title>Coccidioides Species</title>
      <anchor id="ch0147s0010a0001"/>
      <anchor id="ch0147s0010a0002"/>
      <para id="ch0147s0010p0001">In the environment and in culture at room temperature, the<emphasis>Coccidioides</emphasis> fungus exists as a mold producing septate hyphae and arthroconidia that usually develop in alternate hyphal cells (<anchor id="ch0147s0010a0003"/><link linkend="ch0147s0011a0005">Fig. 6</link>). As the arthroconidia mature, the alternating disjunctor cells undergo lytic degradation, releasing the barrel-shaped arthroconidia, approximately 2 to 5 μm, which are the infectious particles. Inside the host and in special media (2× glucose-yeast extract [2×GYE]), the arthroconidia transform into a structure called a spherule. A spherule is a large (typically 20 to 50 μm), thick-walled spherical structure containing hundreds to thousands of endospores, each approximately 2 to 4 μm, which can be released if the spherule ruptures (<anchor id="ch0147s0010a0004"/><link linkend="ch0147s0011a0006">Fig. 7</link>). Each endospore can develop into a spherule as well, continuing the process within the host.</para>
      <para id="ch0147s0010p0002"><emphasis>Coccidioides</emphasis> is a soil-inhabiting fungus with a restricted geographical distribution (<link linkend="ch0147s0055s0001li0047">47</link>). It is confined to regions of the Western Hemisphere that correspond to the lower Sonoran desert life zone (<link linkend="ch0147s0055s0001li0048">48</link>), and although an animal reservoir has been postulated, this has yet to be definitively demonstrated (<link linkend="ch0147s0055s0001li0049">49</link>). In the United States, the region of endemicity includes central and southern California, southern Arizona, southern New Mexico, parts of Utah and Washington, and western Texas. The region of endemicity extends southwards into the desert regions of northern Mexico and parts of Central and South America (<link linkend="ch0147s0055s0001li0049">49</link>).</para>
    </sect1>
    <sect1 id="ch0147s0011">
      <title>Paracoccidioides Species</title>
      <anchor id="ch0147s0011a0001"/>
      <anchor id="ch0147s0011a0002"/>
      <para id="ch0147s0011p0001"><emphasis>P. brasiliensis</emphasis> and <emphasis>P. lutzii</emphasis> are thermally dimorphic fungi. At room temperature, it grows as a mold. Growth requires a lengthy incubation, of up to 30 days. Isolates incubated on rich media, such as yeast-peptone-dextrose (YPD), produce thin septate hyphae 1 to 3 μm in width with the appearance of interwoven threads and occasional chlamydospores. Under conditions of nutritional deprivation (yeast extract, glucose-salts and water-agar media), some isolates produce conidia, which vary in structure from arthroconidia to microconidia of less than 5 μm and can be intercalary, septate, or pedunculated (originating from a narrower base). Conidia respond to temperature changes, germinating into hyphae at 20°C to 24°C or converting to yeasts at 36ºC on appropriate medium (such as modified McVeigh-Morton medium). Yeast cells are mostly oval and characteristically display a mother cell surrounded by multiple buds, a structure thought to resemble a ship’s pilot wheel (<anchor id="ch0147s0011a0003"/><link linkend="ch0147s0009a0005">Fig. 3B</link> and <anchor id="ch0147s0011a0004"/><link linkend="ch0147s0011a0007">8</link>).</para>
      <figure id="ch0147s0011f0001"><title><phrase role="figureLabel"><anchor id="ch0147s0011a0005"/><link linkend="ch0147s0010a0003"><emphasis role="strong">FIGURE 6</emphasis></link></phrase> Mycelial phase of <emphasis>Coccidioides immitis</emphasis> showing alternating arthroconidia. Lactofuchsin stain. Magnification, ~×250.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0147f15.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <figure id="ch0147s0011f0002"><title><phrase role="figureLabel"><anchor id="ch0147s0011a0006"/><link linkend="ch0147s0010a0004"><emphasis role="strong">FIGURE 7</emphasis></link></phrase> KOH preparation of pus from a lesion showing <emphasis>Coccidioides</emphasis> spherule and endospores. Magnification, ~×290. (Reprinted with permission from reference <link linkend="ch0147s0055s0001li0181">181</link>.)
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0147f16.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <figure id="ch0147s0011f0003"><title><phrase role="figureLabel"><anchor id="ch0147s0011a0007"/><link linkend="ch0147s0011a0004"><emphasis role="strong">FIGURE 8</emphasis></link></phrase> Wet mount showing blastoconidia of <emphasis>P. brasiliensis.</emphasis> Magnification, ~×290.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0147f17.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0147s0011p0002">Although<emphasis>Paracoccidioides</emphasis> spp. have been isolated from soil, understanding of its precise environmental habitat remains limited. The region of endemicity extends from Mexico (23°N) to Argentina (34°S), sparing certain countries (Chile, Suriname, the Guianas, Nicaragua, Belize, and most of the Caribbean islands) within these latitudes. Within countries where the disease is endemic, the mycosis is diagnosed only in areas with relatively well-defined ecologic characteristics (presence of tropical and subtropical forest, abundant watercourses, mild temperatures, high rainfall, and coffee/tobacco crops). The greatest numbers of reported cases have come from Brazil, Colombia, and Venezuela (<link linkend="ch0147s0055s0001li0050">50</link>–<link linkend="ch0147s0055s0001li0052">52</link>). <emphasis>P. brasiliensis</emphasis> has been repeatedly recovered from human clinical samples, tissues of the nine-banded armadillo (<emphasis>Dasypus novemcinctus</emphasis>), and more rarely from the Northern naked-tailed armadillo (<emphasis>Cabassous centralis</emphasis>). Occasionally, <emphasis>P. brasiliensis</emphasis> has also been isolated from dogs and detected in other animal species (<link linkend="ch0147s0055s0001li0050">50</link>).</para>
      <anchor id="ch0147s0011a0008"/>
      <beginpage pagenum="2470"/>
    </sect1>
    <sect1 id="ch0147s0012">
      <title>Emergomyces crescens (Emergomyces crescens)</title>
      <anchor id="ch0147s0012a0001"/>
      <anchor id="ch0147s0012a0002"/>
      <para id="ch0147s0012p0001">In the environment and in culture at room temperature,<emphasis>Emergomyces crescens</emphasis> exist as molds that produce small single-celled conidia (about 4 μm) on the sides of the hyphae or on short side branches. Inside the host, the conidia of <emphasis>Adiaspiromyces crescens</emphasis> form adiaspores, as discussed above. As such, the disease entity caused by <emphasis>Es. crescens</emphasis> and <emphasis>Blastomyces parvus</emphasis> is known as Adiaspiromycosis. Although adiaspores enlarge to become enormous, thick-walled structures, no endospores are produced, and the spores eventually die, failing to propagate <emphasis>in vivo</emphasis>, and thus probably do not disseminate from the lungs (<link linkend="ch0147s0055s0001li0053">53</link>). Adiaspores can also be generated <emphasis>in vitro</emphasis> in rich media (YPD or others). Some <emphasis>Emergomyces crescens</emphasis> strains have been found to produce large (25- to 400-μm) multinucleate adiaspores at 37°C. The natural habitat of <emphasis>Emergomyces crescens</emphasis> is the soil, and infection has occurred in numerous rodents, fossorial mammals, and their predators. Human cases of infection or disease were initially rare but were reported from North, Central, and South America, as well as from several European and Asian countries and then more recently from South Africa. Previously, the majority of recent cases were reported from Brazil (<link linkend="ch0147s0055s0001li0044">44</link>), yet following the reports from South Africa (<link linkend="ch0147s0055s0001li0054">54</link>), the geographic extent of diseases caused by these fungi has become unclear.</para>
    </sect1>
    <sect1 id="ch0147s0013">
      <title>Emergomyces Species</title>
      <anchor id="ch0147s0013a0001"/>
      <anchor id="ch0147s0013a0002"/>
      <para id="ch0147s0013p0001"><emphasis>Emergomyces pasteurianus</emphasis> (previously <emphasis>Emmonsia pasteuriana</emphasis>) does not produce adiaspores in tissue; rather, at 37°C on rich media (YPD or others), it produces structures that resemble budding yeast cells (<anchor id="ch0147s0013a0003"/><link linkend="ch0147s0013a0004">Fig. 9</link>). The earliest cases of emergomycosis caused by the species now known as <emphasis>Emergomyces africanus</emphasis> were diagnosed in the Western Cape province of South Africa, but molecular identification of dimorphic fungi in other regions has led to detection of cases in six of nine South African provinces and the Kingdom of Lesotho (<link linkend="ch0147s0055s0001li0055">55</link>).</para>
      <figure id="ch0147s0013f0001"><title><phrase role="figureLabel"><anchor id="ch0147s0013a0004"/><link linkend="ch0147s0013a0003"><emphasis role="strong">FIGURE 9</emphasis></link></phrase> (Left) Mycelial culture of <emphasis>Emergomyces</emphasis> sp. (Right) Lactophenol cotton blue staining of <emphasis>Emergomyces</emphasis> sp. demonstrating slender conidiophores arising from hyphae at right angles. Magnification, ~×1,000.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0147f09.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0147s0013p0002"><emphasis>Emergomyces</emphasis> exists as a mold in the environment or when grown <emphasis>in vitro</emphasis> at a temperature less than 30°C (<link linkend="ch0147s0055s0001li0004">4</link>, <link linkend="ch0147s0055s0001li0056">56</link>, <link linkend="ch0147s0055s0001li0057">57</link>). <emphasis>In vivo</emphasis>, in contrast, budding yeast cells are observed in infected tissue or when the organism is grown at 35°C in the laboratory (<link linkend="ch0147s0055s0001li0056">56</link>). <emphasis>Es. africanus, Es. pasteurianus</emphasis>, and <emphasis>Es. orientalis</emphasis> grow at a minimum temperature of 6°C, with optimum growth at 24°C to 27°C and at a maximum temperature of 40°C. Morphologically, colonies appear beige and are slow growing and filamentous at room temperature. Conidiophores are short, unbranched, arising at right angles from thin-walled hyaline hyphae, and slightly swollen at the top, sometimes with short, secondary conidiophores bearing a group of more than three conidia (<link linkend="ch0147s0055s0001li0004">4</link>, <link linkend="ch0147s0055s0001li0056">56</link>). At human body temperature, colonies appear yeast-like: small, cream to smooth grey-brown, and heaped (<link linkend="ch0147s0055s0001li0004">4</link>). Small oval yeast cells with narrow buds are formed; sometimes, larger cells with broader-based buds may also be present (<link linkend="ch0147s0055s0001li0004">4</link>, <link linkend="ch0147s0055s0001li0056">56</link>).</para>
      <sect2 id="ch0147s0013s0001">
        <title>EPIDEMIOLOGY AND TRANSMISSION</title>
        <anchor id="ch0147s0013s0001a0001"/>
        <anchor id="ch0147s0013s0001a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0147s0014">
      <title>Histoplasmosis</title>
      <anchor id="ch0147s0014a0001"/>
      <anchor id="ch0147s0014a0002"/>
      <para id="ch0147s0014p0001">Inhalation of microconidia is the usual mode of<emphasis>H. capsulatum</emphasis> infection in humans. The incubation period is 1 to 3 weeks. In cases of reinfection, the incubation period appears to be shorter (4 to 7 days after exposure). Histoplasmosis is not contagious, but there have been occasional reports of transmission from an organ donor to a recipient (<link linkend="ch0147s0055s0001li0058">58</link>).</para>
      <para id="ch0147s0014p0002">The major risk factor for infection is environmental exposure (<link linkend="ch0147s0055s0001li0041">41</link>). The risk depends on several factors, including the nature of the environmental site, the activities performed, and the duration and degree of dust or soil exposure. Longer and more intense exposures usually result in more severe pulmonary disease. Most reported outbreaks have been associated with exposures to sites contaminated with <emphasis>H. capsulatum</emphasis> or have followed activities that disturbed accumulations of bird or bat guano (<link linkend="ch0147s0055s0001li0042">42</link>).</para>
      <para id="ch0147s0014p0003">Persons with underlying illnesses are at increased risk for some forms of histoplasmosis. Disseminated infection is more common among individuals with underlying cell-mediated immunological defects, including those with HIV infection, transplant recipients, and individuals receiving tumor necrosis factor alpha inhibitors for rheumatoid arthritis. Immunocompromised persons with histoplasmosis have a higher mortality rate than those who are not immunosuppressed (<link linkend="ch0147s0055s0001li0059">59</link>, <link linkend="ch0147s0055s0001li0060">60</link>).</para>
    </sect1>
    <sect1 id="ch0147s0015">
      <title>Blastomycosis</title>
      <anchor id="ch0147s0015a0001"/>
      <anchor id="ch0147s0015a0002"/>
      <anchor id="ch0147s0015a0003"/>
      <para id="ch0147s0015p0001">Inhalation of conidia is the usual mode of infection leading to blastomycosis. The incubation period has been estimated to be 4 to 6 weeks, although in some cases, disease does not manifest until months following exposure (<link linkend="ch0147s0055s0001li0061">61</link>). Blastomycosis is not contagious.</para>
      <para id="ch0147s0015p0002">Outbreaks have been associated with occupational and recreational activities, often along streams or rivers, and have resulted from exposures to moist soil enriched with decaying vegetation. Apart from outbreaks, blastomycosis is more commonly seen in adults than in children. More men than women are affected, and a disproportionate number of Asians compared to non-Asians was noted in a recent outbreak (<link linkend="ch0147s0055s0001li0062">62</link>, <link linkend="ch0147s0055s0001li0063">63</link>). The disease often occurs in individuals with an outdoor occupation or recreational interest.</para>
      <para id="ch0147s0015p0003"><emphasis>B. dermatitidis</emphasis> is uncommon as an opportunistic pathogen, but it causes more-aggressive disease in persons with underlying cell-mediated immunological defects, such as those with HIV infection and transplant recipients. Immunocompromised persons with blastomycosis have a higher mortality rate than those who are not immunosuppressed (<link linkend="ch0147s0055s0001li0064">64</link>).</para>
    </sect1>
    <sect1 id="ch0147s0016">
      <title>Coccidioidomycosis</title>
      <anchor id="ch0147s0016a0001"/>
      <anchor id="ch0147s0016a0002"/>
      <para id="ch0147s0016p0001">Inhalation of arthroconidia is the usual mode of infection leading to coccidioidomycosis in humans. The incubation period is 1 to 3 weeks. Once individuals have recovered from<emphasis>Coccidioides</emphasis> infection, they are usually immune to reinfection. The infection is not contagious, but occasional person-to-person spread has occurred via contaminated fomites (<link linkend="ch0147s0055s0001li0065">65</link>) or by transmission from an organ donor to a recipient (<link linkend="ch0147s0055s0001li0066">66</link>).</para>
      <para id="ch0147s0016p0002">The major risk factor for infection is environmental exposure. The risk depends on a number of factors, including the nature of the environmental site, the activities performed, and the duration and degree of dust or soil exposure. Infection has been associated with ground-disturbing activities, such as building construction, landscaping, farming, archaeological excavation, and numerous recreational pursuits (<link linkend="ch0147s0055s0001li0067">67</link>). Natural events that result in the generation of dust clouds, such as earthquakes and windstorms, have been associated with an increased risk of infection and have resulted in large outbreaks (<link linkend="ch0147s0055s0001li0068">68</link>), and the effects of climate change suggest continued expansion of the region of endemicity (<link linkend="ch0147s0055s0001li0069">69</link>).</para>
      <para id="ch0147s0016p0003">Disseminated infection is more common among those of black, Asian, or Filipino race and among pregnant women in the third trimester. Individuals with underlying cell-mediated immunological defects, such as those with AIDS and those receiving immunosuppressive medications, are also at increased risk of disease dissemination (<link linkend="ch0147s0055s0001li0070">70</link>).</para>
    </sect1>
    <sect1 id="ch0147s0017">
      <title>Paracoccidioidomycosis</title>
      <anchor id="ch0147s0017a0001"/>
      <anchor id="ch0147s0017a0002"/>
      <para id="ch0147s0017p0001">Inhalation of<emphasis>P. braziliensis</emphasis> or <emphasis>P. lutzii</emphasis> conidia is the usual mode of infection leading to paracoccidioidomycosis in humans. The incubation period is unknown, but it is clear that the fungus can remain dormant for very long periods in the lymph nodes following asymptomatic primary infection. Paracoccidioidomycosis is not contagious (<link linkend="ch0147s0055s0001li0071">71</link>).</para>
      <para id="ch0147s0017p0002">Paracoccidioidomycosis predominates in adults, who account for 85 to 95% of cases, and in persons in agriculture-related occupations. The disease is more often diagnosed in males than in females (ratio of 15:1). Estrogen-mediated inhibition of the mold-to-yeast transformation could help to account for this (<link linkend="ch0147s0055s0001li0071">71</link>). Sporadic cases have been reported in individuals with underlying immunosuppressive conditions, including HIV infection.</para>
    </sect1>
    <sect1 id="ch0147s0018">
      <title>Adiaspiromycosis</title>
      <anchor id="ch0147s0018a0001"/>
      <anchor id="ch0147s0018a0002"/>
      <para id="ch0147s0018p0001">Inhalation of the conidia of<emphasis>Es.</emphasis> (<emphasis>Adiaspiromyces</emphasis>) <emphasis>crescens</emphasis> or <emphasis>B.</emphasis>(<emphasis>Emmonsia</emphasis>) <emphasis>parvus</emphasis> is the usual mode of infection leading to adiaspiromycosis in animals and humans, and even in cases with skin lesions, it is likely that this represents dissemination following inhalational exposure given the systemic manifestations (including liver function abnormalities) (<link linkend="ch0147s0055s0001li0072">72</link>). The incubation period is unknown, although circumstantial evidence suggests that symptoms may develop 1 to 3 weeks following exposure. No risk factors have been identified.</para>
    </sect1>
    <sect1 id="ch0147s0019">
      <title>Emergomycosis</title>
      <anchor id="ch0147s0019a0001"/>
      <anchor id="ch0147s0019a0002"/>
      <para id="ch0147s0019p0001">Infection is presumed to follow inhalation of airborne propagules, and indeed,<emphasis>Es. africanus</emphasis> DNA has frequently been detected in air samples from an area of endemicity (Cape Town, South Africa) where cases of emergomycosis have been diagnosed (<link linkend="ch0147s0055s0001li0035">35</link>). No similar epidemiological details are available for the other <emphasis>Emergomyces</emphasis> species. The majority of emergomycosis cases have occurred in immunocompromised patients, most commonly with defects in cell-mediated immunity caused by HIV infection.</para>
      <sect2 id="ch0147s0019s0001">
        <title>CLINICAL SIGNIFICANCE</title>
        <anchor id="ch0147s0019s0001a0001"/>
        <anchor id="ch0147s0019s0001a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0147s0020">
      <title>Histoplasmosis</title>
      <anchor id="ch0147s0020a0001"/>
      <anchor id="ch0147s0020a0002"/>
      <para id="ch0147s0020p0001">There is a wide spectrum of clinical manifestations of histoplasmosis, ranging from a transient pulmonary infection that subsides without treatment to chronic pulmonary infection or to more widespread disseminated disease (<link linkend="ch0147s0055s0001li0040">40</link>, <link linkend="ch0147s0055s0001li0041">41</link>). Many healthy individuals develop no symptoms when exposed to <emphasis>H. capsulatum</emphasis> in a setting of endemicity. Higher levels of exposure result in an acute symptomatic and often severe flu-like illness. The symptoms, which include fever, chills, headache, nonproductive cough, myalgia, pleuritic chest pain, loss of appetite, and fatigue, usually disappear within a few weeks. The most severe form of this disease is disseminated histoplasmosis. The clinical manifestations range from an acute illness that is fatal within a few weeks if left untreated (often seen in infants, persons with AIDS, and solid-organ transplant recipients) to an indolent, chronic illness that can affect a wide range of sites. Recent data also suggest that histoplasmosis is responsible for an increasing number of hospitalizations, likely from the growing immunosuppressed population (<link linkend="ch0147s0055s0001li0073">73</link>–<link linkend="ch0147s0055s0001li0075">75</link>).</para>
      <para id="ch0147s0020p0002">Hepatic infection is common in nonimmunosuppressed individuals with disseminated histoplasmosis, and adrenal gland destruction is a frequent problem. Mucosal ulcers are found in over 60% of these patients. The mouth and throat are often affected, but lesions also occur on the lips, nose, and other sites. Central nervous system disease occurs in 5 to 20% of patients, presenting as chronic meningitis or focal brain lesions. In persons with AIDS, disseminated histoplasmosis is usually associated with low CD4 T-lymphocyte counts and presents with nonspecific symptoms, such as fever and weight loss. Mucosal lesions are uncommon, but multiple cutaneous lesions may be present. Central nervous system involvement occurs in 10 to 20% of cases (<link linkend="ch0147s0055s0001li0040">40</link>, <link linkend="ch0147s0055s0001li0041">41</link>).</para>
    </sect1>
    <sect1 id="ch0147s0021">
      <title>African Histoplasmosis</title>
      <anchor id="ch0147s0021a0001"/>
      <anchor id="ch0147s0021a0002"/>
      <para id="ch0147s0021p0001">The clinical manifestations of African histoplasmosis differ from those of classical histoplasmosis. The illness is indolent at onset, and the predominant sites affected are the skin and bones, although more recent reports have shown disseminated infection in 77% of those affected (<link linkend="ch0147s0055s0001li0006">6</link>). Individuals with more widespread infection involving the liver, spleen, and other organs have a febrile wasting illness that is fatal within weeks or months if left untreated. Multiple cutaneous lesions often develop on the face and trunk. These lesions often enlarge and ulcerate. Osteomyelitis occurs in about 30% of patients. The infection may spread into contiguous joints, causing arthritis, or into adjacent soft tissue, causing a purulent subcutaneous abscess.</para>
      <anchor id="ch0147s0021a0003"/>
      <beginpage pagenum="2472"/>
    </sect1>
    <sect1 id="ch0147s0022">
      <title>Blastomycosis</title>
      <anchor id="ch0147s0022a0001"/>
      <anchor id="ch0147s0022a0002"/>
      <para id="ch0147s0022p0001">Blastomycosis encompasses a wide clinical spectrum, ranging from a transient pulmonary infection that subsides without treatment to chronic pulmonary infection or to widespread disseminated disease (<link linkend="ch0147s0055s0001li0076">76</link>). Acute pulmonary blastomycosis usually presents as a nonspecific flu-like illness, similar to that seen with community-acquired pneumonia or primary histoplasmosis or coccidioidomycosis. Otherwise healthy persons generally recover after 2 to 12 weeks of symptoms, but some infected individuals experience infection of other sites months later. Other patients with acute blastomycosis fail to recover and develop chronic pulmonary disease or disseminated infection.</para>
      <para id="ch0147s0022p0002">The skin and bones are the most common sites of extrapulmonary disease. The skin is involved in more than 70% of cases, the lesions presenting either as raised verrucous lesions with irregular borders or as ulcers. The latter can also appear on the mucosa of the nose, mouth, and throat. Osteomyelitis occurs in about 30% of patients with disseminated infection, with the spine, ribs, and long bones being the commonest sites of involvement. Arthritis occurs in about 10% of patients. Meningitis is rare, except in immunocompromised individuals. Other organs, such as the male genitourinary tract, adrenal glands, thyroid, liver, spleen, and gastrointestinal tract, are sometimes involved (<link linkend="ch0147s0055s0001li0061">61</link>).</para>
    </sect1>
    <sect1 id="ch0147s0023">
      <title>Coccidioidomycosis</title>
      <anchor id="ch0147s0023a0001"/>
      <anchor id="ch0147s0023a0002"/>
      <para id="ch0147s0023p0001">Although a number of clinical manifestations may present after exposure, more than half of all infections are thought to be subclinical. Apparent illness is most commonly a subacute process known as valley fever (primary coccidioidal infection). Respiratory symptoms such as cough, fever, chills, and fatigue are common and may last weeks to months. In regions of endemicity, primary coccidioidal pneumonia may account for 17 to 29% of all community-acquired pneumonia (<link linkend="ch0147s0055s0001li0077">77</link>, <link linkend="ch0147s0055s0001li0078">78</link>). Up to 50% of patients develop a mild, diffuse erythematous or maculopapular rash covering the trunk and limbs within the first few days of the onset of symptoms, a clinical sign that may be useful to differentiate the patient’s symptoms from those caused by bacterial pneumonia (<link linkend="ch0147s0055s0001li0079">79</link>). More dramatic and persistent is the rash of erythema nodosum or erythema multiforme, which occurs in about 5% of infected persons. Otherwise healthy persons recover without treatment, their symptoms disappearing in a few weeks to months.</para>
      <para id="ch0147s0023p0002">Fewer than 3% of infected individuals develop disseminated coccidioidomycosis. This progressive disease usually develops within 3 to 12 months of the initial infection, although it can occur much later following reactivation of a quiescent infection in an immunosuppressed individual. The clinical manifestations range from a fulminant illness that is fatal within a few weeks if left untreated to an indolent chronic disease that persists for months or years. One or more sites may be involved, but the skin, soft tissue, bones, joints, and meninges are most commonly affected. Cutaneous and subcutaneous lesions are common. Osteomyelitis occurs in about 40% of patients, with the spine, ribs, cranial bones, and ends of the long bones being the most common sites. The disease may spread into contiguous joints causing arthritis, or into adjacent soft tissue, causing subcutaneous abscess formation. Meningitis is the most serious complication of coccidioidomycosis, occurring in 30 to 50% of patients with disseminated disease, and left untreated is almost universally fatal (<link linkend="ch0147s0055s0001li0080">80</link>).</para>
    </sect1>
    <sect1 id="ch0147s0024">
      <title>Paracoccidioidomycosis</title>
      <anchor id="ch0147s0024a0001"/>
      <anchor id="ch0147s0024a0002"/>
      <para id="ch0147s0024p0001">Paracoccidioidomycosis encompasses a subclinical infection resulting from the initial contact with the fungus. The lungs are the usual initial site of<emphasis>Paracoccidioides</emphasis> infection, but the organism then spreads through the lymphatics to the regional lymph nodes. In most cases the primary infection is asymptomatic. However, children and adolescents sometimes present with an acute disseminated form of infection in which superficial and/or visceral lymph node enlargement is the major manifestation. This presentation is also seen in immunocompromised patients. It has a poor prognosis.</para>
      <para id="ch0147s0024p0002">The hallmarks of the chronic adult type of disease are significant lung involvement and extrapulmonary lesions. This is the predominant form occurring in approximately 90% of cases (<link linkend="ch0147s0055s0001li0071">71</link>). In 80% of cases the disease involves the lungs. The disease is slowly progressive and may take months or even years to become established. Ulcerative mucocutaneous lesions of the face, mouth, and nose are the most obvious presenting sign. Other sites of infection include the small and large intestines, liver and spleen, adrenal glands, bones and joints, central nervous system, and male genitourinary tract. In 60 to 80% of cases, active pulmonary involvement and residual fibrotic lesions are observed. A residual form is also recognized in 50 to 80% of cases and is represented by fibrotic scarring at the sites of previously active lesions, which can alter respiratory function and incapacitate the patient. <emphasis>Paracoccidioides</emphasis> infection may become dormant, to be reactivated later under the influence of ill-defined conditions prevalent in rural settings, such as chronic alcoholism, malnutrition, and smoking (<link linkend="ch0147s0055s0001li0071">71</link>).</para>
    </sect1>
    <sect1 id="ch0147s0025">
      <title>Adiaspiromycosis</title>
      <anchor id="ch0147s0025a0001"/>
      <anchor id="ch0147s0025a0002"/>
      <para id="ch0147s0025p0001">In most cases, adiaspiromycosis is a self-limited, localized pulmonary infection with few or no symptoms. Because the adiaspores enlarge but do not reproduce, symptoms and clinical signs depend upon the number of conidia inhaled. In some patients, the disease is discovered incidentally during the evaluation of other pulmonary conditions. However, nonproductive cough, dyspnea, and fever are not uncommon in those with adiaspiromycosis. Severe and fatal cases are rare, although they have been reported (<link linkend="ch0147s0055s0001li0044">44</link>), and can occur in immunocompromised individuals, as recently reported (<link linkend="ch0147s0055s0001li0044">44</link>, <link linkend="ch0147s0055s0001li0081">81</link>), with cutaneous manifestations and elevated liver function tests. A single outbreak of ocular adiaspiromycosis has also been reported (<link linkend="ch0147s0055s0001li0082">82</link>).</para>
    </sect1>
    <sect1 id="ch0147s0026">
      <title>Emergomycosis</title>
      <anchor id="ch0147s0026a0001"/>
      <anchor id="ch0147s0026a0002"/>
      <para id="ch0147s0026p0001">The most common clinical manifestation of emergomycosis (previously described as disseminated emmonsiosis and best described for cases of<emphasis>Emergomyces africanus</emphasis> infection) is the appearance of widespread cutaneous lesions, occurring in 95% of patients (<link linkend="ch0147s0055s0001li0055">55</link>, <link linkend="ch0147s0055s0001li0056">56</link>). Pulmonary manifestations are also common, and radiographic lesions are apparent in over 80% of affected patients (<link linkend="ch0147s0055s0001li0001">1</link>).</para>
      <sect2 id="ch0147s0026s0001">
        <title>COLLECTION, TRANSPORT, AND STORAGE OF SPECIMENS</title>
        <anchor id="ch0147s0026s0001a0001"/>
        <anchor id="ch0147s0026s0001a0002"/>
        <anchor id="ch0147s0026s0001a0003"/>
      </sect2>
    </sect1>
    <sect1 id="ch0147s0027">
      <title>Clinical Specimens</title>
      <anchor id="ch0147s0027a0001"/>
      <anchor id="ch0147s0027a0002"/>
      <para id="ch0147s0027p0001">Methods of collection, transport, and storage of specimens are detailed in<ulink url="ch0139#ch0139s0001">chapter 118</ulink>. Tissue samples should be obtained when appropriate and should be divided and submitted for microbiological and histopathological examination. If possible, special tissue stains such as the Grocott-Gomori methenamine silver (GMS) and periodic acid-Schiff (PAS) stains should be requested. Since colonization with the dimorphic fungal pathogens does not occur, their microscopic detection and/or isolation in culture is consistent with proven infection. Blood, urine, and cerebrospinal fluid (CSF) can also be collected as appropriate for nucleic acid amplification, antigen, and/or antibody testing. The development of next-generation sequencing to detect cell-free pathogen DNA has received extensive attention and may be useful in the diagnosis of endemic fungal infections, although no data obtained with this methodology have been presented yet.</para>
      <sect2 id="ch0147s0027s0001">
        <title>Histoplasma capsulatum</title>
        <anchor id="ch0147s0027s0001a0001"/>
        <anchor id="ch0147s0027s0001a0002"/>
        <para id="ch0147s0027s0001p0001"><emphasis>H. capsulatum</emphasis> organisms can be isolated from sputum or bronchoalveolar lavage fluid specimens in 60 to 85% of cases of chronic pulmonary histoplasmosis if multiple specimens are tested (<link linkend="ch0147s0055s0001li0083">83</link>). In disseminated disease, useful specimens for culture include blood, urine, lymph node, and bone marrow samples. Bone marrow cultures are positive in over 75% of cases. Blood cultures collected with the Isolator lysis-centrifugation system (Wampole Laboratories, Princeton, NJ) or Bactec Myco/F Lytic bottles (BD Diagnostic Systems, Sparks, MD) show the greatest sensitivity. Biopsy specimens of oral, cutaneous, and gastrointestinal lesions, adrenal glands, or liver and spleen have also provided a diagnosis. <emphasis>Histoplasma</emphasis> meningitis is difficult to diagnose, with CSF cultures being positive in no more than two-thirds of cases. The best results are obtained when large volumes of CSF (10 to 20 ml) are cultured on multiple occasions.</para>
      </sect2>
      <sect2 id="ch0147s0027s0002">
        <title>Blastomyces Species</title>
        <anchor id="ch0147s0027s0002a0001"/>
        <anchor id="ch0147s0027s0002a0002"/>
        <para id="ch0147s0027s0002p0001">Sputum samples, bronchoalveolar lavage fluid, or lung biopsy specimens may be submitted. Skin biopsy specimens are useful in the diagnosis of cutaneous disease. Collection of urine after prostatic massage may be helpful in the diagnosis of genitourinary blastomycosis.</para>
      </sect2>
      <sect2 id="ch0147s0027s0003">
        <title>Coccidioides Species</title>
        <anchor id="ch0147s0027s0003a0001"/>
        <anchor id="ch0147s0027s0003a0002"/>
        <para id="ch0147s0027s0003p0001">In addition to lower respiratory tract samples, material for microscopy and culture can be collected from suppurative cutaneous and soft tissue lesions. Organisms can be recovered only infrequently from CSF (~30% of patients) and usually only after culture of large volumes (10 to 20 ml) (<link linkend="ch0147s0055s0001li0084">84</link>).</para>
      </sect2>
      <sect2 id="ch0147s0027s0004">
        <title>Paracoccidioides Species</title>
        <anchor id="ch0147s0027s0004a0001"/>
        <anchor id="ch0147s0027s0004a0002"/>
        <para id="ch0147s0027s0004p0001">In addition to lower respiratory samples, material can be collected from oral or pharyngeal lesions, cutaneous lesions, lymph nodes, adrenal glands, and the gastrointestinal tract. With these specimens, a simple wet mount suffices to reveal<emphasis>P. brasiliensis</emphasis> characteristic yeast forms in over 85% of patients (<link linkend="ch0147s0055s0001li0071">71</link>).</para>
      </sect2>
      <sect2 id="ch0147s0027s0005">
        <title>Emergomyces crescens (Adiaspiromyces crescens)</title>
        <anchor id="ch0147s0027s0005a0001"/>
        <anchor id="ch0147s0027s0005a0002"/>
        <para id="ch0147s0027s0005p0001">The diagnosis of<emphasis>Es. crescens</emphasis> is usually based on observing its unique histopathologic appearance, typically a single, large thick-walled adiaspore within a granuloma.</para>
      </sect2>
      <sect2 id="ch0147s0027s0006">
        <title>Emergomyces Species</title>
        <anchor id="ch0147s0027s0006a0001"/>
        <anchor id="ch0147s0027s0006a0002"/>
        <para id="ch0147s0027s0006p0001">Diagnosis of emergomycosis is currently made by detection of the yeast phase from affected tissue during histopathology examination or by isolation of the fungus from appropriate specimens, such as skin tissue, blood, bone marrow, respiratory tissue, liver tissue, and lymph node (<link linkend="ch0147s0055s0001li0085">85</link>).</para>
      </sect2>
      <sect2 id="ch0147s0027s0007">
        <title>DIRECT EXAMINATION</title>
        <anchor id="ch0147s0027s0007a0001"/>
        <anchor id="ch0147s0027s0007a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0147s0028">
      <title>Microscopy</title>
      <anchor id="ch0147s0028a0001"/>
      <anchor id="ch0147s0028a0002"/>
      <para id="ch0147s0028p0001">Direct microscopic examination of clinical materials may provide a rapid presumptive diagnosis of a systemic fungal infection. However, it is important to appreciate that tissue-form cells of<emphasis>Histoplasma</emphasis> and <emphasis>Blastomyces</emphasis> can appear similar to each other as well as to yeast cells of various <emphasis>Candida</emphasis> species, <emphasis>Cryptococcus neoformans, Cryptococcus gattii</emphasis>, and <emphasis>Talaromyces marneffei</emphasis> (formerly <emphasis>Penicillium marneffei</emphasis>) and to endospores of <emphasis>Coccidioides</emphasis> species. It is often helpful to stain fresh, wet preparations of sputum, bronchoalveolar lavage fluid, CSF, urine, pus, or other material with calcofluor white, a fluorescent compound that binds to the fungal cell wall, to assist with preliminary evaluation.</para>
      <sect2 id="ch0147s0028s0001">
        <title>Histoplasma capsulatum</title>
        <anchor id="ch0147s0028s0001a0001"/>
        <anchor id="ch0147s0028s0001a0002"/>
        <para id="ch0147s0028s0001p0001">Giemsa and Wright’s stains can be used to detect yeast cells of<emphasis>H. capsulatum</emphasis> in blood or bone marrow smears. These cells can also be seen in tissue sections stained with GMS or PAS but usually not with hematoxylin and eosin (H&amp;E). Detection of the small (2- to 4-μm) oval budding yeasts allows a presumptive diagnosis of histoplasmosis. Organisms can be found within macrophages or free in the tissues. It is unusual to find yeast cells on cytological examination of sputum or other respiratory tract fluids. The thick-walled narrow-based budding yeast cells causing African histoplasmosis, approximately 10 to 15 μm in diameter, are about fourfold larger than those of classical <emphasis>H. capsulatum</emphasis> in tissue sections and on occasion may be confused with <emphasis>Blastomyces</emphasis> spp.</para>
      </sect2>
      <sect2 id="ch0147s0028s0002">
        <title>Blastomyces Species</title>
        <anchor id="ch0147s0028s0002a0001"/>
        <anchor id="ch0147s0028s0002a0002"/>
        <para id="ch0147s0028s0002p0001">Direct calcofluor white or KOH mounts or Gram stains of sputum, tissues, and exudates often permit the detection of the large round yeast cells of<emphasis>Blastomyces</emphasis> spp. The broad-based buds often attain the same size as the parent cells before becoming detached. On occasion, larger “giant” yeast forms (&gt;40 μm), or filamentous forms may be found in tissue (<link linkend="ch0147s0055s0001li0086">86</link>). Histopathologic examination using PAS or GMS stains also can be of value. Adiaspores are observed in lung tissue in cases of <emphasis>B. parvus</emphasis> infection.</para>
      </sect2>
      <sect2 id="ch0147s0028s0003">
        <title>Coccidioides Species</title>
        <anchor id="ch0147s0028s0003a0001"/>
        <anchor id="ch0147s0028s0003a0002"/>
        <para id="ch0147s0028s0003p0001">Tissue sections should be stained with PAS, GMS, or H&amp;E to permit the detection of the characteristic large, thick-walled spherules of<emphasis>Coccidioides</emphasis> species. Microscopic examination of wet preparations of sputum, bronchoalveolar lavage fluid, pus, or other samples treated with KOH is also helpful but is less sensitive. <emphasis>Prototheca wickerhamii</emphasis> may resemble small spherules, and <emphasis>Rhinosporidium seeberi</emphasis> may simulate larger ones.</para>
      </sect2>
      <sect2 id="ch0147s0028s0004">
        <title>Paracoccidioides Species</title>
        <anchor id="ch0147s0028s0004a0001"/>
        <anchor id="ch0147s0028s0004a0002"/>
        <para id="ch0147s0028s0004p0001">The characteristic translucent-walled yeast cells of<emphasis>P. brasiliensis</emphasis> and other <emphasis>Paracoccidioides</emphasis> spp. with multiple buds can often be found on direct microscopic examination of sputum, bronchoalveolar lavage fluid, pus from draining lymph nodes, or tissue biopsy specimens. Staining of wet preparations with lactophenol cotton blue, methylene blue, Gram stain, or calcofluor white can be helpful. Tissue sections can be stained with PAS, GMS, or H&amp;E.</para>
        <anchor id="ch0147s0028s0004a0003"/>
        <beginpage pagenum="2474"/>
      </sect2>
      <sect2 id="ch0147s0028s0005">
        <title>Emergomyces crescens (Adiaspiromyces crescens)</title>
        <anchor id="ch0147s0028s0005a0001"/>
        <anchor id="ch0147s0028s0005a0002"/>
        <para id="ch0147s0028s0005p0001">Tissue sections stained with PAS or GMS are most helpful in demonstrating the characteristic adiaspores in lung tissue for diagnosing adiaspore-producing fungi (<emphasis>Es. crescens</emphasis>). It is important to appreciate that in the chronic stage the organism may collapse, forming various shapes that may resemble other fungi, helminths, or pollen grains. Adiaspores must also be distinguished from the spherules of <emphasis>Coccidioides.</emphasis> Adiaspores do not contain endospores and are typically much larger than empty <emphasis>Coccidioides</emphasis> spherules.</para>
      </sect2>
      <sect2 id="ch0147s0028s0006">
        <title>Emergomyces Species</title>
        <anchor id="ch0147s0028s0006a0001"/>
        <anchor id="ch0147s0028s0006a0002"/>
        <para id="ch0147s0028s0006p0001">Tissue may show yeast forms staining positive by PAS. A phenotypic difference between the species now placed in<emphasis>Emergomyces</emphasis> (<emphasis>Es. pasteurianus, Es. africanus, Es. orientalis, Es. canadensis</emphasis>, and <emphasis>Es. europaeus</emphasis>) and the classic <emphasis>Emmonsia</emphasis> (<emphasis>Adiaspiromyces</emphasis>) species (<emphasis>Es. crescens</emphasis> and <emphasis>B. parvus</emphasis>) is that the former produce budding yeasts while the latter produce adiaspores in culture media (<link linkend="ch0147s0055s0001li0056">56</link>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0147s0029">
      <title>Antigen Detection</title>
      <anchor id="ch0147s0029a0001"/>
      <anchor id="ch0147s0029a0002"/>
      <sect2 id="ch0147s0029s0001">
        <title>Histoplasma capsulatum</title>
        <anchor id="ch0147s0029s0001a0001"/>
        <anchor id="ch0147s0029s0001a0002"/>
        <para id="ch0147s0029s0001p0001">The<emphasis>Histoplasma</emphasis> polysaccharide antigen (HPA) test is a microtiter plate-based double-antibody sandwich enzyme immunoassay (EIA) to detect antigen in urine, serum, or CSF in cases of disseminated histoplasmosis with a sensitivity up to 95% (<link linkend="ch0147s0055s0001li0087">87</link>), although it is cross-reactive with coccidioidomycosis, paracoccidioidomycosis, and talaromycosis (<link linkend="ch0147s0055s0001li0088">88</link>). This test is also useful in the early diagnosis of acute pulmonary histoplasmosis and during treatment follow-up (<link linkend="ch0147s0055s0001li0089">89</link>). Ten milliliters of urine, 5 ml of serum, or 1 ml of CSF is the preferred volume for the HPA test, although a minimum volume of 0.5 ml of any specimen is required for a single test. Although it has been recommended that both serum and urine specimens be obtained, urine antigen testing alone is sufficient (<link linkend="ch0147s0055s0001li0090">90</link>). Treatment success or failure may be assessed by collecting specimens at least 14 days after starting treatment and testing the newly acquired samples in parallel with the last specimen that was positive before initiation of treatment (<link linkend="ch0147s0055s0001li0091">91</link>). This test is performed on a fee-for-service basis by several commercial laboratories. Since those assays were designed, a commercial <emphasis>Histoplasma</emphasis> antigen capture monoclonal antibody enzyme-linked immunosorbent assay (ELISA) (IMMY monoclonal ELISA; HGM), has been developed by IMMY (Immuno-Mycologics, Norman, Oklahoma, USA). The reagents have been evaluated in two laboratories in the United States and showed high performance in diagnosing histoplasmosis (<link linkend="ch0147s0055s0001li0092">92</link>, <link linkend="ch0147s0055s0001li0093">93</link>); they have now also been tested in two Latin American countries (Colombia and Guatemala) with excellent sensitivity (98%) and specificity (97%) (<link linkend="ch0147s0055s0001li0094">94</link>). Antigen detection kits have recently become commercially available (<link linkend="ch0147s0055s0001li0060">60</link>), facilitating implementation in clinical laboratories and reducing technical issues related to reproducibility and quality control. A very important advancement is the recent development of a histoplasma antigen lateral-flow assay that holds promise as a simple and reliable testing platform (sensitivity 96%, specificity 90%), but it is not yet commercially available (<link linkend="ch0147s0055s0001li0095">95</link>).</para>
        <para id="ch0147s0029s0001p0002">The detection of serum (1→3)-β-<emphasis role="smallcaps">D</emphasis>-glucan (BG), a component of the fungal cell wall, has undergone limited evaluation in histoplasmosis; however, preliminary evidence suggests that it is useful in the detection of histoplasmosis (87% sensitivity and 65% specificity), yet a positive result must be confirmed with <emphasis>Histoplasma</emphasis> specific testing (<link linkend="ch0147s0055s0001li0096">96</link>).</para>
      </sect2>
      <sect2 id="ch0147s0029s0002">
        <title>Blastomyces Species</title>
        <anchor id="ch0147s0029s0002a0001"/>
        <anchor id="ch0147s0029s0002a0002"/>
        <para id="ch0147s0029s0002p0001"><emphasis>Blastomyces</emphasis> antigen testing is a microtiter plate-based double-antibody sandwich EIA to detect antigenuria and antigenemia in disseminated blastomycosis. The sensitivity is 89% in disseminated blastomycosis, with higher sensitivity in urine than in serum (<link linkend="ch0147s0055s0001li0097">97</link>). However, specificity is modest and only 79% overall due to cross-reactivity with other endemic agents of mycoses (<link linkend="ch0147s0055s0001li0088">88</link>). Clinical reports have suggested a lower sensitivity, but serial urine testing is useful for monitoring disease (<link linkend="ch0147s0055s0001li0098">98</link>). This test is provided on a fee-for-service basis by MiraVista Diagnostics.</para>
        <para id="ch0147s0029s0002p0002">The detection of serum BG in blastomycosis has been incompletely evaluated; however, preliminary evidence suggests that it is not useful in the detection of<emphasis>Blastomyces</emphasis> (<link linkend="ch0147s0055s0001li0096">96</link>).</para>
      </sect2>
      <sect2 id="ch0147s0029s0003">
        <title>Coccidioides Species</title>
        <anchor id="ch0147s0029s0003a0001"/>
        <anchor id="ch0147s0029s0003a0002"/>
        <para id="ch0147s0029s0003p0001">A coccidioidal urinary antigen test (MiraVista) has also been developed and exhibited a sensitivity of 71% in a largely immunosuppressed population (<link linkend="ch0147s0055s0001li0099">99</link>). In a veterinary (canine) population, the sensitivity was shown to be much lower (&lt;20%) (<link linkend="ch0147s0055s0001li0100">100</link>). Antigen testing may be useful in testing CSF (<link linkend="ch0147s0055s0001li0101">101</link>). The sample requirements are the same as those for the HPA test. An antigen test detecting coccidioidal chitinase-1 has been recently developed and is pending prospective evaluation (<link linkend="ch0147s0055s0001li0102">102</link>).</para>
        <para id="ch0147s0029s0003p0002">Serum (1→3)-β-<emphasis role="smallcaps">D</emphasis>-glucan has undergone limited evaluation in the detection of coccidioidomycosis and has a limited role (44% sensitivity) in this population (<link linkend="ch0147s0055s0001li0103">103</link>).</para>
      </sect2>
      <sect2 id="ch0147s0029s0004">
        <title>Paracoccidioides Species</title>
        <anchor id="ch0147s0029s0004a0001"/>
        <anchor id="ch0147s0029s0004a0002"/>
        <para id="ch0147s0029s0004p0001">At present, paracoccidioidomycosis antigen testing is not available as a routine diagnostic test. A 43-kDa glycoprotein and an 87-kDa heat shock protein have been described as useful targets for serum antigen detection (<link linkend="ch0147s0055s0001li0104">104</link>, <link linkend="ch0147s0055s0001li0105">105</link>). Several reports have described the detection of <emphasis>P. brasiliensis</emphasis> antigen in urine, CSF, and bronchoalveolar lavage fluid samples (<link linkend="ch0147s0055s0001li0105">105</link>). Others have noted that antigen levels in serum diminished or even disappeared during successful treatment (<link linkend="ch0147s0055s0001li0106">106</link>).</para>
      </sect2>
      <sect2 id="ch0147s0029s0005">
        <title>Emergomyces (Adiaspiromyces) crescens</title>
        <anchor id="ch0147s0029s0005a0001"/>
        <anchor id="ch0147s0029s0005a0002"/>
        <para id="ch0147s0029s0005p0001">No antigen test exists at this time for the diagnosis of adiaspiromycosis.</para>
      </sect2>
      <sect2 id="ch0147s0029s0006">
        <title>Emergomyces Species</title>
        <anchor id="ch0147s0029s0006a0001"/>
        <anchor id="ch0147s0029s0006a0002"/>
        <para id="ch0147s0029s0006p0001">No antigen test exists at this time for the diagnosis of emergomycosis, and<emphasis>Emergomyces</emphasis> spp. do not appear to reliably produce (1→3)-β-<emphasis role="smallcaps">D</emphasis>-glucan (<link linkend="ch0147s0055s0001li0055">55</link>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0147s0030">
      <title>Nucleic Acid Detection in Clinical Materials</title>
      <anchor id="ch0147s0030a0001"/>
      <anchor id="ch0147s0030a0002"/>
      <para id="ch0147s0030p0001">Only recently has a commercially available system become available for the detection of fungal nucleic acids in human clinical samples (GeneSTAT.MDx<emphasis>Coccidioides</emphasis> test) (see below). However, a number of in-house methods remain under investigation, several of which are highlighted in this section. Conserved regions of rRNA genes have been used as targets in a number of PCR-based detection assays. It is important to appreciate that amplification of conserved genes can result in products derived both from pathogenic fungi and from genetically related nonpathogenic fungal species. The nonspecific nucleic acids could arise from colonization of the original sample with saprophytic organisms, from contamination during sample collection, or from contamination of PCR reagents with fungal DNA. It is very important that the identity of amplicons detected using conserved genes be verified by direct sequencing. In more recent studies, genes specific to the fungus of interest have been chosen as PCR targets, thus eliminating this specificity problem.</para>
      <anchor id="ch0147s0030a0003"/>
      <beginpage pagenum="2475"/>
      <sect2 id="ch0147s0030s0001">
        <title>Histoplasmosis</title>
        <anchor id="ch0147s0030s0001a0001"/>
        <anchor id="ch0147s0030s0001a0002"/>
        <para id="ch0147s0030s0001p0001">An increasing number of publications have described the use of PCR to detect<emphasis>H. capsulatum</emphasis> DNA in fixed paraffin-embedded tissue samples, blood, bronchial lavage fluids, bone marrow, and ophthalmic samples. Early studies targeted the internal transcribed spacer (ITS) rRNA gene region, but the use of targets unique to <emphasis>H. capsulatum</emphasis> has provided better assay specificity. Bialek et al. designed a nested PCR that targeted the gene coding for a unique 100-kDa protein of <emphasis>H. capsulatum</emphasis> (<link linkend="ch0147s0055s0001li0107">107</link>), which has successfully been used to detect <emphasis>H. capsulatum</emphasis> DNA in clinical samples (bronchoalveolar lavage fluid, sputum, biopsy specimens, body fluid, and whole blood) from patients with histoplasmosis in French Guiana and Colombia (sensitivity, 100%; specificity, 95%) (<link linkend="ch0147s0055s0001li0108">108</link>, <link linkend="ch0147s0055s0001li0109">109</link>). The original format of nested or seminested PCR has been adapted to real-time PCR and offers some advantages over culture methods, such as rapid analysis and increased sensitivity (<link linkend="ch0147s0055s0001li0110">110</link>). This work has been expanded on with the development of a reverse transcription-quantitative PCR (RT-qPCR) assay with high sensitivity, allowing the diagnosis of histoplasmosis from blood and bronchoalveolar lavage fluid (<link linkend="ch0147s0055s0001li0111">111</link>).</para>
      </sect2>
      <sect2 id="ch0147s0030s0002">
        <title>Blastomycosis</title>
        <anchor id="ch0147s0030s0002a0001"/>
        <anchor id="ch0147s0030s0002a0002"/>
        <para id="ch0147s0030s0002p0001">PCR of ribosomal genes, the ITS region, repetitive sequences, and species- or genus-specific genes has been evaluated for the molecular detection of<emphasis>B. dermatitidis</emphasis> and <emphasis>B. gilchristii</emphasis> (<link linkend="ch0147s0055s0001li0001">1</link>). The majority of these tests have been evaluated on paraffin-embedded tissue, although a RT-PCR assay to identify <emphasis>B. dermatitidis</emphasis>/<emphasis>B. gilchristii</emphasis> in clinical specimens was recently published (<link linkend="ch0147s0055s0001li0112">112</link>).</para>
      </sect2>
      <sect2 id="ch0147s0030s0003">
        <title>Coccidioidomycosis</title>
        <anchor id="ch0147s0030s0003a0001"/>
        <anchor id="ch0147s0030s0003a0002"/>
        <para id="ch0147s0030s0003p0001">Various PCR assays have proven sensitive and specific on isolate material (<link linkend="ch0147s0055s0001li0113">113</link>). A PCR-based assay was granted approval by the Food and Drug Administration (FDA) for the detection of <emphasis>Coccidioides</emphasis> from clinical samples (GeneSTAT.MDx, available through DxNA LLC, St. George, UT) (<link linkend="ch0147s0055s0001li0114">114</link>). Few clinical studies have been published to date, although the sensitivity of PCR appears to be superior to that of culture (~50%) (<link linkend="ch0147s0055s0001li0115">115</link>, <link linkend="ch0147s0055s0001li0116">116</link>). An RT-PCR assay to distinguish <emphasis>C. immitis</emphasis> from <emphasis>C. posadasii</emphasis> was recently described (<link linkend="ch0147s0055s0001li0117">117</link>).</para>
      </sect2>
      <sect2 id="ch0147s0030s0004">
        <title>Paracoccidioidomycosis</title>
        <anchor id="ch0147s0030s0004a0001"/>
        <anchor id="ch0147s0030s0004a0002"/>
        <para id="ch0147s0030s0004p0001">The number of tests developed and evaluated so far for the detection of<emphasis>P. brasiliensis</emphasis> in clinical samples is very limited (<link linkend="ch0147s0055s0001li0060">60</link>). The preferred target sequences have been gp43 and rRNA genes. A real-time PCR targeting the ITS-1 region was developed to detect <emphasis>P. brasiliensis</emphasis> DNA in both cultures and clinical specimens. Although this molecular test was evaluated with a small number of patients, the authors reported 100% sensitivity and specificity (<link linkend="ch0147s0055s0001li0118">118</link>). A nested-PCR assay targeting the immunogenic gp43 gene was evaluated in the detection of <emphasis>P. brasiliensis</emphasis> DNA in lung homogenates from infected and uninfected mice, with 91% sensitivity (<link linkend="ch0147s0055s0001li0119">119</link>). A real-time PCR amplifying the recombinant protein PB27 gene was designed, and primers and probe sequences were deposited in Brazilian Coordination of Technological Innovation and Transfer (CTIT) (<link linkend="ch0147s0055s0001li0120">120</link>). Preliminary results using 78 clinical samples from confirmed cases showed a sensitivity of 94% and specificity of 100%. More studies are needed to further validate this test (<link linkend="ch0147s0055s0001li0120">120</link>, <link linkend="ch0147s0055s0001li0121">121</link>).</para>
      </sect2>
      <sect2 id="ch0147s0030s0005">
        <title>Adiaspiromycosis</title>
        <anchor id="ch0147s0030s0005a0001"/>
        <anchor id="ch0147s0030s0005a0002"/>
        <para id="ch0147s0030s0005p0001">A panfungal PCR targeting the ribosomal ITS-1 and -2 regions identified<emphasis>A. crescens</emphasis> from a bronchoalveolar lavage fluid sample of a patient with confirmed adiaspiromycosis (<link linkend="ch0147s0055s0001li0122">122</link>); however, PCR testing for these organisms has thus far been limited.</para>
      </sect2>
      <sect2 id="ch0147s0030s0006">
        <title>Emergomycosis</title>
        <anchor id="ch0147s0030s0006a0001"/>
        <anchor id="ch0147s0030s0006a0002"/>
        <para id="ch0147s0030s0006p0001">PCR of tissue biopsies using broad fungal targets (targeting a region of the 28S rRNA and the ITS-2 regions) have been assessed for the detection of<emphasis>Emergomyces</emphasis> spp. (<link linkend="ch0147s0055s0001li0055">55</link>, <link linkend="ch0147s0055s0001li0123">123</link>).</para>
      </sect2>
      <sect2 id="ch0147s0030s0007">
        <title>ISOLATION PROCEDURES</title>
        <anchor id="ch0147s0030s0007a0001"/>
        <anchor id="ch0147s0030s0007a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0147s0031">
      <title>Biosafety</title>
      <anchor id="ch0147s0031a0001"/>
      <anchor id="ch0147s0031a0002"/>
      <para id="ch0147s0031p0001">The mere lifting of a culture plate lid is often sufficient to cause the release of large numbers of conidia into the air, and screw-cap tubes or sealed plates should be used. Should a sporulating culture be dropped, millions of conidia may be dispersed. It is also important to note that local infections, including granuloma formation, have been reported following accidental percutaneous inoculation during injection of laboratory animals or while performing autopsies of humans with histoplasmosis, coccidioidomycosis, or blastomycosis (<link linkend="ch0147s0055s0001li0124">124</link>).</para>
      <para id="ch0147s0031p0002">All procedures involving the manipulation of sporulating cultures of<emphasis>Coccidioides, Paracoccidioides, Blastomyces, Emergomyces</emphasis>, and <emphasis>Histoplasma</emphasis> species and for processing soil or other environmental materials known or likely to contain these organisms should be performed inside a class II biological safety cabinet under conditions of biosafety level 3 containment. Biosafety level 2 practices and facilities are recommended for handling and processing clinical specimens and animal tissues (<link linkend="ch0147s0055s0001li0125">125</link>). Hyaline molds of unknown identity should always be examined and manipulated inside a class II biosafety cabinet. Such molds should never be handled on an open laboratory bench.</para>
      <para id="ch0147s0031p0003">Although<emphasis>Emergomyces</emphasis> species have not been formally classified as risk group II or III pathogens, it is recommended that mycelial cultures of these fungi be handled carefully in a class II biosafety cabinet with additional use of personal protective equipment, e.g., N95 respirator masks (<link linkend="ch0147s0055s0001li0057">57</link>).</para>
    </sect1>
    <sect1 id="ch0147s0032">
      <title>Culture for Mold Phase</title>
      <anchor id="ch0147s0032a0001"/>
      <anchor id="ch0147s0032a0002"/>
      <para id="ch0147s0032p0001">In general, the organisms discussed in this chapter can be readily cultivated in the mold phase on general fungal media, such as Sabouraud dextrose agar or potato dextrose agar, incubated at 25°C. Incubation at 37°C is also helpful to recover the yeast phase of most dimorphic organisms. Media containing antibiotics such as chloramphenicol or gentamicin should be used when culturing clinical materials, such as sputum, that may be contaminated with bacteria. Media containing cycloheximide are useful to inhibit saprophytic fungi and to provide a useful differential tool in identification. Many unrelated saprophytic soil fungi fail to grow on media containing cycloheximide, fail to grow altogether at 37°C, or fail to convert to the yeast phase at 37°C. Screw-cap slants are preferable to plates for culturing dimorphic fungi. If plates are used, they should be sealed so that mold spores cannot escape into the ambient air. Seals that are permeable to air, such as Shrink Seals (Scientific Device Laboratory, Des Plaines, IL), are useful for this purpose. In general, colonies develop within 3 to 7 days, but some strains of<emphasis>Histoplasma</emphasis> and <emphasis>Paracoccidioides</emphasis> may require incubation for as long as 4 to 6 weeks.</para>
      <anchor id="ch0147s0032a0003"/>
      <beginpage pagenum="2476"/>
    </sect1>
    <sect1 id="ch0147s0033">
      <title>Culture for Yeast Phase</title>
      <anchor id="ch0147s0033a0001"/>
      <anchor id="ch0147s0033a0002"/>
      <para id="ch0147s0033p0001"><emphasis>Histoplasma, Blastomyces</emphasis>, and <emphasis>Paracoccidioides</emphasis> species can be recovered in the yeast phase by using appropriate media incubated at 37°C, although this is seldom performed in clinical laboratories, as the rate of conversion from the mycelial form is not 100%. At human body temperature, <emphasis>Emergomyces</emphasis> colonies appear yeast-like: small, cream to smooth grey-brown, and heaped (<link linkend="ch0147s0055s0001li0004">4</link>).</para>
      <sect2 id="ch0147s0033s0001">
        <title>Histoplasma capsulatum</title>
        <anchor id="ch0147s0033s0001a0001"/>
        <anchor id="ch0147s0033s0001a0002"/>
        <para id="ch0147s0033s0001p0001">The yeast phase of<emphasis>Histoplasma</emphasis> spp. can be recovered in rich media such as brain heart infusion agar (BHI) or BHI with blood (BHIB). Plates or slants should be incubated at 37°C under aerobic conditions for at least 4 weeks.</para>
      </sect2>
      <sect2 id="ch0147s0033s0002">
        <title>Blastomyces Species</title>
        <anchor id="ch0147s0033s0002a0001"/>
        <anchor id="ch0147s0033s0002a0002"/>
        <para id="ch0147s0033s0002p0001">The yeast phase of<emphasis>Blastomyces dermatitis</emphasis>/<emphasis>B. gilchristii</emphasis> can be induced by culturing on rich media such as BHI, BHIB, Pine’s medium, and Kelley’s agar by incubation at 37°C under aerobic conditions. Yeasts are usually visible within 1 to 2 weeks, but media should be held for at least 4 weeks before being discarded. <emphasis>B. parvus</emphasis> produces adiaspores <emphasis>in vitro</emphasis> within 3 weeks when cultivated on Phytone yeast extract agar, BHI, or BHIB (<link linkend="ch0147s0055s0001li0015">15</link>).</para>
        <anchor id="ch0147s0033s0002a0003"/>
        <beginpage pagenum="2477"/>
      </sect2>
      <sect2 id="ch0147s0033s0003">
        <title>Paracoccidioides Species</title>
        <anchor id="ch0147s0033s0003a0001"/>
        <anchor id="ch0147s0033s0003a0002"/>
        <para id="ch0147s0033s0003p0001">The yeast phase of<emphasis>Paracoccidioides</emphasis> species can be recovered in media such as BHI, Pine’s medium, or Kelley’s agar by incubation at 37°C. The organism grows slowly, and plates or slants should be held for at least 4 weeks.</para>
      </sect2>
      <sect2 id="ch0147s0033s0004">
        <title>Emergomyces (Adiaspiromyces) crescens</title>
        <anchor id="ch0147s0033s0004a0001"/>
        <anchor id="ch0147s0033s0004a0002"/>
        <para id="ch0147s0033s0004p0001"><emphasis>Emergomyces (Adiaspiromyces) crescens</emphasis> produce adiaspores <emphasis>in vitro</emphasis> when cultivated on Phytone yeast extract agar, BHI, or BHIB at 37°C to 40°C for 2 to 4 weeks.</para>
      </sect2>
      <sect2 id="ch0147s0033s0005">
        <title>Emergomyces Species</title>
        <anchor id="ch0147s0033s0005a0001"/>
        <anchor id="ch0147s0033s0005a0002"/>
        <para id="ch0147s0033s0005p0001"><emphasis>Es. pasteurianus</emphasis> produces yeast-like cells after culture on BHI at 37°C for approximately 10 days. The <emphasis>Emergomyces</emphasis> species recently recognized in South Africa do not produce adiaspores at 37°C or 40°C, although the mycelial cultures were converted to the yeast phase by incubating streaked or single-colony subcultures on brain heart infusion agar at 37°C after 10 to 14 days (<link linkend="ch0147s0055s0001li0056">56</link>).</para>
      </sect2>
      <sect2 id="ch0147s0033s0006">
        <title>IDENTIFICATION</title>
        <anchor id="ch0147s0033s0006a0001"/>
        <anchor id="ch0147s0033s0006a0002"/>
        <para id="ch0147s0033s0006p0001">In general, these organisms may be identified by their characteristic morphologic features, including conversion to the yeast phase, although this is infrequently done in clinical laboratories, and identification is more frequently confirmed by direct DNA sequencing. Slide cultures should not be performed on suspected dimorphic isolates due to the possibility of laboratory infection from accidental inhalation of infectious conidia unless biosafety level 3 facilities are available.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0147s0034">
      <title>Histoplasma capsulatum</title>
      <anchor id="ch0147s0034a0001"/>
      <anchor id="ch0147s0034a0002"/>
      <para id="ch0147s0034p0001">The mold phase of<emphasis>H. capsulatum</emphasis> can be recovered after incubation at 25°C. The colony is initially white or buff-brown. Both types may be isolated from the same patient, and eventually the brown type may convert to the white type. On subculture, as few as 30% of macroconidia show tubercles. Microconidia are abundant in fresh isolates of <emphasis>H. capsulatum.</emphasis> After multiple subcultures, the production of both macroconidia and microconidia may be diminished. The presence of both macroconidia and microconidia is not required for identification of <emphasis>H. capsulatum</emphasis>, as authentic <emphasis>H. capsulatum</emphasis> isolates that fail to produce either macroconidia or microconidia have been recognized (<link linkend="ch0147s0055s0001li0126">126</link>). Macroconidia but no microconidia can also be seen in the saprophytic fungus <emphasis>Sepedonium</emphasis> as well as in the <emphasis>Chrysosporium</emphasis> state of the fungus <emphasis>Renispora flavissima</emphasis> (<link linkend="ch0147s0055s0001li0127">127</link>). Authentic <emphasis>H. capsulatum</emphasis> isolates can be phenotypically recognized by their thermal dimorphism, slow growth, and the presence of both tuberculate macroconidia and microconidia.</para>
      <para id="ch0147s0034p0002">Once the characteristic morphology has been recognized, mold-phase<emphasis>H. capsulatum</emphasis> isolates can be confirmed by conversion to the yeast phase, although this is infrequently done in clinical laboratories. If conversion to the yeast phase is desired, the isolate is transferred to BHI or BHIB agar and incubated at 37°C for at least 7 to 10 days. Hyphal cells may form buds directly or develop enlarged, transitional cells that subsequently begin to bud. The microconidia may also convert to budding yeast cells. Complete conversion rarely is achieved, and multiple transfers to fresh BHI or BHIB medium may be required. The colony develops a white, smooth, yeast-like appearance, and microscopic examination reveals oval, budding yeasts approximately 1 to 3 by 3 to 5 μm. <emphasis>Histoplasma</emphasis> cells have a narrower base of attachment between the bud and parent cell than do those of <emphasis>B. dermatitidis</emphasis>.</para>
      <para id="ch0147s0034p0003">The AccuProbe test (Hologic, San Diego, CA) was previously used to confirm isolates as<emphasis>H. capsulatum</emphasis>; however, this test is no longer available. The use of matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) for culture identification has also been validated and allows prompt and simple identification from either yeast or mycelial cultures (<link linkend="ch0147s0055s0001li0128">128</link>). Panfungal RT-PCR for diagnosis is also used for culture identification in some labs and reference centers and has high reproducibility and specificity.</para>
    </sect1>
    <sect1 id="ch0147s0035">
      <title>Blastomyces Species</title>
      <anchor id="ch0147s0035a0001"/>
      <anchor id="ch0147s0035a0002"/>
      <para id="ch0147s0035p0001">At 25 to 30°C, isolates of<emphasis>Blastomyces dermatitidis</emphasis>/<emphasis>B. gilchristii</emphasis> produce a variety of forms ranging from a fluffy white colony that is visible within 2 to 3 days to a glabrous, tan, nonconidiating colony that grows more slowly on Sabouraud dextrose agar. Microscopic examination shows microconidia that are oval or pyriform, usually smooth walled, and formed on short lateral or terminal branches along the hyphae. Atypical forms of <emphasis>Blastomyces</emphasis> are infrequently encountered in tissue (very small or microforms, 2 to 4 μm in diameter) (<link linkend="ch0147s0055s0001li0061">61</link>). <emphasis>Blastomyces dermatitidis</emphasis>/<emphasis>B. gilchristii</emphasis> also grow readily on inhibitory media containing cycloheximide. Conidia of <emphasis>Scedosporium apiospermum</emphasis> and of some <emphasis>Chrysosporium</emphasis> species are morphologically similar and can be mistaken for <emphasis>Blastomyces</emphasis> species. These species either fail to grow at 37°C (some <emphasis>Chrysosporium</emphasis> species) or grow as molds when incubated at 37°C <emphasis>(S. apiospermum</emphasis>).</para>
      <para id="ch0147s0035p0002">The identification can be confirmed by conversion to the yeast phase. Generally, isolates of<emphasis>Blastomyces dermatitidis</emphasis>/<emphasis>B. gilchristii</emphasis> convert readily to the yeast phase on BHI, BHIB, or Pine’s or Kelley’s medium incubated at 37°C. Yeast cells are hyaline, smooth walled, and thick walled, generally 8 to 15 μm in diameter, with the bud connected to the parent cell by a broad base up to 4 to 5 μm in diameter. Conversion may be observed in 2 to 3 days, although it more commonly takes 1 to 2 weeks. <emphasis>B. parvus</emphasis> produces hyphae at 37°C and produces smaller adiaspores (8 to 20 μm in diameter) at 40°C. <emphasis>B. parvus</emphasis> and <emphasis>A. crescens</emphasis> are indistinguishable in morphology and appearance at 25°C.</para>
    </sect1>
    <sect1 id="ch0147s0036">
      <title>Coccidioides Species</title>
      <anchor id="ch0147s0036a0001"/>
      <anchor id="ch0147s0036a0002"/>
      <para id="ch0147s0036p0001">At 25 to 30°C, isolates of<emphasis>Coccidioides</emphasis> species display considerable variation in colony morphology. Colonies can range from moist, glabrous, and grayish to abundant, floccose, and white. Colonies may become tan and even red with age on Sabouraud dextrose agar or 2×GYE (<link linkend="ch0147s0055s0001li0129">129</link>). Microscopic examination shows hyphae that are thin and septate, with fertile (spore-producing) hyphae usually arising at right angles. Arthroconidia are hyaline, one-celled, short, cylindrical to barrel shaped, moderately thick walled, smooth walled, and 2 to 8 by 3 to 5 μm. Arthroconidia alternate with thin-walled empty disjunctor cells. At maturity, the disjunctor cells undergo lytic degradation, releasing the arthroconidia. After this fragmentation, the arthroconidia may display frill-like remains of the disjunctor cells on each end. Isolates of <emphasis>Coccidioides</emphasis> grow well on inhibitory mold agar containing cycloheximide, which helps to distinguish this organism from similar soil saprophytes such as <emphasis>Malbranchea</emphasis> species. It is also important to distinguish true alternate arthroconidia from aging mycelia that, due to cytoplasmic shrinkage, display an appearance that can be misinterpreted as arthroconidia. True arthroconidia eventually fragment and disperse; aging mycelia do not. The two species of <emphasis>Coccidioides</emphasis> cannot be readily distinguished morphologically.</para>
      <para id="ch0147s0036p0002">When incubated at 37°C<emphasis>in vitro</emphasis>, the spherule/endospore form is produced. The organism can produce spherules <emphasis>in vitro</emphasis> when incubated at 37 to 40°C in appropriate media and increased CO<subscript>2</subscript> tension, but this procedure is rarely performed on routine clinical isolates (<link linkend="ch0147s0055s0001li0130">130</link>).</para>
      <para id="ch0147s0036p0003">The AccuProbe test for<emphasis>Coccidioides</emphasis> has been discontinued.</para>
    </sect1>
    <sect1 id="ch0147s0037">
      <title>Paracoccidioides Species</title>
      <anchor id="ch0147s0037a0001"/>
      <anchor id="ch0147s0037a0002"/>
      <para id="ch0147s0037p0001">When incubated at 25 to 30°C, isolates display slow growth and produce a variety of forms ranging from glabrous leathery, brownish, flat colonies with a few tufts of aerial mycelium to wrinkled, folded, floccose colonies to velvety, white-to-beige forms on Sabouraud dextrose agar. The colonies are very similar in appearance to those of<emphasis>B. dermatitidis.</emphasis> Most strains grow for long periods of time without the production of conidia.</para>
      <para id="ch0147s0037p0002">When cultures are transferred to 37°C on rich media such as BHI or Pine’s or Kelley’s agar, the resulting yeast colonies are generally folded (cerebriform) in appearance. Mycelial elements may be seen mixed with yeast cells. Conversion to the yeast phase also is quite slow. Yeasts are 2 to 30 μm in diameter and are oval or irregular in shape, displaying the characteristic pilot’s-wheel appearance of multiple thin-necked round buds developing around the parent cell. The walls are thinner than those of<emphasis>B. dermatitidis</emphasis> yeast cells, and the buds are not broad based.</para>
      <para id="ch0147s0037p0003">Identification is usually confirmed by demonstrating thermal dimorphism. Slow-growing, nonsporulating isolates are more characteristic of<emphasis>P. brasiliensis</emphasis> than of <emphasis>B. dermatitidis</emphasis>.</para>
    </sect1>
    <sect1 id="ch0147s0038">
      <title>Emergomyces (Adiaspiromyces) crescens</title>
      <anchor id="ch0147s0038a0001"/>
      <anchor id="ch0147s0038a0002"/>
      <para id="ch0147s0038p0001">At 25°C,<emphasis>Adiaspiromyces crescens</emphasis> grow as glabrous (waxy), colorless colonies, which produce yellowish white aerial mycelia in time. Some strains display pale orange to grayish orange aerial mycelia. The colonies often have areas that alternate between a tufted mycelium and a glabrous consistency. Reverse pigmentation is pale gray to grayish brown on Sabouraud dextrose or potato dextrose agar. On microscopic examination, the hyphae are septate and branching. Sporulation is enhanced on potato dextrose or pablum cereal agar. Numerous conidia are produced either directly from the sides of the hyphae or on short stalks that branch at right angles from the hyphae. Each stalk bears a single terminal conidium. Sometimes the swollen end may bear one to three secondary spine-like pegs, which in turn form a secondary conidium in a flower-like arrangement (<link linkend="ch0147s0055s0001li0131">131</link>). The conidia are round, oval, or pyriform and measure 2 to 4 μm by 3 to 5 μm. The conidial wall is smooth but may roughen with age. <emphasis>B parvus</emphasis> and <emphasis>A. crescens</emphasis> are indistinguishable in morphology and appearance at 25°C.</para>
      <para id="ch0147s0038p0002"><emphasis>Es. crescens</emphasis> displays no hyphal growth at 37°C and forms larger adiaspores (20 to 140 μm in diameter) on BHI or Phytone yeast extract agar at this temperature.</para>
    </sect1>
    <sect1 id="ch0147s0039">
      <title>Emergomyces Species</title>
      <anchor id="ch0147s0039a0001"/>
      <anchor id="ch0147s0039a0002"/>
      <para id="ch0147s0039p0001"><emphasis>Emergomyces pasteurianus</emphasis> displays some features at 25°C that are similar to those of <emphasis>Es. crescens</emphasis> and <emphasis>B. parvus.</emphasis> At 37°C on BHIB, this species produces yeast-like cells that are oval or lemon shaped, budding on a narrow base, and 2 to 4 μm. The colonies are creamy and smooth. This species does not produce adiaspores <emphasis>in vitro</emphasis> or <emphasis>in vivo</emphasis> (<link linkend="ch0147s0055s0001li0132">132</link>). Since the genus <emphasis>Emergomyces</emphasis> has been only recently proposed and described, it may be too early to give general guidelines for the recognition of each of its five species, <emphasis>Es. pasteurianus, Es. africanus, Es. orientalis, Es. canadensis</emphasis>, and <emphasis>Es. europaeus</emphasis>.</para>
      <sect2 id="ch0147s0039s0001">
        <title>TYPING SYSTEMS</title>
        <anchor id="ch0147s0039s0001a0001"/>
        <anchor id="ch0147s0039s0001a0002"/>
        <para id="ch0147s0039s0001p0001">In general, typing systems have been used to show geographic differences among isolates and cryptic species. In some genera, diversity can be shown among isolates collected from a single geographic area.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0147s0040">
      <title>Histoplasma capsulatum</title>
      <anchor id="ch0147s0040a0001"/>
      <anchor id="ch0147s0040a0002"/>
      <para id="ch0147s0040p0001">Isolates can be divided into at least eight clades, as described earlier (<link linkend="ch0147s0055s0001li0007">7</link>). This typing system can be used to place an unknown isolate into one of the major worldwide geographic groupings. For further delineation, restriction fragment length polymorphism (RFLP) typing with the yeast phase-specific nuclear gene <emphasis>yps-3</emphasis> and/or mitochondrial DNA probes and randomly amplified polymorphic DNA-based and ITS-based typing methods have been used in several studies (<link linkend="ch0147s0055s0001li0133">133</link>). These studies have shown that considerable polymorphisms can be demonstrated among individual patient isolates from a particular geographic location (<link linkend="ch0147s0055s0001li0133">133</link>), that animal and soil strains from Brazil display indistinguishable subtypes (<link linkend="ch0147s0055s0001li0134">134</link>), and that strains from patients in Brazil, where mucocutaneous histoplasmosis is much more common than in the United States, display distinct ITS and <emphasis>yps-3</emphasis> subtypes not seen in strains from U.S. patients (<link linkend="ch0147s0055s0001li0135">135</link>). Subsequently, a study compared multiple typing methods that have been developed to study <emphasis>H. capsulatum</emphasis> epidemiology in 51 environmental, animal, and human isolates from Brazil. The M13 PCR fingerprinting and PCR-RFLP analyses produced very similar results and separated the <emphasis>H. capsulatum</emphasis> isolates into three major groups (<link linkend="ch0147s0055s0001li0136">136</link>). These groups have been proposed to represent cryptic species: <emphasis>H. mississippiense</emphasis> (NAm1) and <emphasis>H. ohiense</emphasis> (NAm2) are endemic to North America, while <emphasis>H. capsulatum</emphasis> (Panama), <emphasis>H. suramericanum</emphasis> (LAmA), and other genetic clusters, such as LAmB, Northeast BR1, and Northeast BR2, are endemic to Latin America (<link linkend="ch0147s0055s0001li0137">137</link>).</para>
      <anchor id="ch0147s0040a0003"/>
      <beginpage pagenum="2478"/>
    </sect1>
    <sect1 id="ch0147s0041">
      <title>Blastomyces Species</title>
      <anchor id="ch0147s0041a0001"/>
      <anchor id="ch0147s0041a0002"/>
      <para id="ch0147s0041p0001">In a study using RFLP analysis with several rRNA gene probes to study 59 isolates from the United States, India, and Africa, three major groups were defined. These groups were further divided using randomly amplified polymorphic DNA fingerprinting into 5, 15, and 12 types, respectively, that correlated with the geographic origin of the isolate (<link linkend="ch0147s0055s0001li0138">138</link>). Interestingly, these studies showed that soil isolates collected from an outbreak of blastomycosis in Eagle River, WI, were not responsible for the majority of cases of disease in that outbreak. A study exploring polymorphisms in the promoter region upstream of the <emphasis>BAD-1</emphasis> virulence gene revealed further genetic diversity with large insertions in the promoter region (<link linkend="ch0147s0055s0001li0139">139</link>). A modification in the taxonomy of this genus has resulted in the removal of the genus <emphasis>Emmonsia</emphasis>, and several of these species are now classified as <emphasis>Blastomyces</emphasis> species (<link linkend="ch0147s0055s0001li0004">4</link>). Isolates of <emphasis>B. parvus</emphasis> are separated by typing into two groups, one group isolated from the North American prairies and the second group from the desert southwest of the United States or from Italy (<link linkend="ch0147s0055s0001li0015">15</link>).</para>
    </sect1>
    <sect1 id="ch0147s0042">
      <title>Coccidioides Species</title>
      <anchor id="ch0147s0042a0001"/>
      <anchor id="ch0147s0042a0002"/>
      <para id="ch0147s0042p0001">Two major clades, corresponding to the species<emphasis>C. immitis</emphasis> and <emphasis>C. posadasii</emphasis>, were defined when an extensive population sample, including isolates from Venezuela, Mexico, and Brazil, was studied by using a set of nine microsatellite markers (<link linkend="ch0147s0055s0001li0140">140</link>). Typing of isolates to <emphasis>C. immitis</emphasis> (CA) or <emphasis>C. posadasii</emphasis> (non-CA) species can be accomplished by examining any of 17 sites fixed for alternate alleles (<link linkend="ch0147s0055s0001li0141">141</link>). Microsatellite typing conducted with 121 clinical isolates from Arizona concluded that this disease in Arizona could not be linked to a dominant strain of <emphasis>C. posadasii</emphasis> (<link linkend="ch0147s0055s0001li0142">142</link>). More recent work using whole-genome sequencing has identified <emphasis>C. posadasii</emphasis> as the more ancient of the two species and demonstrates evidence of distinct geographic clades within Arizona (<link linkend="ch0147s0055s0001li0020">20</link>).</para>
    </sect1>
    <sect1 id="ch0147s0043">
      <title>Paracoccidioides Species</title>
      <anchor id="ch0147s0043a0001"/>
      <anchor id="ch0147s0043a0002"/>
      <para id="ch0147s0043p0001">Multilocus sequence typing at eight loci demonstrated the existence of numerous distinct species within<emphasis>Paracoccidioides</emphasis> (<link linkend="ch0147s0055s0001li0023">23</link>). The <emphasis>gp43</emphasis> gene encoding a dominant glycoprotein antigen has been studied by several groups as a useful target for subtyping. In an earlier study, microsatellite sequences were compared as markers to discriminate among a set of <emphasis>P. brasiliensis</emphasis> human isolates causing either chronic or acute disease (<link linkend="ch0147s0055s0001li0143">143</link>). The authors did not observe any clustering of isolates associated with either acute or chronic disease.</para>
    </sect1>
    <sect1 id="ch0147s0044">
      <title>Emergomyces (Adiaspiromyces) crescens</title>
      <anchor id="ch0147s0044a0001"/>
      <anchor id="ch0147s0044a0002"/>
      <para id="ch0147s0044p0001">Based on ITS sequences, isolates of<emphasis>Es. crescens</emphasis> fall into two phylogenetic groups, North American and Eurasian, depending on the continents from which the isolates were obtained (<link linkend="ch0147s0055s0001li0001">1</link>).</para>
    </sect1>
    <sect1 id="ch0147s0045">
      <title>Emergomyces Species</title>
      <anchor id="ch0147s0045a0001"/>
      <anchor id="ch0147s0045a0002"/>
      <para id="ch0147s0045p0001">Multilocus sequence typing (e.g., using sequences from rDNA large subunit, ITS, beta tubulin, and two other conserved genes) has been found to be useful for resolving groups within<emphasis>Emergomyces</emphasis> (<link linkend="ch0147s0055s0001li0004">4</link>, <link linkend="ch0147s0055s0001li0056">56</link>).</para>
      <sect2 id="ch0147s0045s0001">
        <title>SEROLOGIC TESTS</title>
        <anchor id="ch0147s0045s0001a0001"/>
        <anchor id="ch0147s0045s0001a0002"/>
        <para id="ch0147s0045s0001p0001">Serologic tests for endemic mycoses are available as kits for in-house testing or as laboratory-derived tests at specialized testing centers.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0147s0046">
      <title>Histoplasmosis</title>
      <anchor id="ch0147s0046a0001"/>
      <anchor id="ch0147s0046a0002"/>
      <para id="ch0147s0046p0001">Serologic tests have an important role in the rapid diagnosis of several forms of<emphasis>H. capsulatum</emphasis> infection but are most useful for persons with chronic pulmonary or disseminated histoplasmosis (<link linkend="ch0147s0055s0001li0144">144</link>). Of the different methods that have been developed, the immunodiffusion (ID), complement fixation (CF), and latex agglutination (LA) tests are the most popular. The principal antigen used in these tests is histoplasmin, a soluble filtrate of mycelial-phase broth cultures. Histoplasmin contains <emphasis>H. capsulatum</emphasis> species-specific H and M antigens as well as C antigen (a galactomannan antigen largely responsible for cross-reactivity with other fungi) (<link linkend="ch0147s0055s0001li0145">145</link>). The H antigen is a β-glucosidase against which antibodies are formed during acute histoplasmosis. The M antigen is a catalase against which antibodies are produced during all phases of the disease. The H and M antigens were once thought to be specific proteins for the detection of anti-<emphasis>H. capsulatum</emphasis> antibodies. The M antigen, however, was found to be not specific unless used in a deglycosylated form.</para>
      <para id="ch0147s0046p0002">The ID test is a qualitative method that detects precipitins specific to the H and M glycoprotein antigens of<emphasis>H. capsulatum</emphasis> present in histoplasmin. Both serum and CSF can be used. Patients with negative serum reactions during the acute phase of infection should have additional samples taken 3 to 4 weeks later. ID test kits and reagents are available from Gibson Laboratories (Lexington, KY), IMMY, and Meridian Bioscience (Cincinnati, OH). Commercial kits include mycelial-phase culture filtrates containing <emphasis>H. capsulatum</emphasis> H and M antigens, positive-control sera containing antibodies against both H and M antigens, and ID plates. Positive-control sera must be included each time the test is performed and must react with both the H and M antigens. The ID test is a useful screening procedure or can be used as an adjunct to the CF test. It is more specific but less sensitive than the CF test.</para>
      <para id="ch0147s0046p0003">The CF test is a quantitative procedure in which two antigens are employed: histoplasmin and a suspension of intact merthiolate-killed<emphasis>H. capsulatum</emphasis> yeast-phase cells. The latter is more sensitive (~80% versus ~20%) but less specific (~90% versus ~99%) than histoplasmin (<link linkend="ch0147s0055s0001li0091">91</link>, <link linkend="ch0147s0055s0001li0146">146</link>). Serum, peritoneal fluid, or CSF can be used in the CF test. Patients with negative serum reactions during the acute phase of infection should have additional samples taken 3 to 4 weeks later. No commercial kits are available, but antigens, antisera, and other reagents can be purchased from several commercial sources (e.g., IMMY and Meridian). Negative-control serum and positive-control serum from human histoplasmosis cases demonstrating a CF titer of 1:32 or greater with the homologous antigen should be tested each time the CF test is performed.</para>
      <para id="ch0147s0046p0004">An ELISA for the detection of antibodies to<emphasis>Histoplasma capsulatum</emphasis> using metaperiodate treated purified histoplasmin was reported with sensitivities of 100% in acute disease, 90% in chronic disease, 89% in disseminated infection in individuals without HIV infection, 86% in disseminated disease in the setting of HIV infection, and 100% in mediastinal histoplasmosis (<link linkend="ch0147s0055s0001li0147">147</link>).</para>
      <para id="ch0147s0046p0005">An LA test using histoplasmin as the antigen is commercially available (LA-Histo antibody system; IMMY). This semiquantitative test detects immunoglobulin M (IgM) antibodies and is used primarily for the presumptive diagnosis of acute histoplasmosis. It is less helpful for the detection of chronic infection. An EIA test for IgM and IgG antibodies (MiraVista) has also been found to be useful to increase the sensitivity of diagnostic testing in<emphasis>Histoplasma</emphasis> meningitis (<link linkend="ch0147s0055s0001li0148">148</link>).</para>
      <anchor id="ch0147s0046a0003"/>
      <beginpage pagenum="2479"/>
    </sect1>
    <sect1 id="ch0147s0047">
      <title>Blastomycosis</title>
      <anchor id="ch0147s0047a0001"/>
      <anchor id="ch0147s0047a0002"/>
      <para id="ch0147s0047p0001">Substantial improvement in the performance of serologic testing for blastomycosis has been achieved over the last 2 decades; however, current serologic testing is not useful for a definitive diagnosis of blastomycosis, given the cross-reactivity with other endemic mycoses. Past work has focused on the use of two purified surface antigens of<emphasis>B. dermatitidis</emphasis>, one termed the A antigen and the other the WI-1 antigen. Both molecules are released from the yeast phase of <emphasis>B. dermatitidis</emphasis> by autolysis and can be recovered from culture filtrates. Comparison of the two antigens has shown that patient serologic responses are similar (<link linkend="ch0147s0055s0001li0149">149</link>).</para>
      <para id="ch0147s0047p0002">However, serologic testing for blastomycosis lacks both the requisite sensitivity and specificity. Serologic testing by immunodiffusion measures the antibody to<emphasis>B. dermatitidis</emphasis> A antigen. This test is relatively specific, but sensitivity ranges from 28 to 64% (<link linkend="ch0147s0055s0001li0150">150</link>). Patients with negative serum reactions during the acute phase of infection should have additional samples taken 3 to 4 weeks later. An EIA is now commercially available (IMMY) and exhibits improved performance characteristics.</para>
      <para id="ch0147s0047p0003">Complement fixation testing has also been evaluated, although this test has shown even lower sensitivity and specificity (9 to 43%) (<link linkend="ch0147s0055s0001li0151">151</link>). ID test kits and reagents are available from Gibson, MiraVista, and IMMY. Commercial kits include purified <emphasis>B. dermatitidis</emphasis> A antigen, positive-control serum containing antibodies against A antigen, and ID plates. The positive-control serum must be included each time the test is performed and must react with the homologous reference antigen to form the A precipitin line.</para>
    </sect1>
    <sect1 id="ch0147s0048">
      <title>Coccidioidomycosis</title>
      <anchor id="ch0147s0048a0001"/>
      <anchor id="ch0147s0048a0002"/>
      <para id="ch0147s0048p0001">Despite the fact that sensitive procedures such as EIA have been developed, the ID and CF tests remain the most specific methods for the serologic diagnosis of coccidioidomycosis. The principal antigen used in these tests is a soluble filtrate of mycelial-phase broth cultures.</para>
      <para id="ch0147s0048p0002">The simultaneous use of heated and unheated antigens permits the ID test to be employed to detect either IgM or IgG antibodies on a single plate. The immunodiffusion tube precipitin (IDTP) test utilizes heated coccidioidin as antigen, detects IgM, and gives results comparable to those obtained with the classical tube precipitin test. It is most useful for diagnosing recent infection. The immunodiffusion complement fixation (IDCF) test utilizes unheated coccidioidin, detects IgG antibodies, and gives results comparable to those obtained by the CF method (see below). It is less sensitive but more specific than the CF test (<link linkend="ch0147s0055s0001li0152">152</link>). Commercial kits are available (Gibson, IMMY, and Meridian) and include unheated and heat-treated coccidioidin antigens, positive-control sera containing IgM or IgG antibodies, and ID plates. Positive-control sera must be included each time the test is performed and must react with the homologous reference antigen to form a precipitin line. The ID test is useful for initial screening of specimens and can be followed by other tests if positive.</para>
      <para id="ch0147s0048p0003">The CF test is a sensitive quantitative method in which unheated coccidioidin is used to detect IgG antibodies. The major disadvantage of CF is that it is a laborious and time-consuming procedure that requires experienced personnel for optimum performance. No commercial kits are available, but reagents for in-house use can be obtained from several commercial sources (IMMY and Meridian). Negative-control serum and a positive-control serum from a human case of coccidioidomycosis (with a titer of ≥1:32) should be included each time the test is performed. Anticomplementary activity in serum samples can occur and may be resolved by subsequent ID testing. In addition to serum, the CF test can be performed with CSF, pleural, or joint fluid samples.</para>
      <para id="ch0147s0048p0004">A qualitative LA test using heat-treated coccidioidin as antigen is available from several commercial sources (e.g., the LA-Cocci antibody system from IMMY and the<emphasis>Coccidioides</emphasis> latex agglutination system from Meridian). This test is simple and rapid to perform; however, the rate of false positives is higher than that observed with the IDTP and/or CF methods. It is not recommended for screening CSF specimens, because false-positive reactions can occur (<link linkend="ch0147s0055s0001li0153">153</link>).</para>
      <para id="ch0147s0048p0005">The Premier<emphasis>Coccidioides</emphasis> EIA (Meridian) is a qualitative test for detection of IgM and IgG antibodies in serum or CSF specimens. The antigen used in this test is a mixture of purified TP and CF antigens. False-positive reactions have been obtained with sera from some patients with blastomycosis and in patients with alternative diagnoses, and this test is now often used for “screening,” with positive EIA results being evaluated by IDTP and IDCF tests for confirmation (<link linkend="ch0147s0055s0001li0154">154</link>). Other EIA tests have also been recently developed (MiraVista) with a favorable sensitivity; however, this test is less specific than immunodiffusion (<link linkend="ch0147s0055s0001li0155">155</link>).</para>
      <para id="ch0147s0048p0006">A point-of-care lateral-flow assay (IMMY) has also been developed, although the performance characteristics (31% sensitivity) likely will limit its clinical utility (<link linkend="ch0147s0055s0001li0156">156</link>).</para>
    </sect1>
    <sect1 id="ch0147s0049">
      <title>Paracoccidioidomycosis</title>
      <anchor id="ch0147s0049a0001"/>
      <anchor id="ch0147s0049a0002"/>
      <para id="ch0147s0049p0001">The most popular serologic methods for diagnosis of paracoccidioidomycosis are ID and CF, but other tests, such as enzyme-linked immunosorbent assays, counterimmunoelectrophoresis, dot blotting, and immunoblotting, have also been employed (<link linkend="ch0147s0055s0001li0157">157</link>). The ID test demonstrates circulating antibodies in over 90% of cases. A reactive result allows a diagnosis to be made. The CF test allows a more precise evaluation of the patient’s response to treatment, but cross-reactions with <emphasis>Histoplasma capsulatum</emphasis> antigens can occur. The principal antigens used in these tests are derived from culture filtrates of mycelial-phase or yeast-phase broth cultures of <emphasis>P. brasiliensis.</emphasis> The major diagnostic antigen found in these preparations is a 43-kDa glycoprotein. Cell wall antigens have proved less useful than culture filtrate antigens, largely because wall antigens are dominated by cross-reactive galactomannan (<link linkend="ch0147s0055s0001li0157">157</link>). Commercial mycelial-form culture filtrate antigen can be obtained for in-house use from IMMY. No commercial kits are available for this test. The CF test is performed with <emphasis>P. brasiliensis</emphasis> yeast-form culture filtrate antigen. No commercial kits or reagents are available.</para>
      <para id="ch0147s0049p0002">Improvements in serodiagnosis include the detection of antibodies against chemically characterized and/or recombinant<emphasis>P. brasiliensis</emphasis> antigens, notably gp43, pb27, and the 87-kDa heat shock protein. A combination of two recombinant products has resulted in increased sensitivity (92%) and specificity (88%) (<link linkend="ch0147s0055s0001li0158">158</link>, <link linkend="ch0147s0055s0001li0159">159</link>). It has been found by double immunodiffusion (DID) that the serum from patients with paracoccidioidomycosis due to <emphasis>P. brasiliensis</emphasis> does not recognize antigen contained in the cell-free preparations of <emphasis>P. lutzii</emphasis>, unlike the serum from patients with paracoccidioidomycosis due to <emphasis>P. lutzii</emphasis>, which recognizes both antigens (<emphasis>P. lutzii</emphasis> and <emphasis>P. brasiliensis</emphasis>), suggesting that <emphasis>P. lutzii</emphasis> is antigenically more complex and has species-specific antigens but also shares antigens with <emphasis>P. brasiliensis</emphasis> (<link linkend="ch0147s0055s0001li0160">160</link>). It is important to mention that interlaboratory reproducibility continues to be an important issue despite efforts to standardize techniques and characterize antigen targets (<link linkend="ch0147s0055s0001li0161">161</link>).</para>
      <anchor id="ch0147s0049a0003"/>
      <beginpage pagenum="2480"/>
      <para id="ch0147s0049p0003">With the advances in<emphasis>Paracoccidioides</emphasis> genus characterization, a higher complexity has been added to the standardization of laboratory techniques for the diagnosis of paracoccidioidomycosis. All of the isolates of the different phylogenetic species of the <emphasis>Paracoccidioides</emphasis> genus are able to cause paracoccidioidomycosis, but lower levels or even a lack of expression of gp43 and other antigens can lead to inaccuracies (<link linkend="ch0147s0055s0001li0160">160</link>, <link linkend="ch0147s0055s0001li0162">162</link>). Many efforts currently under way to find new markers, new epitopes, and new techniques and approaches have recently been described (<link linkend="ch0147s0055s0001li0163">163</link>, <link linkend="ch0147s0055s0001li0164">164</link>).</para>
    </sect1>
    <sect1 id="ch0147s0050">
      <title>Adiaspiromycosis and Emergomycosis</title>
      <anchor id="ch0147s0050a0001"/>
      <anchor id="ch0147s0050a0002"/>
      <para id="ch0147s0050p0001">No serologic tests are available for diagnosis of adiaspiromycosis or emergomycosis, although different methods are currently under active investigation.</para>
      <sect2 id="ch0147s0050s0001">
        <title>ANTIMICROBIAL SUSCEPTIBILITIES</title>
        <anchor id="ch0147s0050s0001a0001"/>
        <anchor id="ch0147s0050s0001a0002"/>
        <para id="ch0147s0050s0001p0001">Established treatment options for<emphasis>Histoplasma, Blastomyces, Emergomyces, Coccidioides</emphasis>, and <emphasis>Paracoccidioides</emphasis> species include amphotericin B and the triazoles voriconazole, posaconazole, itraconazole, and fluconazole. Isavuconazole, a new triazole, has limited clinical data in the treatment of endemic fungi, although it appears to be a useful alternative agent in selected cases (<link linkend="ch0147s0055s0001li0165">165</link>). The echinocandins have a limited role in the treatment of endemic fungi and should not be used as monotherapy. <emphasis>In vitro</emphasis> antifungal susceptibility testing for dimorphic fungi remains unstandardized, and no susceptibility breakpoints have been determined for these organisms (<link linkend="ch0147s0055s0001li0166">166</link>). <anchor id="ch0147s0050s0001a0003"/><link linkend="ch0147s0051a0003">Table 1</link> lists the <emphasis>in vitro</emphasis> susceptibilities of these organisms to established and investigational antifungal agents as reported in studies that were performed in accordance with CLSI documents M38 (for filamentous fungi) (<link linkend="ch0147s0055s0001li0166">166</link>) and M27 (for yeasts) (<link linkend="ch0147s0055s0001li0167">167</link>). Fluconazole treatment failures have been reported in some cases of histoplasmosis and coccidioidomycosis, partially attributed to organisms that demonstrated drug MICs of ≥64 μg/ml, although they remained responsive to itraconazole (<link linkend="ch0147s0055s0001li0168">168</link>, <link linkend="ch0147s0055s0001li0169">169</link>). Newer agents are in various stages of clinical development (fosmanogepix, olorofim, and others) and may have utility in the treatment of endemic mycoses (<link linkend="ch0147s0055s0001li0170">170</link>, <link linkend="ch0147s0055s0001li0171">171</link>).</para>
      </sect2>
      <sect2 id="ch0147s0050s0002">
        <title>EVALUATION, INTERPRETATION, AND REPORTING OF RESULTS</title>
        <anchor id="ch0147s0050s0002a0001"/>
        <anchor id="ch0147s0050s0002a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0147s0051">
      <title>Histoplasmosis</title>
      <anchor id="ch0147s0051a0001"/>
      <anchor id="ch0147s0051a0002"/>
      <para id="ch0147s0051p0001">The definitive diagnosis of histoplasmosis can be accomplished by direct microscopic detection of<emphasis>H. capsulatum</emphasis> yeast cells in clinical specimens or its isolation in culture. However, isolation and identification may take more than 2 to 4 weeks.</para>
      <para id="ch0147s0051p0002">Antigen detection complements other diagnostic methods for histoplasmosis and is particularly useful in immunocompromised patients with more extensive disease, often providing a rapid diagnosis before positive cultures can be identified.<emphasis>Histoplasma</emphasis> antigen has been detected in serum, urine, CSF, and bronchoalveolar lavage fluid specimens obtained from individuals with disseminated histoplasmosis. The sensitivity of antigen detection in disseminated histoplasmosis is higher in immunocompromised patients than in immunocompetent patients and in patients with more severe illness. Antigen levels are higher in urine than in serum. For patients with AIDS and disseminated histoplasmosis, sensitivity is between 81% and 95% in urine and 86% in serum (<link linkend="ch0147s0055s0001li0172">172</link>). Specificity is ~98%. Antigen has been detected in the CSF of patients with <emphasis>Histoplasma</emphasis> meningitis.</para>
      <para id="ch0147s0051p0003">Antigen levels in the urine and serum decline with effective treatment, becoming undetectable in most patients (<link linkend="ch0147s0055s0001li0089">89</link>). Failure of antigen concentrations to fall during treatment suggests therapeutic failure. In patients who have responded to treatment and in whom antigen levels have previously fallen, an increase in antigen levels in the urine or serum is suggestive of relapse.</para>
      <para id="ch0147s0051p0004">The LA test for<emphasis>Histoplasma</emphasis> antibodies is most useful for the diagnosis of acute infection, with positive results being obtained within 2 to 3 weeks after exposure. An LA titer of 1:16 is presumptive evidence of infection, and a titer of ≥1:32 is considered strong presumptive evidence of active or recent infection (<link linkend="ch0147s0055s0001li0173">173</link>). Because false-positive reactions can occur, the results should be confirmed by the ID test. Low-titer results from single specimens should be interpreted with caution. In such cases, the test should be performed on another specimen collected 4 to 6 weeks later.</para>
      <para id="ch0147s0051p0005">In the ID test, precipitins specific to the M antigen of<emphasis>H. capsulatum</emphasis> are the first to appear (4 to 8 weeks after exposure) and can be detected in up to 75% of persons with acute histoplasmosis. However, they can also be found in nearly all individuals with chronic pulmonary infection, as well as in those who have undergone a recent skin test with histoplasmin. Precipitins specific to the H antigen are specific for active disease but occur in fewer than 20% of cases. They usually disappear within the first 6 months of infection and are seldom, if ever, found in the absence of M precipitins. The presence of precipitins specific to both H and M antigens is highly suggestive of active histoplasmosis, regardless of other serologic test results.</para>
      <para id="ch0147s0051p0006">The CF test is useful in the diagnosis of acute, chronic, disseminated, and meningeal forms of histoplasmosis. In acute infections, antibodies to the yeast antigen are the first to appear (about 4 weeks after exposure) and the last to disappear after resolution of the infection. Antibodies to histoplasmin appear later and reach lower titers than those observed for the yeast antigen. In contrast, histoplasmin titers are usually higher in persons with chronic histoplasmosis. CF test results can be difficult to interpret, because cross-reactions can occur with sera from persons with blastomycosis, coccidioidomycosis, and other fungal infections. In such instances, titers usually range between 1:8 and 1:32 and occur mainly against the yeast form antigen. However, many serum samples from culture-confirmed cases of disseminated histoplasmosis yield titers in the same range. CF titers of 1:8 or greater with either antigen are considered presumptive evidence of histoplasmosis. Titers above 1:32 and rising titers in serial samples offer stronger evidence of infection.</para>
      <para id="ch0147s0051p0007">Titers of CF antibodies to<emphasis>H. capsulatum</emphasis> decrease following resolution of the infection but increase in individuals with chronic progressive disease. However, clinical and microbiological findings should also be considered in assessing the patient’s prognosis or making treatment decisions. In some patients, positive CF titers decline slowly and persist long after the disease has been cured. The significance of persistently elevated or fluctuating CF titers is unclear, as is the effect of antifungal treatment on antibody clearance (<link linkend="ch0147s0055s0001li0146">146</link>).</para>
      <table id="ch0147s0051t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0147s0051a0003"/><link linkend="ch0147s0050s0001a0003">TABLE 1</link></phrase></emphasis> <emphasis>In vitro</emphasis> susceptibilities of dimorphic fungi to antifungal agents<superscript><emphasis><anchor id="ch0147s0051a0004"/><link linkend="ch0147s0051a0005">a</link></emphasis></superscript>
</title>
        
        <tgroup cols="5">
          <tbody>
            <row>
              <entry><phrase role="center">Fungus</phrase>
              </entry>
              <entry><phrase role="center">Antifungal agent</phrase>
              </entry>
              <entry><phrase role="center">MIC range (μg/ml)</phrase>
              </entry>
              <entry><phrase role="center">MIC<subscript>90</subscript> (μg/ml)</phrase>
              </entry>
              <entry><phrase role="center">Reference(s)</phrase>
              </entry>
            </row>
            <row>
              <entry><emphasis>B. dermatitidis</emphasis>
              </entry>
              <entry>Amphotericin B</entry>
              <entry><phrase role="center">≤0.03–1</phrase>
              </entry>
              <entry><phrase role="center">0.5</phrase>
              </entry>
              <entry>182–184</entry>
            </row>
            <row>
              <entry/>
              <entry>Fluconazole</entry>
              <entry><phrase role="center">1–64</phrase>
              </entry>
              <entry><phrase role="center">NR</phrase>
              </entry>
              <entry>185</entry>
            </row>
            <row>
              <entry/>
              <entry>Itraconazole</entry>
              <entry><phrase role="center">≤0.03–4</phrase>
              </entry>
              <entry><phrase role="center">0.125</phrase>
              </entry>
              <entry>182–185</entry>
            </row>
            <row>
              <entry/>
              <entry>Posaconazole</entry>
              <entry><phrase role="center">≤0.03–1</phrase>
              </entry>
              <entry><phrase role="center">NR</phrase>
              </entry>
              <entry>185, 186</entry>
            </row>
            <row>
              <entry/>
              <entry>Voriconazole</entry>
              <entry><phrase role="center">≤0.03–16</phrase>
              </entry>
              <entry><phrase role="center">0.25</phrase>
              </entry>
              <entry>182–184</entry>
            </row>
            <row>
              <entry/>
              <entry>Isavuconazole</entry>
              <entry><phrase role="center">0.5–4</phrase>
              </entry>
              <entry><phrase role="center">NR</phrase>
              </entry>
              <entry>185</entry>
            </row>
            <row>
              <entry/>
              <entry>Anidulafungin</entry>
              <entry><phrase role="center">2–8</phrase>
              </entry>
              <entry><phrase role="center">NR</phrase>
              </entry>
              <entry>186</entry>
            </row>
            <row>
              <entry/>
              <entry>Caspofungin</entry>
              <entry><phrase role="center">0.5–8</phrase>
              </entry>
              <entry><phrase role="center">NR</phrase>
              </entry>
              <entry>186</entry>
            </row>
            <row>
              <entry><emphasis>Coccidioides</emphasis> spp.</entry>
              <entry>Amphotericin B</entry>
              <entry><phrase role="center">0.125–4</phrase>
              </entry>
              <entry><phrase role="center">0.5–1</phrase>
              </entry>
              <entry>183, 184, 187, 188</entry>
            </row>
            <row>
              <entry/>
              <entry>Fluconazole</entry>
              <entry><phrase role="center">2–&gt;64</phrase>
              </entry>
              <entry><phrase role="center">64</phrase>
              </entry>
              <entry>184, 187, 188</entry>
            </row>
            <row>
              <entry/>
              <entry>Itraconazole</entry>
              <entry><phrase role="center">0.125–16</phrase>
              </entry>
              <entry><phrase role="center">1</phrase>
              </entry>
              <entry>183, 184, 188</entry>
            </row>
            <row>
              <entry/>
              <entry>Posaconazole</entry>
              <entry><phrase role="center">0.06–16</phrase>
              </entry>
              <entry><phrase role="center">1</phrase>
              </entry>
              <entry>185, 188, 189</entry>
            </row>
            <row>
              <entry/>
              <entry>Voriconazole</entry>
              <entry><phrase role="center">≤0.03–8</phrase>
              </entry>
              <entry><phrase role="center">0.25</phrase>
              </entry>
              <entry>183–185, 188</entry>
            </row>
            <row>
              <entry/>
              <entry>Isavuconazole</entry>
              <entry><phrase role="center">0.125–1</phrase>
              </entry>
              <entry><phrase role="center">0.5</phrase>
              </entry>
              <entry>185</entry>
            </row>
            <row>
              <entry/>
              <entry>Caspofungin</entry>
              <entry><phrase role="center">8–64</phrase>
              </entry>
              <entry><phrase role="center">32</phrase>
              </entry>
              <entry>187</entry>
            </row>
            <row>
              <entry><emphasis>H. capsulatum</emphasis>
              </entry>
              <entry>Amphotericin B</entry>
              <entry><phrase role="center">≤0.03–2</phrase>
              </entry>
              <entry><phrase role="center">0.25</phrase>
              </entry>
              <entry>182–184</entry>
            </row>
            <row>
              <entry/>
              <entry>Fluconazole</entry>
              <entry><phrase role="center">≤0.125–64</phrase>
              </entry>
              <entry><phrase role="center">NR</phrase>
              </entry>
              <entry>48</entry>
            </row>
            <row>
              <entry/>
              <entry>Itraconazole</entry>
              <entry><phrase role="center">≤0.03–8</phrase>
              </entry>
              <entry><phrase role="center">0.06</phrase>
              </entry>
              <entry>182–184</entry>
            </row>
            <row>
              <entry/>
              <entry>Posaconazole</entry>
              <entry><phrase role="center">≤0.03–2</phrase>
              </entry>
              <entry><phrase role="center">NR</phrase>
              </entry>
              <entry>185, 186</entry>
            </row>
            <row>
              <entry/>
              <entry>Voriconazole</entry>
              <entry><phrase role="center">≤0.03–2</phrase>
              </entry>
              <entry><phrase role="center">0.25</phrase>
              </entry>
              <entry>49, 182, 183</entry>
            </row>
            <row>
              <entry/>
              <entry>Isavuconazole</entry>
              <entry><phrase role="center">0.125–2</phrase>
              </entry>
              <entry><phrase role="center">2</phrase>
              </entry>
              <entry>185</entry>
            </row>
            <row>
              <entry/>
              <entry>Anidulafungin</entry>
              <entry><phrase role="center">2–4</phrase>
              </entry>
              <entry><phrase role="center">NR</phrase>
              </entry>
              <entry>186</entry>
            </row>
            <row>
              <entry/>
              <entry>Caspofungin</entry>
              <entry><phrase role="center">0.5–4</phrase>
              </entry>
              <entry><phrase role="center">NR</phrase>
              </entry>
              <entry>186</entry>
            </row>
            <row>
              <entry><emphasis>P. brasiliensis</emphasis>
              </entry>
              <entry>Amphotericin B</entry>
              <entry><phrase role="center">0.125–4</phrase>
              </entry>
              <entry><phrase role="center">NR</phrase>
              </entry>
              <entry>184</entry>
            </row>
            <row>
              <entry/>
              <entry>Fluconazole</entry>
              <entry><phrase role="center">≤0.125–64</phrase>
              </entry>
              <entry><phrase role="center">NR</phrase>
              </entry>
              <entry>184</entry>
            </row>
            <row>
              <entry/>
              <entry>Itraconazole</entry>
              <entry><phrase role="center">≤0.03–1</phrase>
              </entry>
              <entry><phrase role="center">NR</phrase>
              </entry>
              <entry>184</entry>
            </row>
            <row>
              <entry/>
              <entry>Voriconazole</entry>
              <entry><phrase role="center">≤0.03–2</phrase>
              </entry>
              <entry><phrase role="center">NR</phrase>
              </entry>
              <entry>184</entry>
            </row>
            <row>
              <entry/>
              <entry>Isavuconazole</entry>
              <entry><phrase role="center">NR</phrase>
              </entry>
              <entry><phrase role="center">NR</phrase>
              </entry>
              <entry/>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0147s0051a0005"/><link linkend="ch0147s0051a0004">a</link></emphasis></superscript><emphasis>Emergomyces</emphasis> susceptibility testing is limited, with few isolates tested thus far (<link linkend="ch0147s0055s0001li0014">14</link>). NR, not reported.</para>
      <para id="ch0147s0051p0008">Serologic tests are particularly useful in patients with<emphasis>Histoplasma</emphasis> meningitis. The detection of precipitins specific to H and M antigens in CSF specimens is sufficient to make a diagnosis in the appropriate clinical setting and often is the only positive diagnostic test.</para>
      <anchor id="ch0147s0051a0006"/>
      <beginpage pagenum="2481"/>
    </sect1>
    <sect1 id="ch0147s0052">
      <title>Blastomycosis</title>
      <anchor id="ch0147s0052a0001"/>
      <anchor id="ch0147s0052a0002"/>
      <para id="ch0147s0052p0001">Although microscopic examination and culture remain the most sensitive means of establishing the diagnosis of blastomycosis, serologic tests can also provide useful information. A positive reaction in an ID test using the A antigen of<emphasis>B. dermatitidis</emphasis> is suggestive of blastomycosis (<link linkend="ch0147s0055s0001li0174">174</link>). However, a negative ID test does not rule out the diagnosis, as the sensitivity of this method has been reported to range from ~30% for cases of localized infection to ~90% for cases of disseminated blastomycosis. In established cases of the disease, a decline in the number or the disappearance of precipitin lines is evidence of a favorable prognosis.</para>
      <para id="ch0147s0052p0002">With urine specimens, the<emphasis>Blastomyces</emphasis> antigen test has been reported to have a sensitivity of 89% for disseminated infection and 100% for pulmonary disease, although recent experience has reported a lower sensitivity in clinical practice (<link linkend="ch0147s0055s0001li0098">98</link>). However, cross-reactive antigens occurred in urine from all patients with paracoccidioidomycosis and from 96% of patients with histoplasmosis (<link linkend="ch0147s0055s0001li0097">97</link>).</para>
    </sect1>
    <sect1 id="ch0147s0053">
      <title>Coccidioidomycosis</title>
      <anchor id="ch0147s0053a0001"/>
      <anchor id="ch0147s0053a0002"/>
      <para id="ch0147s0053p0001">Although the definitive laboratory diagnosis of coccidioidomycosis depends on microscopic examination and culture, serologic tests are of proven usefulness in diagnosis and management. A positive IDTP test result is indicative of acute coccidioidomycosis. IDTP-reactive IgM antibodies can be detected in up to 75% of cases within 1 week of symptom onset, and ~90% are positive within 3 weeks. Although infrequent, a positive IDTP test result within CSF is indicative of acute meningitis. In cases where the IDTP test is negative but the CF test is positive, patients should be investigated for microbiologic or histopathologic evidence of other endemic mycoses. In addition, sera should be obtained at 3-week intervals and examined by CF and ID tests for coccidioidomycosis, histoplasmosis, and blastomycosis if travel to regions of endemicity has occurred.</para>
      <para id="ch0147s0053p0002">A positive IDCF test result is presumptive evidence of recent or chronic infection. IDCF-reactive IgG antibodies can usually be detected within 2 to 6 weeks after onset of symptoms. Although the IDCF test is generally not performed as a quantitative test, it can be used in this manner. Titers obtained using the quantitative IDCF are not identical to titers obtained from the CF test, but the observed trends are comparable.</para>
      <para id="ch0147s0053p0003">The LA test is more sensitive than the IDTP test in detecting acute infection but is less specific. For this reason, a positive test result with undiluted serum should be confirmed by the ID and/or CF test.</para>
      <para id="ch0147s0053p0004">The CF test does not become positive until about 4 to 12 weeks after infection, but CF antibodies persist for long periods in individuals with chronic pulmonary or disseminated coccidioidomycosis (<link linkend="ch0147s0055s0001li0175">175</link>). Testing of serial specimens to detect rising or falling titers can reveal the progression or regression of illness and the response to antifungal treatment. A CF titer to coccidioidin at any dilution should be considered presumptive evidence of coccidioidomycosis. In most instances, the titer is proportional to the extent of the infection, and failure of the CF titer to fall during treatment of disseminated coccidioidomycosis is an ominous sign (<link linkend="ch0147s0055s0001li0176">176</link>). Titers of 1:2 or 1:4 are usually indicative of early or residual disease. CF titers of &gt;1:16 should lead to a careful assessment of the patient for possible spread of the disease beyond the respiratory tract (<link linkend="ch0147s0055s0001li0177">177</link>). More than 60% of patients with disseminated coccidioidomycosis have CF titers of &gt;1:32. However, false-negative results can occur in immunocompromised individuals, such as persons with AIDS. Patients with clinical presentations consistent with coccidioidomycosis but with negative or low serum CF titers should be retested at 3- to 4-week intervals.</para>
      <anchor id="ch0147s0053a0003"/>
      <beginpage pagenum="2482"/>
      <para id="ch0147s0053p0005">The detection of CF antibodies in the CSF is usually diagnostic of coccidioidal meningitis and remains the single most useful test for diagnosis of that infection.</para>
      <para id="ch0147s0053p0006">Antigen testing for coccidioidomycosis is insensitive and typically not used for diagnosis. When serology is negative in a severely immunocompromised patient suspected to have underlying coccidioidomycosis, antigen testing may be useful, and it may play a role in the diagnosis of coccidioidal meningitis (<link linkend="ch0147s0055s0001li0178">178</link>, <link linkend="ch0147s0055s0001li0179">179</link>).</para>
    </sect1>
    <sect1 id="ch0147s0054">
      <title>Paracoccidioidomycosis</title>
      <anchor id="ch0147s0054a0001"/>
      <anchor id="ch0147s0054a0002"/>
      <para id="ch0147s0054p0001">The definitive diagnosis of paracoccidioidomycosis depends on microscopic examination and culture. However, isolation and identification of<emphasis>P. brasiliensis</emphasis> from clinical specimens may take up to 4 weeks.</para>
      <para id="ch0147s0054p0002">Serologic tests are useful for the rapid presumptive diagnosis of paracoccidioidomycosis, particularly in cases of disseminated infection (<link linkend="ch0147s0055s0001li0157">157</link>). The ID test with yeast-form culture filtrate antigen is highly specific and is positive in 65 to 100% of cases of acute or chronic pulmonary infection or disseminated paracoccidioidomycosis. The CF test with yeast-form culture filtrate antigen is less specific than the ID test, and cross-reactions can occur with cases of histoplasmosis. However, CF titers of ≥1:8 are considered presumptive evidence of paracoccidioidomycosis. Low CF titers are usually associated with localized infection, while higher titers are found in those with multifocal disease. Falling CF titers are often predictive of successful treatment, and high or fluctuating CF titers are suggestive of a poor prognosis. Some reports, however, have indicated that ID and CF results do not correlate well with the clinical status of the patient (<link linkend="ch0147s0055s0001li0180">180</link>). Many efforts are under way to search for new serological markers for the diagnosis and monitoring of paracoccidioidomycosis, especially because of the recent advances in characterizing the taxonomy of the genus (<link linkend="ch0147s0055s0001li0162">162</link>).</para>
    </sect1>
    <sect1 id="ch0147s0055">
      <title>Adiaspiromycosis and Emergomycosis</title>
      <anchor id="ch0147s0055a0001"/>
      <anchor id="ch0147s0055a0002"/>
      <para id="ch0147s0055p0001">The definitive diagnosis of adiaspiromycosis can be accomplished by direct microscopic detection of<emphasis>Es. crescens</emphasis> adiaspores or <emphasis>Emergomyces</emphasis> yeast cells in clinical specimens or their isolation in culture. No serological tests are currently available.</para>
      <sect2 id="ch0147s0055s0001">
        <title>REFERENCES</title>
        <anchor id="ch0147s0055s0001a0001"/>
        <anchor id="ch0147s0055s0001a0002"/>
        <itemizedlist mark="none" role="biblioEntryList">
          <listitem id="ch0147s0055s0001li0001" role="bibliographyEntry">
            <para>1.<emphasis role="strong">Thompson GR III, Le T, Chindamporn A, Kauffman CA, Alastruey-Izquierdo A, Ampel NM, Andes DR, Armstrong-James D, Ayanlowo O, Baddley JW, Barker BM, Lopes Bezerra L, Buitrago MJ, Chamani-Tabriz L, Chan JFW, Chayakulkeeree M, Cornely OA, Cunwei C, Gangneux JP, Govender NP, Hagen F, Hedayati MT, Hohl TM, Jouvion G, Kenyon C, Kibbler CC, Klimko N, Kong DCM, Krause R, Lee Lee L, Meintjes G, Miceli MH, Rath PM, Spec A, Queiroz-Telles F, Variava E, Verweij PE, Schwartz IS, Pasqualotto AC.</emphasis> 2021. Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">21:</emphasis>e364–e374.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0002" role="bibliographyEntry">
            <para>2.<emphasis role="strong">Hawksworth DL.</emphasis> 2011. A new dawn for the naming of fungi: impacts of decisions made in Melbourne in July 2011 on the future publication and regulation of fungal names. <citetitle><emphasis>IMA Fungus</emphasis></citetitle> <emphasis role="strong">2:</emphasis>155–162.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0003" role="bibliographyEntry">
            <para>3.<emphasis role="strong">Peterson SW, Sigler L.</emphasis> 1998. Molecular genetic variation in <citetitle><emphasis>Emmonsia crescens</emphasis></citetitle> and <citetitle><emphasis>Emmonsia parva</emphasis></citetitle>, etiologic agents of adiaspiromycosis, and their phylogenetic relationship to <citetitle><emphasis>Blastomyces dermatitidis</emphasis></citetitle> (<citetitle><emphasis>Ajellomyces dermatitidis</emphasis></citetitle>) and other systemic fungal pathogens. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>2918–2925.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0004" role="bibliographyEntry">
            <para>4.<emphasis role="strong">Dukik K, Muñoz JF, Jiang Y, Feng P, Sigler L, Stielow JB, Freeke J, Jamalian A, van den Ende BG, McEwen JG, Clay OK, Schwartz IS, Govender NP, Maphanga TG, Cuomo CA, Moreno LF, Kenyon C, Borman AM, de Hoog S.</emphasis> 2017. Novel taxa of thermally dimorphic systemic pathogens in the <citetitle><emphasis>Ajellomycetaceae (Onygenales). Mycoses</emphasis></citetitle> <emphasis role="strong">60:</emphasis>296–309.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0005" role="bibliographyEntry">
            <para>5.<emphasis role="strong">Untereiner WA, Scott JA, Naveau FA, Sigler L, Bachewich J, Angus A.</emphasis> 2004. The Ajellomycetaceae, a new family of vertebrate-associated Onygenales. <citetitle><emphasis>Mycologia</emphasis></citetitle> <emphasis role="strong">96:</emphasis>812–821.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0006" role="bibliographyEntry">
            <para>6.<emphasis role="strong">Valero C, Gago S, Monteiro MC, Alastruey-Izquierdo A, Buitrago MJ.</emphasis> 2018. African histoplasmosis: new clinical and microbiological insights. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>51–59.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0007" role="bibliographyEntry">
            <para>7.<emphasis role="strong">Kasuga T, White TJ, Koenig G, McEwen J, Restrepo A, Castañeda E, Da Silva Lacaz C, Heins-Vaccari EM, De Freitas RS, Zancopé-Oliveira RM, Qin Z, Negroni R, Carter DA, Mikami Y, Tamura M, Taylor ML, Miller GF, Poonwan N, Taylor JW.</emphasis> 2003. Phylogeography of the fungal pathogen <citetitle><emphasis>Histoplasma capsulatum. Mol Ecol</emphasis></citetitle> <emphasis role="strong">12:</emphasis>3383–3401.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0008" role="bibliographyEntry">
            <para>8.<emphasis role="strong">Arunmozhi Balajee S, Hurst SF, Chang LS, Miles M, Beeler E, Hale C, Kasuga T, Benedict K, Chiller T, Lindsley MD.</emphasis> 2013. Multilocus sequence typing of <citetitle><emphasis>Histoplasma capsulatum</emphasis></citetitle> in formalin-fixed paraffin-embedded tissues from cats living in non-endemic regions reveals a new phylogenetic clade. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>345–351.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0009" role="bibliographyEntry">
            <para>9.<emphasis role="strong">Teixeira MM, Patané JS, Taylor ML, Gómez BL, Theodoro RC, de Hoog S, Engelthaler DM, Zancopé-Oliveira RM, Felipe MS, Barker BM.</emphasis> 2016. Worldwide phylogenetic distributions and population dynamics of the genus <citetitle><emphasis>Histoplasma. PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">10:</emphasis>e0004732.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0010" role="bibliographyEntry">
            <para>10.<emphasis role="strong">Sepúlveda VE, Márquez R, Turissini DA, Goldman WE, Matute DR.</emphasis> 2017. Genome sequences reveal cryptic speciation in the human pathogen <citetitle><emphasis>Histoplasma capsulatum. mBio</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e01339-17.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0011" role="bibliographyEntry">
            <para>11.<emphasis role="strong">Meece JK, Anderson JL, Fisher MC, Henk DA, Sloss BL, Reed KD.</emphasis> 2011. Population genetic structure of clinical and environmental isolates of <citetitle><emphasis>Blastomyces dermatitidis</emphasis></citetitle>, based on 27 polymorphic microsatellite markers. <citetitle><emphasis>Appl Environ Microbiol</emphasis></citetitle> <emphasis role="strong">77:</emphasis>5123–5131.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0012" role="bibliographyEntry">
            <para>12.<emphasis role="strong">Brown EM, McTaggart LR, Zhang SX, Low DE, Stevens DA, Richardson SE.</emphasis> 2013. Phylogenetic analysis reveals a cryptic species <citetitle><emphasis>Blastomyces gilchristii</emphasis></citetitle>, sp. nov. within the human pathogenic fungus <citetitle><emphasis>Blastomyces dermatitidis. PLoS One</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e59237.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0013" role="bibliographyEntry">
            <para>13.<emphasis role="strong">Schwartz IS, Wiederhold NP, Pattterson TF, Sigler L.</emphasis> 2017. <citetitle><emphasis>Blastomyces helicus</emphasis></citetitle>, an emerging dimorphic fungal pathogen causing fatal pulmonary and disseminated disease in humans and animals in western Canada and United States. <citetitle><emphasis>Open Forum Infect Dis</emphasis></citetitle> <emphasis role="strong">4</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>S83–S84.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0014" role="bibliographyEntry">
            <para>14.<emphasis role="strong">Dukik K, Al-Hatmi AMS, Curfs-Breuker I, Faro D, de Hoog S, Meis JF.</emphasis> 2018. Antifungal susceptibility of emerging dimorphic pathogens in the family <citetitle><emphasis>Ajellomycetaceae. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">62:</emphasis>e01886-17.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0015" role="bibliographyEntry">
            <anchor id="ch0147s0055s0001a0003"/>
            <para>15.<emphasis role="strong">Jiang Y, Dukik K, Muñoz JF, Sigler L, Schwartz IS, Govender NP, Kenyon C, Feng P, van den Ende BG, Stielow JB, Stchigel AM, Lu H, de Hoog S.</emphasis> 2018. Phylogeny, ecology and taxonomy of systemic pathogens and their relatives in <citetitle><emphasis>Ajellomycetaceae (Onygenales</emphasis></citetitle>): <citetitle><emphasis>Blastomyces, Emergomyces, Emmonsia, Emmonsiellopsis. Fungal Divers</emphasis></citetitle> <emphasis role="strong">90:</emphasis>245–291.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0016" role="bibliographyEntry">
            <para>16.<emphasis role="strong">Meece JK, Anderson JL, Gruszka S, Sloss BL, Sullivan B, Reed KD.</emphasis> 2013. Variation in clinical phenotype of human infection among genetic groups of <citetitle><emphasis>Blastomyces dermatitidis. J Infect Dis</emphasis></citetitle> <emphasis role="strong">207:</emphasis>814–822.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0017" role="bibliographyEntry">
            <para>17.<emphasis role="strong">Muñoz JF, Gauthier GM, Desjardins CA, Gallo JE, Holder J, Sullivan TD, Marty AJ, Carmen JC, Chen Z, Ding L, Gujja S, Magrini V, Misas E, Mitreva M, Priest M, Saif S, Whiston EA, Young S, Zeng Q, Goldman WE, Mardis ER, Taylor JW, McEwen JG, Clay OK, Klein BS, Cuomo CA.</emphasis> 2015. The dynamic genome and transcriptome of the human fungal pathogen <citetitle><emphasis>Blastomyces</emphasis></citetitle> and close relative <citetitle><emphasis>Emmonsia. PLoS Genet</emphasis></citetitle> <emphasis role="strong">11:</emphasis>e1005493.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0018" role="bibliographyEntry">
            <para>18.<emphasis role="strong">Litvintseva AP, Marsden-Haug N, Hurst S, Hill H, Gade L, Driebe EM, Ralston C, Roe C, Barker BM, Goldoft M, Keim P, Wohrle R, Thompson GR III, Engelthaler DM, Brandt ME, Chiller T.</emphasis> 2015. Valley fever: finding new places for an old disease: <citetitle><emphasis>Coccidioides immitis</emphasis></citetitle> found in Washington State soil associated with recent human infection. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">60:</emphasis>e1–e3.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0019" role="bibliographyEntry">
            <para>19.<emphasis role="strong">Neafsey DE, Barker BM, Sharpton TJ, Stajich JE, Park DJ, Whiston E, Hung CY, McMahan C, White J, Sykes S, Heiman D, Young S, Zeng Q, Abouelleil A, Aftuck L, Bessette D, Brown A, FitzGerald M, Lui A, Macdonald JP, Priest M, Orbach MJ, Galgiani JN, Kirkland TN, Cole GT, Birren BW, Henn MR, Taylor JW, Rounsley SD.</emphasis> 2010. Population genomic sequencing of <citetitle><emphasis>Coccidioides</emphasis></citetitle> fungi reveals recent hybridization and transposon control. <citetitle><emphasis>Genome Res</emphasis></citetitle> <emphasis role="strong">20:</emphasis>938–946.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0020" role="bibliographyEntry">
            <para>20.<emphasis role="strong">Engelthaler DM, Roe CC, Hepp CM, Teixeira M, Driebe EM, Schupp JM, Gade L, Waddell V, Komatsu K, Arathoon E, Logemann H, Thompson GR III, Chiller T, Barker B, Keim P, Litvintseva AP.</emphasis> 2016. Local population structure and patterns of Western Hemisphere dispersal for <citetitle><emphasis>Coccidioides</emphasis></citetitle> spp., the fungal cause of valley fever. <citetitle><emphasis>mBio</emphasis></citetitle> <emphasis role="strong">7:</emphasis>e00550-16.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0021" role="bibliographyEntry">
            <para>21.<emphasis role="strong">Barker BM, Litvintseva AP, Riquelme M, Vargas-Gastelum L.</emphasis> 2019. <citetitle><emphasis>Coccidioides</emphasis></citetitle> ecology and genomics. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">57</emphasis>(Suppl 1):S21-S29.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0022" role="bibliographyEntry">
            <para>22.<emphasis role="strong">Sharpton TJ, Stajich JE, Rounsley SD, Gardner MJ, Wortman JR, Jordar VS, Maiti R, Kodira CD, Neafsey DE, Zeng Q, Hung CY, McMahan C, Muszewska A, Grynberg M, Mandel MA, Kellner EM, Barker BM, Galgiani JN, Orbach MJ, Kirkland TN, Cole GT, Henn MR, Birren BW, Taylor JW.</emphasis> 2009. Comparative genomic analyses of the human fungal pathogens <citetitle><emphasis>Coccidioides</emphasis></citetitle> and their relatives. <citetitle><emphasis>Genome Res</emphasis></citetitle> <emphasis role="strong">19:</emphasis>1722–1731.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0023" role="bibliographyEntry">
            <para>23.<emphasis role="strong">Matute DR, McEwen JG, Puccia R, Montes BA, San-Blas G, Bagagli E, Rauscher JT, Restrepo A, Morais F, Niño-Vega G, Taylor JW.</emphasis> 2006. Cryptic speciation and recombination in the fungus <citetitle><emphasis>Paracoccidioides brasiliensis</emphasis></citetitle> as revealed by gene genealogies. <citetitle><emphasis>Mol Biol Evol</emphasis></citetitle> <emphasis role="strong">23:</emphasis>65–73.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0024" role="bibliographyEntry">
            <para>24.<emphasis role="strong">Teixeira MM, Theodoro RC, de Carvalho MJ, Fernandes L, Paes HC, Hahn RC, Mendoza L, Bagagli E, San-Blas G, Felipe MS.</emphasis> 2009. Phylogenetic analysis reveals a high level of speciation in the <citetitle><emphasis>Paracoccidioides</emphasis></citetitle> genus. <citetitle><emphasis>Mol Phylogenet Evol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>273–283.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0025" role="bibliographyEntry">
            <para>25.<emphasis role="strong">Theodoro RC, Teixeira MM, Felipe MS, Paduan KS, Ribolla PM, San-Blas G, Bagagli E.</emphasis> 2012. Genus <citetitle><emphasis>Paracoccidioides</emphasis></citetitle>: species recognition and biogeographic aspects. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">7:</emphasis>e37694.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0026" role="bibliographyEntry">
            <para>26.<emphasis role="strong">Teixeira MM, Theodoro RC, Oliveira FF, Machado GC, Hahn RC, Bagagli E, San-Blas G, Soares Felipe MS.</emphasis> 2014. <citetitle><emphasis>Paracoccidioides lutzii</emphasis></citetitle> sp. nov.: biological and clinical implications. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>19–28.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0027" role="bibliographyEntry">
            <para>27.<emphasis role="strong">Teixeira MM, Theodoro RC, Nino-Vega G, Bagagli E, Felipe MS.</emphasis> 2014. <citetitle><emphasis>Paracoccidioides</emphasis></citetitle> species complex: ecology, phylogeny, sexual reproduction, and virulence. <citetitle><emphasis>PLoS Pathog</emphasis></citetitle> <emphasis role="strong">10:</emphasis>e1004397.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0028" role="bibliographyEntry">
            <para>28.<emphasis role="strong">Turissini DA, Gomez OM, Teixeira MM, McEwen JG, Matute DR.</emphasis> 2017. Species boundaries in the human pathogen <citetitle><emphasis>Paracoccidioides. Fungal Genet Biol</emphasis></citetitle> <emphasis role="strong">106:</emphasis>9–25.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0029" role="bibliographyEntry">
            <para>29.<emphasis role="strong">Mavengere H, Mattox K, Teixeira MM, Sepúlveda VE, Gomez OM, Hernandez O, McEwen J, Matute DR.</emphasis> 2020. <citetitle><emphasis>Paracoccidioides</emphasis></citetitle> genomes reflect high levels of species divergence and little interspecific gene flow. <citetitle><emphasis>mBio</emphasis></citetitle> <emphasis role="strong">11:</emphasis>e01999-20.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0030" role="bibliographyEntry">
            <para>30.<emphasis role="strong">Teixeira MM, Theodoro RC, Derengowski LS, Nicola AM, Bagagli E, Felipe MS.</emphasis> 2013. Molecular and morphological data support the existence of a sexual cycle in species of the genus <citetitle><emphasis>Paracoccidioides. Eukaryot Cell</emphasis></citetitle> <emphasis role="strong">12:</emphasis>380–389.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0031" role="bibliographyEntry">
            <para>31.<emphasis role="strong">Herr RA, Tarcha EJ, Taborda PR, Taylor JW, Ajello L, Mendoza L.</emphasis> 2001. Phylogenetic analysis of <citetitle><emphasis>Lacazia loboi</emphasis></citetitle> places this previously uncharacterized pathogen within the dimorphic Onygenales. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">39:</emphasis>309–314.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0032" role="bibliographyEntry">
            <para>32.<emphasis role="strong">Muñoz JF, Gallo JE, Misas E, Priest M, Imamovic A, Young S, Zeng Q, Clay OK, McEwen JG, Cuomo CA.</emphasis> 2014. Genome update of the dimorphic human pathogenic fungi causing paracoccidioidomycosis. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e3348.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0033" role="bibliographyEntry">
            <para>33.<emphasis role="strong">Desjardins CA, Champion MD, Holder JW, Muszewska A, Goldberg J, Bailão AM, Brigido MM, Ferreira ME, Garcia AM, Grynberg M, Gujja S, Heiman DI, Henn MR, Kodira CD, León-Narváez H, Longo LV, Ma LJ, Malavazi I, Matsuo AL, Morais FV, Pereira M, Rodríguez-Brito S, Sakthikumar S, Salem-Izacc SM, Sykes SM, Teixeira MM, Vallejo MC, Walter ME, Yandava C, Young S, Zeng Q, Zucker J, Felipe MS, Goldman GH, Haas BJ, McEwen JG, Nino-Vega G, Puccia R, San-Blas G, Soares CM, Birren BW, Cuomo CA.</emphasis> 2011. Comparative genomic analysis of human fungal pathogens causing paracoccidioidomycosis. <citetitle><emphasis>PLoS Genet</emphasis></citetitle> <emphasis role="strong">7:</emphasis>e1002345.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0034" role="bibliographyEntry">
            <para>34.<emphasis role="strong">Muñoz JF, Farrer RA, Desjardins CA, Gallo JE, Sykes S, Sakthikumar S, Misas E, Whiston EA, Bagagli E, Soares CM, Teixeira MM, Taylor JW, Clay OK, McEwen JG, Cuomo CA.</emphasis> 2016. Genome diversity, recombination, and virulence across the major lineages of <citetitle><emphasis>Paracoccidioides. mSphere</emphasis></citetitle> <emphasis role="strong">1:</emphasis>e00213-16.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0035" role="bibliographyEntry">
            <para>35.<emphasis role="strong">Schwartz IS, McLoud JD, Berman D, Botha A, Lerm B, Colebunders R, Levetin E, Kenyon C.</emphasis> 2018. Molecular detection of airborne <citetitle><emphasis>Emergomyces africanus</emphasis></citetitle>, a thermally dimorphic fungal pathogen, in Cape Town, South Africa. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">12:</emphasis>e0006174.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0036" role="bibliographyEntry">
            <para>36.<emphasis role="strong">Wang P, Kenyon C, de Hoog S, Guo L, Fan H, Liu H, Li Z, Sheng R, Yang Y, Jiang Y, Zhang L, Xu Y.</emphasis> 2017. A novel dimorphic pathogen, <citetitle><emphasis>Emergomyces orientalis</emphasis></citetitle> (Onygenales), agent of disseminated infection. <citetitle><emphasis>Mycoses</emphasis></citetitle> <emphasis role="strong">60:</emphasis>310–319.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0037" role="bibliographyEntry">
            <para>37.<emphasis role="strong">Schwartz IS, Sanche S, Wiederhold NP, Patterson TF, Sigler L.</emphasis> 2018. <citetitle><emphasis>Emergomyces canadensis</emphasis></citetitle>, a dimorphic fungus causing fatal systemic human disease in North America. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">24:</emphasis>758–761.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0038" role="bibliographyEntry">
            <para>38.<emphasis role="strong">Yang Y, Ye Q, Li K, Li Z, Bo X, Li Z, Xu Y, Wang S, Wang P, Chen H, Wang J.</emphasis> 2017. Genomics and comparative genomic analyses provide insight into the taxonomy and pathogenic potential of novel <citetitle><emphasis>Emmonsia</emphasis></citetitle> pathogens. <citetitle><emphasis>Front Cell Infect Microbiol</emphasis></citetitle> <emphasis role="strong">7:</emphasis>105.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0039" role="bibliographyEntry">
            <para>39.<emphasis role="strong">Rofael M, Schwartz IS, Sigler L, Kong LK, Nelson N.</emphasis> 2018. <citetitle><emphasis>Emmonsia helica</emphasis></citetitle> infection in HIV-infected man, California, USA. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">24:</emphasis>166–168.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0040" role="bibliographyEntry">
            <para>40.<emphasis role="strong">Kauffman CA.</emphasis> 2011. Histoplasmosis, p 321–335. <citetitle><emphasis>In</emphasis></citetitle> Kauffman CA, Pappas PG, Sobel JD, Dismukes WE (ed), <citetitle><emphasis>Essentials of Clinical Mycology</emphasis></citetitle>, 2nd ed. Springer-Verlag, New York, NY.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0041" role="bibliographyEntry">
            <para>41.<emphasis role="strong">Deepe GS.</emphasis> 2015. <citetitle><emphasis>Histoplasma capsulatum</emphasis></citetitle>, p 2948–2962. <citetitle><emphasis>In</emphasis></citetitle> Mandell GL, Bennett JE, Dollin R, Blaser MJ (ed), <citetitle><emphasis>Mandell</emphasis></citetitle>, <citetitle><emphasis>Douglas and Bennett’s Principles and Practice of infectious Diseases</emphasis></citetitle>, 8th ed. Elsevier Churchill Livingstone, Philadelphia, PA.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0042" role="bibliographyEntry">
            <para>42.<emphasis role="strong">Lenhart SW, Schafer MP, Singal M, Hajjeh RA.</emphasis> 2004. <citetitle><emphasis>Histoplasmosis: protecting workers at risk. DHHS (NIOSH) publication no. 2005-109.</emphasis></citetitle> National Institute for Occupational Safety and Health, Washington, DC. <ulink url="http://www.cdc.gov/niosh/docs/2005-109/pdfs/2005-109.pdf">http://www.cdc.gov/niosh/docs/2005-109/pdfs/2005-109.pdf</ulink>.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0043" role="bibliographyEntry">
            <para>43.<emphasis role="strong">Gómez BL.</emphasis> 2011. Histoplasmosis: epidemiology in Latin America. <citetitle><emphasis>Curr Fungal Infect Rep</emphasis></citetitle> <emphasis role="strong">5:</emphasis>199–205.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0044" role="bibliographyEntry">
            <para>44.<emphasis role="strong">Anstead GM, Sutton DA, Graybill JR.</emphasis> 2012. Adiaspiromycosis causing respiratory failure and a review of human infections due to <citetitle><emphasis>Emmonsia</emphasis></citetitle> and <citetitle><emphasis>Chrysosporium</emphasis></citetitle> spp. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>1346–1354.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0045" role="bibliographyEntry">
            <para>45.<emphasis role="strong">Reed KD, Meece JK, Archer JR, Peterson AT.</emphasis> 2008. Ecologic niche modeling of <citetitle><emphasis>Blastomyces dermatitidis</emphasis></citetitle> in Wisconsin. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">3:</emphasis>e2034.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0046" role="bibliographyEntry">
            <anchor id="ch0147s0055s0001a0004"/>
            <para>46.<emphasis role="strong">Smith JA, Kauffman CA.</emphasis> 2010. Blastomycosis. <citetitle><emphasis>Proc Am Thorac Soc</emphasis></citetitle> <emphasis role="strong">7:</emphasis>173–180.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0047" role="bibliographyEntry">
            <para>47.<emphasis role="strong">Thompson GR III.</emphasis> 2011. Pulmonary coccidioidomycosis. <citetitle><emphasis>Semin Respir Crit Care Med</emphasis></citetitle> <emphasis role="strong">32:</emphasis>754–763.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0048" role="bibliographyEntry">
            <para>48.<emphasis role="strong">Dobos RR, Benedict K, Jackson BR, McCotter OZ.</emphasis> 2021. Using soil survey data to model potential <citetitle><emphasis>Coccidioides</emphasis></citetitle> soil habitat and inform Valley fever epidemiology. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">16:</emphasis>e0247263.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0049" role="bibliographyEntry">
            <para>49.<emphasis role="strong">Brown J, Benedict K, Park BJ, Thompson GR III.</emphasis> 2013. Coccidioidomycosis: epidemiology. <citetitle><emphasis>Clin Epidemiol</emphasis></citetitle> <emphasis role="strong">5:</emphasis>185–197.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0050" role="bibliographyEntry">
            <para>50.<emphasis role="strong">Restrepo A, González A, Agudelo CA.</emphasis> 2011. Paracoccidioidomycosis, p 367–385. <citetitle><emphasis>In</emphasis></citetitle> Kauffman CA, Pappas PG, Sobel JD, Dismukes WE (ed), <citetitle><emphasis>Essentials of Clinical Mycology</emphasis></citetitle>, 2nd ed. Springer-Verlag, New York, NY.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0051" role="bibliographyEntry">
            <para>51.<emphasis role="strong">Restrepo A, Gómez BL, Tobón A.</emphasis> 2012. Paracoccidioidomycosis: Latin America’s own fungal disorder. <citetitle><emphasis>Curr Fungal Infect Rep</emphasis></citetitle> <emphasis role="strong">6:</emphasis>303–311.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0052" role="bibliographyEntry">
            <para>52.<emphasis role="strong">Martinez R.</emphasis> 2017. New trends in paracoccidioidomycosis epidemiology. <citetitle><emphasis>J Fungi</emphasis></citetitle> <emphasis role="strong">3:</emphasis>1. 10.3390/jof3010001.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0053" role="bibliographyEntry">
            <para>53.<emphasis role="strong">Watts JC, Callaway CS, Chandler FW, Kaplan W.</emphasis> 1975. Human pulmonary adiospiromycosis. <citetitle><emphasis>Arch Pathol</emphasis></citetitle> <emphasis role="strong">99:</emphasis>11–15.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0054" role="bibliographyEntry">
            <para>54.<emphasis role="strong">van Hougenhouck-Tulleken WG, Papavarnavas NS, Nel JS, Blackburn LY, Govender NP, Spencer DC, Lippincott CK.</emphasis> 2014. HIV-associated disseminated emmonsiosis, Johannesburg, South Africa. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">20:</emphasis>2164–2166.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0055" role="bibliographyEntry">
            <para>55.<emphasis role="strong">Schwartz IS, Govender NP, Corcoran C, Dlamini S, Prozesky H, Burton R, Mendelson M, Taljaard J, Lehloenya R, Calligaro G, Colebunders R, Kenyon C.</emphasis> 2015. Clinical characteristics, diagnosis, management, and outcomes of disseminated emmonsiosis: a retrospective case series. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">61:</emphasis>1004–1012.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0056" role="bibliographyEntry">
            <para>56.<emphasis role="strong">Kenyon C, Bonorchis K, Corcoran C, Meintjes G, Locketz M, Lehloenya R, Vismer HF, Naicker P, Prozesky H, van Wyk M, Bamford C, du Plooy M, Imrie G, Dlamini S, Borman AM, Colebunders R, Yansouni CP, Mendelson M, Govender NP.</emphasis> 2013. A dimorphic fungus causing disseminated infection in South Africa. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">369:</emphasis>1416–1424.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0057" role="bibliographyEntry">
            <para>57.<emphasis role="strong">Maphanga TG, Britz E, Zulu TG, Mpembe RS, Naicker SD, Schwartz IS, Govender NP.</emphasis> 2017. <citetitle><emphasis>In vitro</emphasis></citetitle> antifungal susceptibility of yeast and mold phases of isolates of dimorphic fungal pathogen <citetitle><emphasis>Emergomyces africanus</emphasis></citetitle> (formerly <citetitle><emphasis>Emmonsia</emphasis></citetitle> sp.) from HIV-infected South African patients. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>1812–1820.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0058" role="bibliographyEntry">
            <para>58.<emphasis role="strong">Cuellar-Rodriguez J, Avery RK, Lard M, Budev M, Gordon SM, Shrestha NK, van Duin D, Oethinger M, Mawhorter SD.</emphasis> 2009. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">49:</emphasis>710–716.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0059" role="bibliographyEntry">
            <para>59.<emphasis role="strong">Nacher M, Adenis A, Mc Donald S, Do Socorro Mendonca Gomes M, Singh S, Lopes Lima I, Malcher Leite R, Hermelijn S, Wongsokarijo M, Van Eer M, Marques Da Silva S, Mesquita Da Costa M, Silva M, Calvacante M, do Menino Jesus Silva Leitao T, Gómez BL, Restrepo A, Tobon A, Canteros CE, Aznar C, Blanchet D, Vantilcke V, Vautrin C, Boukhari R, Chiller T, Scheel C, Ahlquist A, Roy M, Lortholary O, Carme B, Couppié P, Vreden S.</emphasis> 2013. Disseminated histoplasmosis in HIV-infected patients in South America: a neglected killer continues on its rampage. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">7:</emphasis>e2319.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0060" role="bibliographyEntry">
            <para>60.<emphasis role="strong">Teles FR, Martins ML.</emphasis> 2011. Laboratorial diagnosis of paracoccidioidomycosis and new insights for the future of fungal diagnosis. <citetitle><emphasis>Talanta</emphasis></citetitle> <emphasis role="strong">85:</emphasis>2254–2264.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0061" role="bibliographyEntry">
            <para>61.<emphasis role="strong">Saccente M, Woods GL.</emphasis> 2010. Clinical and laboratory update on blastomycosis. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">23:</emphasis>367–381.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0062" role="bibliographyEntry">
            <para>62.<emphasis role="strong">Roy M, Benedict K, Deak E, Kirby MA, McNiel JT, Sickler CJ, Eckardt E, Marx RK, Heffernan RT, Meece JK, Klein BS, Archer JR, Theurer J, Davis JP, Park BJ.</emphasis> 2013. A large community outbreak of blastomycosis in Wisconsin with geographic and ethnic clustering. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">57:</emphasis>655–662.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0063" role="bibliographyEntry">
            <para>63.<emphasis role="strong">Merkhofer RM Jr, O’Neill MB, Xiong D, Hernandez-Santos N, Dobson H, Fites JS, Shockey AC, Wuethrich M, Pepperell CS, Klein BS.</emphasis> 2019. Investigation of genetic susceptibility to blastomycosis reveals interleukin-6 as a potential susceptibility locus. <citetitle><emphasis>mBio</emphasis></citetitle> <emphasis role="strong">10:</emphasis>e01224-19.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0064" role="bibliographyEntry">
            <para>64.<emphasis role="strong">Pappas PG, Threlkeld MG, Bedsole GD, Cleveland KO, Gelfand MS, Dismukes WE.</emphasis> 1993. Blastomycosis in immunocompromised patients. <citetitle><emphasis>Medicine (Baltimore)</emphasis></citetitle> <emphasis role="strong">72:</emphasis>311–325.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0065" role="bibliographyEntry">
            <para>65.<emphasis role="strong">Stagliano D, Epstein J, Hickey P.</emphasis> 2007. Fomite-transmitted coccidioidomycosis in an immunocompromised child. <citetitle><emphasis>Pediatr Infect Dis J</emphasis></citetitle> <emphasis role="strong">26:</emphasis>454–456.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0066" role="bibliographyEntry">
            <para>66.<emphasis role="strong">Vucicevic D, Carey EJ, Blair JE.</emphasis> 2011. Coccidioidomycosis in liver transplant recipients in an endemic area. <citetitle><emphasis>Am J Transplant</emphasis></citetitle> <emphasis role="strong">11:</emphasis>111–119.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0067" role="bibliographyEntry">
            <para>67.<emphasis role="strong">Nguyen C, Barker BM, Hoover S, Nix DE, Ampel NM, Frelinger JA, Orbach MJ, Galgiani JN.</emphasis> 2013. Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">26:</emphasis>505–525.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0068" role="bibliographyEntry">
            <para>68.<emphasis role="strong">Schneider E, Hajjeh RA, Spiegel RA, Jibson RW, Harp EL, Marshall GA, Gunn RA, McNeil MM, Pinner RW, Baron RC, Burger RC, Hutwagner LC, Crump C, Kaufman L, Reef SE, Feldman GM, Pappagianis D, Werner SB.</emphasis> 1997. A coccidioidomycosis outbreak following the Northridge, Calif, earthquake. <citetitle><emphasis>JAMA</emphasis></citetitle> <emphasis role="strong">277:</emphasis>904–908.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0069" role="bibliographyEntry">
            <para>69.<emphasis role="strong">Gorris ME, Treseder KK, Zender CS, Randerson JT.</emphasis> 2019. Expansion of coccidioidomycosis endemic regions in the United States in response to climate change. <citetitle><emphasis>Geohealth</emphasis></citetitle> <emphasis role="strong">3:</emphasis>308–327.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0070" role="bibliographyEntry">
            <para>70.<emphasis role="strong">Bays DJ, Thompson GR III.</emphasis> 2021. Coccidioidomycosis. <citetitle><emphasis>Infect Dis Clin North Am</emphasis></citetitle> <emphasis role="strong">35:</emphasis>453–469.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0071" role="bibliographyEntry">
            <para>71.<emphasis role="strong">Niño-Vega GA, et al.</emphasis> 2017. <citetitle><emphasis>Paracoccidioides</emphasis></citetitle> spp. and paracoccidioidomycosis, p 281–308. <citetitle><emphasis>In</emphasis></citetitle> Mora-Montes HM, Lopes-Becerra LM (ed), <citetitle><emphasis>Current Progress on Medical Mycology.</emphasis></citetitle> Springer International Publishing, Cham, Switzerland.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0072" role="bibliographyEntry">
            <para>72.<emphasis role="strong">Kenyon C, Corcoran C, Govender NP.</emphasis> 2014. An <citetitle><emphasis>Emmonsia</emphasis></citetitle> species causing disseminated infection in South Africa. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">370:</emphasis>284.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0073" role="bibliographyEntry">
            <para>73.<emphasis role="strong">Benedict K, Derado G, Mody RK.</emphasis> 2016. Histoplasmosis-associated hospitalizations in the United States, 2001-2012. <citetitle><emphasis>Open Forum Infect Dis</emphasis></citetitle> <emphasis role="strong">3:</emphasis>ofv219.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0074" role="bibliographyEntry">
            <para>74.<emphasis role="strong">Restrepo A, Cano LE.</emphasis> 1981. Recovery of fungi from seeded sputum samples: effect of culture media and digestion procedures. <citetitle><emphasis>Rev Inst Med Trop São Paulo</emphasis></citetitle> <emphasis role="strong">23:</emphasis>178–184.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0075" role="bibliographyEntry">
            <para>75.<emphasis role="strong">Tobón AM, Gómez BL.</emphasis> 2021. Pulmonary histoplasmosis. <citetitle><emphasis>Mycopathologia</emphasis></citetitle> <emphasis role="strong">186:</emphasis>697–705.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0076" role="bibliographyEntry">
            <para>76.<emphasis role="strong">Chapman SW, Dismukes WE, Proia LA, Bradsher RW, Pappas PG, Threlkeld MG, Kauffman CA, Infectious Diseases Society of America.</emphasis> 2008. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">46:</emphasis>1801–1812.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0077" role="bibliographyEntry">
            <para>77.<emphasis role="strong">Vugia DJWC, Cummings KC, Karon A.</emphasis> 2009. Increase in coccidioidomycosis—California, 2000–2007. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">58:</emphasis>105–109.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0078" role="bibliographyEntry">
            <para>78.<emphasis role="strong">Sunenshine RH, Anderson S, Erhart L, Vossbrink A, Kelly PC, Engelthaler D, Komatsu K.</emphasis> 2007. Public health surveillance for coccidioidomycosis in Arizona. <citetitle><emphasis>Ann N Y Acad Sci</emphasis></citetitle> <emphasis role="strong">1111:</emphasis>96–102.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0079" role="bibliographyEntry">
            <para>79.<emphasis role="strong">Kim MM, Blair JE, Carey EJ, Wu Q, Smilack JD.</emphasis> 2009. Coccidioidal pneumonia, Phoenix, Arizona, USA, 2000-2004. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">15:</emphasis>397–401.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0080" role="bibliographyEntry">
            <para>80.<emphasis role="strong">Vincent T, Galgiani JN, Huppert M, Salkin D.</emphasis> 1993. The natural history of coccidioidal meningitis: VA-Armed Forces cooperative studies, 1955-1958. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">16:</emphasis>247–254.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0081" role="bibliographyEntry">
            <para>81.<emphasis role="strong">Pelegrín I, Ayats J, Xiol X, Cuenca-Estrella M, Jucglà A, Boluda S, Fernàndez-Sabé N, Rafecas A, Gudiol F, Cabellos C.</emphasis> 2011. Disseminated adiaspiromycosis: case report of a liver transplant patient with human immunodeficiency infection, and literature review. <citetitle><emphasis>Transpl Infect Dis</emphasis></citetitle> <emphasis role="strong">13:</emphasis>507–514.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0082" role="bibliographyEntry">
            <para>82.<emphasis role="strong">Mendes MO, Moraes MA, Renoiner EI, Dantas MH, Lanzieri TM, Fonseca CF, Luna EJ, Hatch DL.</emphasis> 2009. Acute conjunctivitis with episcleritis and anterior uveitis linked to adiaspiromycosis and freshwater sponges, Amazon region, Brazil, 2005. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">15:</emphasis>633–639.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0083" role="bibliographyEntry">
            <para>83.<emphasis role="strong">Kauffman CA.</emphasis> 2009. Histoplasmosis. <citetitle><emphasis>Clin Chest Med</emphasis></citetitle> <emphasis role="strong">30:</emphasis>217–225.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0084" role="bibliographyEntry">
            <anchor id="ch0147s0055s0001a0005"/>
            <para>84.<emphasis role="strong">Mathisen G, Shelub A, Truong J, Wigen C.</emphasis> 2010. Coccidioidal meningitis: clinical presentation and management in the fluconazole era. <citetitle><emphasis>Medicine (Baltimore)</emphasis></citetitle> <emphasis role="strong">89:</emphasis>251–284.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0085" role="bibliographyEntry">
            <para>85.<emphasis role="strong">Schwartz IS, Kenyon C, Feng P, Govender NP, Dukik K, Sigler L, Jiang Y, Stielow JB, Muñoz JF, Cuomo CA, Botha A, Stchigel AM, de Hoog GS.</emphasis> 2015. 50 years of <citetitle><emphasis>Emmonsia</emphasis></citetitle> disease in humans: the dramatic emergence of a cluster of novel fungal pathogens. <citetitle><emphasis>PLoS Pathog</emphasis></citetitle> <emphasis role="strong">11:</emphasis>e1005198.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0086" role="bibliographyEntry">
            <para>86.<emphasis role="strong">Wu SJ, Valyi-Nagy T, Engelhard HH, Do MA, Janda WM.</emphasis> 2005. Secondary intracerebral blastomycosis with giant yeast forms. <citetitle><emphasis>Mycopathologia</emphasis></citetitle> <emphasis role="strong">160:</emphasis>253–257.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0087" role="bibliographyEntry">
            <para>87.<emphasis role="strong">Connolly PA, Durkin MM, Lemonte AM, Hackett EJ, Wheat LJ.</emphasis> 2007. Detection of histoplasma antigen by a quantitative enzyme immunoassay. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">14:</emphasis>1587–1591.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0088" role="bibliographyEntry">
            <para>88.<emphasis role="strong">Wheat J, Wheat H, Connolly P, Kleiman M, Supparatpinyo K, Nelson K, Bradsher R, Restrepo A.</emphasis> 1997. Cross-reactivity in <citetitle><emphasis>Histoplasma capsulatum</emphasis></citetitle> variety capsulatum antigen assays of urine samples from patients with endemic mycoses. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">24:</emphasis>1169–1171.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0089" role="bibliographyEntry">
            <para>89.<emphasis role="strong">Hage CA, Kirsch EJ, Stump TE, Kauffman CA, Goldman M, Connolly P, Johnson PC, Wheat LJ, Baddley JW.</emphasis> 2011. Histoplasma antigen clearance during treatment of histoplasmosis in patients with AIDS determined by a quantitative antigen enzyme immunoassay. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">18:</emphasis>661–666.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0090" role="bibliographyEntry">
            <para>90.<emphasis role="strong">Libert D, Procop GW, Ansari MQ.</emphasis> 2018. Histoplasma urinary antigen testing obviates the need for coincident serum antigen testing. <citetitle><emphasis>Am J Clin Pathol</emphasis></citetitle> <emphasis role="strong">149:</emphasis>362–368.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0091" role="bibliographyEntry">
            <para>91.<emphasis role="strong">Azar MM, Hage CA.</emphasis> 2017. Laboratory diagnostics for histoplasmosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>1612–1620.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0092" role="bibliographyEntry">
            <para>92.<emphasis role="strong">Zhang X, Gibson B Jr, Daly TM.</emphasis> 2013. Evaluation of commercially available reagents for diagnosis of histoplasmosis infection in immunocompromised patients. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>4095–4101.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0093" role="bibliographyEntry">
            <para>93.<emphasis role="strong">Theel ES, Harring JA, Dababneh AS, Rollins LO, Bestrom JE, Jespersen DJ.</emphasis> 2015. Reevaluation of commercial reagents for detection of <citetitle><emphasis>Histoplasma capsulatum</emphasis></citetitle> antigen in urine. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>1198–1203.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0094" role="bibliographyEntry">
            <para>94.<emphasis role="strong">Cáceres DH, Samayoa BE, Medina NG, Tobón AM, Guzmán BJ, Mercado D, Restrepo A, Chiller T, Arathoon EE, Gómez BL.</emphasis> 2018. Multicenter validation of commercial antigenuria reagents to diagnose progressive disseminated histoplasmosis in people living with HIV/AIDS in two Latin American countries. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>e01959-17.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0095" role="bibliographyEntry">
            <para>95.<emphasis role="strong">Cáceres DH, Gómez BL, Tobón AM, Chiller TM, Lindsley MD.</emphasis> 2020. Evaluation of a <citetitle><emphasis>Histoplasma</emphasis></citetitle> antigen lateral flow assay for the rapid diagnosis of progressive disseminated histoplasmosis in Colombian patients with AIDS. <citetitle><emphasis>Mycoses</emphasis></citetitle> <emphasis role="strong">63:</emphasis>139–144.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0096" role="bibliographyEntry">
            <para>96.<emphasis role="strong">Girouard G, Lachance C, Pelletier R.</emphasis> 2007. Observations on (1-3)-beta-D-glucan detection as a diagnostic tool in endemic mycosis caused by <citetitle><emphasis>Histoplasma</emphasis></citetitle> or <citetitle><emphasis>Blastomyces. J Med Microbiol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>1001–1002.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0097" role="bibliographyEntry">
            <para>97.<emphasis role="strong">Durkin M, Witt J, Lemonte A, Wheat B, Connolly P.</emphasis> 2004. Antigen assay with the potential to aid in diagnosis of blastomycosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>4873–4875.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0098" role="bibliographyEntry">
            <para>98.<emphasis role="strong">Frost HM, Novicki TJ.</emphasis> 2015. <citetitle><emphasis>Blastomyces</emphasis></citetitle> antigen detection for diagnosis and management of blastomycosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>3660–3662.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0099" role="bibliographyEntry">
            <para>99.<emphasis role="strong">Durkin M, Connolly P, Kuberski T, Myers R, Kubak BM, Bruckner D, Pegues D, Wheat LJ.</emphasis> 2008. Diagnosis of coccidioidomycosis with use of the <citetitle><emphasis>Coccidioides</emphasis></citetitle> antigen enzyme immunoassay. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">47:</emphasis>e69–e73.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0100" role="bibliographyEntry">
            <para>100.<emphasis role="strong">Kirsch EJ, Greene RT, Prahl A, Rubin SI, Sykes JE, Durkin MM, Wheat LJ.</emphasis> 2012. Evaluation of <citetitle><emphasis>Coccidioides</emphasis></citetitle> antigen detection in dogs with coccidioidomycosis. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">19:</emphasis>343–345.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0101" role="bibliographyEntry">
            <para>101.<emphasis role="strong">Kassis C, Zaidi S, Kuberski T, Moran A, Gonzalez O, Hussain S, Hartmann-Manrique C, Al-Jashaami L, Chebbo A, Myers RA, Wheat LJ.</emphasis> 2015. Role of <citetitle><emphasis>Coccidioides</emphasis></citetitle> antigen testing in the cerebrospinal fluid for the diagnosis of coccidioidal meningitis. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">61:</emphasis>1521–1526.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0102" role="bibliographyEntry">
            <para>102.<emphasis role="strong">Grill FJ, Grys TE, Grill MF, Roeder A, Blair JE, Lake DF.</emphasis> 2021. Development of a quantitative antigen assay to detect coccidioidal chitinase-1 (CTS1) in human serum. <citetitle><emphasis>Open Forum Infect Dis</emphasis></citetitle> <emphasis role="strong">8</emphasis>:ofab344.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0103" role="bibliographyEntry">
            <para>103.<emphasis role="strong">Thompson GR III, Bays DJ, Johnson SM, Cohen SH, Pappagianis D, Finkelman MA.</emphasis> 2012. Serum (1→3)-β-D-glucan measurement in coccidioidomycosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>3060–3062.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0104" role="bibliographyEntry">
            <para>104.<emphasis role="strong">Marques da Silva SH, Queiroz-Telles F, Colombo AL, Blotta MH, Lopes JD, Pires De Camargo Z.</emphasis> 2004. Monitoring gp43 antigenemia in paracoccidioidomycosis patients during therapy. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>2419–2424.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0105" role="bibliographyEntry">
            <para>105.<emphasis role="strong">Marques da Silva SH, Colombo AL, Blotta MH, Lopes JD, Queiroz-Telles F, Pires de Camargo Z.</emphasis> 2003. Detection of circulating gp43 antigen in serum, cerebrospinal fluid, and bronchoalveolar lavage fluid of patients with paracoccidioidomycosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>3675–3680.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0106" role="bibliographyEntry">
            <para>106.<emphasis role="strong">Gómez BL, Figueroa JI, Hamilton AJ, Diez S, Rojas M, Tobón AM, Hay RJ, Restrepo A.</emphasis> 1998. Antigenemia in patients with paracoccidioidomycosis: detection of the 87-kilodalton determinant during and after antifungal therapy. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>3309–3316.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0107" role="bibliographyEntry">
            <para>107.<emphasis role="strong">Bialek R, Feucht A, Aepinus C, Just-Nübling G, Robertson VJ, Knobloch J, Hohle R.</emphasis> 2002. Evaluation of two nested PCR assays for detection of <citetitle><emphasis>Histoplasma capsulatum</emphasis></citetitle> DNA in human tissue. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>1644–1647.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0108" role="bibliographyEntry">
            <para>108.<emphasis role="strong">Muñoz C, Gómez BL, Tobón A, Arango K, Restrepo A, Correa MM, Muskus C, Cano LE, González A.</emphasis> 2010. Validation and clinical application of a molecular method for identification of <citetitle><emphasis>Histoplasma capsulatum</emphasis></citetitle> in human specimens in Colombia, South America. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">17:</emphasis>62–67.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0109" role="bibliographyEntry">
            <para>109.<emphasis role="strong">Maubon D, Simon S, Aznar C.</emphasis> 2007. Histoplasmosis diagnosis using a polymerase chain reaction method. Application on human samples in French Guiana, South America. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">58:</emphasis>441–444.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0110" role="bibliographyEntry">
            <para>110.<emphasis role="strong">Imhof A, Schaer C, Schoedon G, Schaer DJ, Walter RB, Schaffner A, Schneemann M.</emphasis> 2003. Rapid detection of pathogenic fungi from clinical specimens using LightCycler real-time fluorescence PCR. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">22:</emphasis>558–560.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0111" role="bibliographyEntry">
            <para>111.<emphasis role="strong">Alanio A, Gits-Muselli M, Lanternier F, Sturny-Leclere A, Benazra M, Hamane S, Rodrigues AM, Garcia-Hermoso D, Lortholary O, Dromer F, Bretagne S, French Mycoses Study Group.</emphasis> 2021. Evaluation of a new <citetitle><emphasis>Histoplasma</emphasis></citetitle> spp. quantitative RT-PCR assay. <citetitle><emphasis>J Mol Diagn</emphasis></citetitle> <emphasis role="strong">23:</emphasis>698–709.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0112" role="bibliographyEntry">
            <para>112.<emphasis role="strong">Kaplan M, Zhu Y, Kus JV, McTaggart L, Chaturvedi V, Chaturvedi S.</emphasis> 2021. Development of a duplex real-time PCR assay for the differentiation of <citetitle><emphasis>Blastomyces dermatitidis</emphasis></citetitle> and <citetitle><emphasis>Blastomyces gilchristii</emphasis></citetitle> and a retrospective analysis of culture and primary specimens from blastomycosis cases from New York (2005 to 2019). <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">59:</emphasis>e02078-20.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0113" role="bibliographyEntry">
            <para>113.<emphasis role="strong">Vucicevic D, Blair JE, Binnicker MJ, McCullough AE, Kusne S, Vikram HR, Parish JM, Wengenack NL.</emphasis> 2010. The utility of <citetitle><emphasis>Coccidioides</emphasis></citetitle> polymerase chain reaction testing in the clinical setting. <citetitle><emphasis>Mycopathologia</emphasis></citetitle> <emphasis role="strong">170:</emphasis>345–351.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0114" role="bibliographyEntry">
            <para>114.<emphasis role="strong">Saubolle MA, Wojack BR, Wertheimer AM, Fuayagem AZ, Young S, Koeneman BA.</emphasis> 2018. Multicenter clinical validation of a cartridge-based real-time PCR system for detection of <citetitle><emphasis>Coccidioides</emphasis></citetitle> spp. in lower respiratory specimens. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>e01277-17.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0115" role="bibliographyEntry">
            <para>115.<emphasis role="strong">Thompson GR III, Sharma S, Bays DJ, Pruitt R, Engelthaler DM, Bowers J, Driebe EM, Davis M, Libke R, Cohen SH, Pappagianis D.</emphasis> 2013. Coccidioidomycosis: adenosine deaminase levels, serologic parameters, culture results, and polymerase chain reaction testing in pleural fluid. <citetitle><emphasis>Chest</emphasis></citetitle> <emphasis role="strong">143:</emphasis>776–781.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0116" role="bibliographyEntry">
            <para>116.<emphasis role="strong">Dizon D, Mitchell M, Dizon B, Libke R, Peterson MW.</emphasis> 2019. The utility of real-time polymerase chain reaction in detecting <citetitle><emphasis>Coccidioides immitis</emphasis></citetitle> among clinical specimens in the Central California San Joaquin Valley. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">57:</emphasis>688–693.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0117" role="bibliographyEntry">
            <anchor id="ch0147s0055s0001a0006"/>
            <para>117.<emphasis role="strong">Chaturvedi S, Victor TR, Marathe A, Sidamonidze K, Crucillo KL, Chaturvedi V.</emphasis> 2021. Real-time PCR assay for detection and differentiation of <citetitle><emphasis>Coccidioides immitis</emphasis></citetitle> and <citetitle><emphasis>Coccidioides posadasii</emphasis></citetitle> from culture and clinical specimens. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">15:</emphasis>e0009765.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0118" role="bibliographyEntry">
            <para>118.<emphasis role="strong">Buitrago MJ, Merino P, Puente S, Gomez-Lopez A, Arribi A, Zancopé-Oliveira RM, Gutierrez MC, Rodriguez-Tudela JL, Cuenca-Estrella M.</emphasis> 2009. Utility of real-time PCR for the detection of <citetitle><emphasis>Paracoccidioides brasiliensis</emphasis></citetitle> DNA in the diagnosis of imported paracoccidioidomycosis. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>879–882.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0119" role="bibliographyEntry">
            <para>119.<emphasis role="strong">Bialek R, Ibricevic A, Aepinus C, Najvar LK, Fothergill AW, Knobloch J, Graybill JR.</emphasis> 2000. Detection of <citetitle><emphasis>Paracoccidioides brasiliensis</emphasis></citetitle> in tissue samples by a nested PCR assay. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">38:</emphasis>2940–2942.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0120" role="bibliographyEntry">
            <para>120.<emphasis role="strong">Rocha-Silva F, Gomes LI, Gracielle-Melo C, Goes AM, Caligiorne RB.</emphasis> 2017. Real time polymerase chain reaction (rt-PCR): a new patent to diagnostic purposes for paracoccidioidomycosis. <citetitle><emphasis>Recent Pat Endocr Metab Immune Drug Discov</emphasis></citetitle> <emphasis role="strong">10:</emphasis>143–149.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0121" role="bibliographyEntry">
            <para>121.<emphasis role="strong">Rocha-Silva F, Maria de Figueiredo S, Rutren La Santrer EF, Machado AS, Fernandes B, Assunção CB, Góes AM, Caligiorne RB.</emphasis> 2018. Paracoccidioidomycosis: detection of <citetitle><emphasis>Paracoccidioides brasiliensis</emphasis></citetitle> genome in biological samples by quantitative chain reaction polymerase (qPCR). <citetitle><emphasis>Microb Pathog</emphasis></citetitle> <emphasis role="strong">121:</emphasis>359–362.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0122" role="bibliographyEntry">
            <para>122.<emphasis role="strong">Dot JM, Debourgogne A, Champigneulle J, Salles Y, Brizion M, Puyhardy JM, Collomb J, Plénat F, Machouart M.</emphasis> 2009. Molecular diagnosis of disseminated adiaspiromycosis due to <citetitle><emphasis>Emmonsia crescens. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>1269–1273.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0123" role="bibliographyEntry">
            <para>123.<emphasis role="strong">Rooms I, Mugisha P, Gambichler T, Hadaschik E, Esser S, Rath PM, Haase G, Wilmes D, McCormick-Smith I, Rickerts V.</emphasis> 2019. Disseminated emergomycosis in a person with HIV infection, Uganda. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">25:</emphasis>1750–1751.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0124" role="bibliographyEntry">
            <para>124.<emphasis role="strong">Gugnani HC, Randhawa HS.</emphasis> 2020. Laboratory-acquired fungal infections: a review. <citetitle><emphasis>Arch Microbiol Immunol</emphasis></citetitle> <emphasis role="strong">4:</emphasis>51–56.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0125" role="bibliographyEntry">
            <para>125.<emphasis role="strong">CDC.</emphasis> Biosafety in Microbiological and Biomedical Laboratories, 6th edition. <ulink url="https://www.cdc.gov/labs/BMBL.html">https://www.cdc.gov/labs/BMBL.html</ulink>. Accessed 14 March 2023.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0126" role="bibliographyEntry">
            <para>126.<emphasis role="strong">Sutton DA, Padhye AA, Standard PG, Rinaldi MG.</emphasis> 1997. An aberrant variant of <citetitle><emphasis>Histoplasma capsulatum</emphasis></citetitle> var. capsulatum. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">35:</emphasis>734–735.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0127" role="bibliographyEntry">
            <para>127.<emphasis role="strong">Gaur PK, Lichtwardt RW.</emphasis> 1980. Comparative study of a new <citetitle><emphasis>Chrysosporium</emphasis></citetitle> species with <citetitle><emphasis>Histoplasma capsulatum. Sabouraudia</emphasis></citetitle> <emphasis role="strong">18:</emphasis>105–114.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0128" role="bibliographyEntry">
            <para>128.<emphasis role="strong">Valero C, Buitrago MJ, Gago S, Quiles-Melero I, García-Rodríguez J.</emphasis> 2018. A matrix-assisted laser desorption/ionization time of flight mass spectrometry reference database for the identification of <citetitle><emphasis>Histoplasma capsulatum. Med Mycol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>307–314.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0129" role="bibliographyEntry">
            <para>129.<emphasis role="strong">Sutton DA.</emphasis> 2007. Diagnosis of coccidioidomycosis by culture: safety considerations, traditional methods, and susceptibility testing. <citetitle><emphasis>Ann N Y Acad Sci</emphasis></citetitle> <emphasis role="strong">1111:</emphasis>315–325.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0130" role="bibliographyEntry">
            <para>130.<emphasis role="strong">Mead HL, Teixeira MM, Galgiani JN, Barker BM.</emphasis> 2019. Characterizing in vitro spherule morphogenesis of multiple strains of both species of <citetitle><emphasis>Coccidioides. Med Mycol</emphasis></citetitle> <emphasis role="strong">57:</emphasis>478–488.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0131" role="bibliographyEntry">
            <para>131.<emphasis role="strong">Sigler L.</emphasis> 2005. Adiaspiromycosis and other infections caused by Emmonsia species, p 810–824. <citetitle><emphasis>In</emphasis></citetitle> Merz WG, Hay RJ (ed), <citetitle><emphasis>Topley and Wilson’s Microbiology and Microbial Infections</emphasis></citetitle>, 10th ed. Wiley, New York, NY.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0132" role="bibliographyEntry">
            <para>132.<emphasis role="strong">Gori S, Drouhet E, Gueho E, Huerre M, Lofaro A, Parenti M, Dupont B.</emphasis> 1998. Cutaneous disseminated mycosis in a patient with AIDS due to a new dimorphic fungus. <citetitle><emphasis>J Mycol Med</emphasis></citetitle> 8:57–63.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0133" role="bibliographyEntry">
            <para>133.<emphasis role="strong">Taylor JW, Geiser DM, Burt A, Koufopanou V.</emphasis> 1999. The evolutionary biology and population genetics underlying fungal strain typing. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">12:</emphasis>126–146.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0134" role="bibliographyEntry">
            <para>134.<emphasis role="strong">Muniz MM, Pizzini CV, Peralta JM, Reiss E, Zancopé-Oliveira RM.</emphasis> 2001. Genetic diversity of <citetitle><emphasis>Histoplasma capsulatum</emphasis></citetitle> strains isolated from soil, animals, and clinical specimens in Rio de Janeiro State, Brazil, by a PCR-based random amplified polymorphic DNA assay. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">39:</emphasis>4487–4494.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0135" role="bibliographyEntry">
            <para>135.<emphasis role="strong">Karimi K, Wheat LJ, Connolly P, Cloud G, Hajjeh R, Wheat E, Alves K, Lacaz Cd CS, Keath E.</emphasis> 2002. Differences in histoplasmosis in patients with acquired immunodeficiency syndrome in the United States and Brazil. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">186:</emphasis>1655–1660.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0136" role="bibliographyEntry">
            <para>136.<emphasis role="strong">Muniz MM, Morais E Silva Tavares P, Meyer W, Nosanchuk JD, Zancope-Oliveira RM.</emphasis> 2010. Comparison of different DNA-based methods for molecular typing of <citetitle><emphasis>Histoplasma capsulatum. Appl Environ Microbiol</emphasis></citetitle> <emphasis role="strong">76:</emphasis>4438–4447.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0137" role="bibliographyEntry">
            <para>137.<emphasis role="strong">Rakislova N, Hurtado JC, Palhares AEM, Ferreira L, Freire M, Lacerda M, Monteiro W, Navarro M, Casas I, Teixeira MM, Castillo P, Rodrigo-Calvo MT, Marimon L, Guerrero J, Varo R, Delgado V, Quintó L, Marco F, Letang E, Vila J, Bassat Q, Menéndez C, Ordi J, Martínez MJ.</emphasis> 2021. High prevalence and mortality due to <citetitle><emphasis>Histoplasma capsulatum</emphasis></citetitle> in the Brazilian Amazon: an autopsy study. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">15:</emphasis>e0009286.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0138" role="bibliographyEntry">
            <para>138.<emphasis role="strong">McCullough MJ, DiSalvo AF, Clemons KV, Park P, Stevens DA.</emphasis> 2000. Molecular epidemiology of <citetitle><emphasis>Blastomyces dermatitidis. Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">30:</emphasis>328–335.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0139" role="bibliographyEntry">
            <para>139.<emphasis role="strong">Meece JK, Anderson JL, Klein BS, Sullivan TD, Foley SL, Baumgardner DJ, Brummitt CF, Reed KD.</emphasis> 2010. Genetic diversity in <citetitle><emphasis>Blastomyces dermatitidis</emphasis></citetitle>: implications for PCR detection in clinical and environmental samples. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>285–290.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0140" role="bibliographyEntry">
            <para>140.<emphasis role="strong">Fisher MC, Koenig GL, White TJ, Taylor JW.</emphasis> 2002. Molecular and phenotypic description of <citetitle><emphasis>Coccidioides posadasii</emphasis></citetitle> sp. nov., previously recognized as the non-California population of <citetitle><emphasis>Coccidioides immitis. Mycologia</emphasis></citetitle> <emphasis role="strong">94:</emphasis>73–84.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0141" role="bibliographyEntry">
            <para>141.<emphasis role="strong">Koufopanou V, Burt A, Taylor JW.</emphasis> 1997. Concordance of gene genealogies reveals reproductive isolation in the pathogenic fungus <citetitle><emphasis>Coccidioides immitis. Proc Natl Acad Sci USA</emphasis></citetitle> <emphasis role="strong">94:</emphasis>5478–5482.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0142" role="bibliographyEntry">
            <para>142.<emphasis role="strong">Jewell K, Cheshier R, Cage GD.</emphasis> 2008. Genetic diversity among clinical <citetitle><emphasis>Coccidioides</emphasis></citetitle> spp. isolates in Arizona. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>449–455.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0143" role="bibliographyEntry">
            <para>143.<emphasis role="strong">Nascimento E, Martinez R, Lopes AR, de Souza Bernardes LA, Barco CP, Goldman MH, Taylor JW, McEwen JG, Nobrega MP, Nobrega FG, Goldman GH.</emphasis> 2004. Detection and selection of microsatellites in the genome of <citetitle><emphasis>Paracoccidioides brasiliensis</emphasis></citetitle> as molecular markers for clinical and epidemiological studies. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>5007–5014.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0144" role="bibliographyEntry">
            <para>144.<emphasis role="strong">Lindsley MD, Warnock DW, Morrison CJ.</emphasis> 2006. Serological and molecular diagnosis of fungal infection, p 569–605. <citetitle><emphasis>In</emphasis></citetitle> Rose NR, Hamilton RG, Detrick B (ed), <citetitle><emphasis>Manual of Molecular and Clinical Laboratory Immunology</emphasis></citetitle>, 7th ed. ASM Press, Washington, DC.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0145" role="bibliographyEntry">
            <para>145.<emphasis role="strong">Guimarães AJ, Nosanchuk JD, Zancopé-Oliveira RM.</emphasis> 2006. Diagnosis of histoplasmosis. <citetitle><emphasis>Braz J Microbiol</emphasis></citetitle> <emphasis role="strong">37:</emphasis>1–13.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0146" role="bibliographyEntry">
            <para>146.<emphasis role="strong">Kauffman CA.</emphasis> 2007. Histoplasmosis: a clinical and laboratory update. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">20:</emphasis>115–132.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0147" role="bibliographyEntry">
            <para>147.<emphasis role="strong">Guimarães AJ, Pizzini CV, De Abreu Almeida M, Peralta JM, Nosanchuk JD, Zancopé-Oliveira RM.</emphasis> 2010. Evaluation of an enzyme-linked immunosorbent assay using purified, deglycosylated histoplasmin for different clinical manifestations of histoplasmosis. <citetitle><emphasis>Microbiol Res (Pavia)</emphasis></citetitle> <emphasis role="strong">1:</emphasis>e2.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0148" role="bibliographyEntry">
            <para>148.<emphasis role="strong">Bloch KC, Myint T, Raymond-Guillen L, Hage CA, Davis TE, Wright PW, Chow FC, Woc-Colburn L, Khairy RN, Street AC, Yamamoto T, Albers A, Wheat LJ.</emphasis> 2018. Improvement in diagnosis of <citetitle><emphasis>Histoplasma</emphasis></citetitle> meningitis by combined testing for <citetitle><emphasis>Histoplasma</emphasis></citetitle> antigen and immunoglobulin G and immunoglobulin M anti-<citetitle><emphasis>Histoplasma</emphasis></citetitle> antibody in cerebrospinal fluid. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">66:</emphasis>89–94.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0149" role="bibliographyEntry">
            <para>149.<emphasis role="strong">Soufleris AJ, Klein BS, Courtney BT, Proctor ME, Jones JM.</emphasis> 1994. Utility of anti-WI-1 serological testing in the diagnosis of blastomycosis in Wisconsin residents. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">19:</emphasis>87–92.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0150" role="bibliographyEntry">
            <para>150.<emphasis role="strong">Klein BS, Vergeront JM, Kaufman L, Bradsher RW, Kumar UN, Mathai G, Varkey B, Davis JP.</emphasis> 1987. Serological tests for blastomycosis: assessments during a large point-source outbreak in Wisconsin. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">155:</emphasis>262–268.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0151" role="bibliographyEntry">
            <para>151.<emphasis role="strong">Klein BS, Kuritsky JN, Chappell WA, Kaufman L, Green J, Davies SF, Williams JE, Sarosi GA.</emphasis> 1986. Comparison of the enzyme immunoassay, immunodiffusion, and complement fixation tests in detecting antibody in human serum to the A antigen of <citetitle><emphasis>Blastomyces dermatitidis. Am Rev Respir Dis</emphasis></citetitle> <emphasis role="strong">133:</emphasis>144–148.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0152" role="bibliographyEntry">
            <para>152.<emphasis role="strong">Pappagianis D.</emphasis> 2001. Serologic studies in coccidioidomycosis. <citetitle><emphasis>Semin Respir Infect</emphasis></citetitle> <emphasis role="strong">16:</emphasis>242–250.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0153" role="bibliographyEntry">
            <anchor id="ch0147s0055s0001a0007"/>
            <para>153.<emphasis role="strong">Pappagianis D, Krasnow RI, Beall S.</emphasis> 1976. False-positive reactions of cerebrospinal fluid and diluted sera with the coccidioidal latex-agglutination test. <citetitle><emphasis>Am J Clin Pathol</emphasis></citetitle> <emphasis role="strong">66:</emphasis>916–921.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0154" role="bibliographyEntry">
            <para>154.<emphasis role="strong">Twarog M, Thompson GR III.</emphasis> 2015. Coccidioidomycosis: recent updates. <citetitle><emphasis>Semin Respir Crit Care Med</emphasis></citetitle> <emphasis role="strong">36:</emphasis>746–755.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0155" role="bibliographyEntry">
            <para>155.<emphasis role="strong">Malo J, Holbrook E, Zangeneh T, Strawter C, Oren E, Robey I, Erickson H, Chahal R, Durkin M, Thompson C, Hoover SE, Ampel NM, Wheat LJ, Knox KS.</emphasis> 2017. Enhanced antibody detection and diagnosis of coccidioidomycosis with the MiraVista IgG and IgM detection enzyme immunoassay. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>893–901.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0156" role="bibliographyEntry">
            <para>156.<emphasis role="strong">Donovan FM, Ramadan FA, Khan SA, Bhaskara A, Lainhart WD, Narang AT, Mosier JM, Ellingson KD, Bedrick EJ, Saubolle MA, Galgiani JN.</emphasis> 2020. Comparison of a novel rapid lateral flow assay to enzyme immunoassay results for early diagnosis of coccidioidomycosis. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">73:</emphasis>e2746-e2753.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0157" role="bibliographyEntry">
            <para>157.<emphasis role="strong">Shikanai-Yasuda MA, Mendes RP, Colombo AL, Queiroz-Telles F, Kono ASG, Paniago AMM, Nathan A, Valle ACFD, Bagagli E, Benard G, Ferreira MS, Teixeira MM, Silva-Vergara ML, Pereira RM, Cavalcante RS, Hahn R, Durlacher RR, Khoury Z, Camargo ZP, Moretti ML, Martinez R.</emphasis> 2017. Brazilian guidelines for the clinical management of paracoccidioidomycosis. <citetitle><emphasis>Rev Soc Bras Med Trop</emphasis></citetitle> <emphasis role="strong">50:</emphasis>715–740.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0158" role="bibliographyEntry">
            <para>158.<emphasis role="strong">Díez S, Gómez BL, McEwen JG, Restrepo A, Hay RJ, Hamilton AJ.</emphasis> 2003. Combined use of <citetitle><emphasis>Paracoccidioides brasiliensis</emphasis></citetitle> recombinant 27-kilodalton and purified 87-kilodalton antigens in an enzyme-linked immunosorbent assay for serodiagnosis of paracoccidioidomycosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>1536–1542.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0159" role="bibliographyEntry">
            <para>159.<emphasis role="strong">Fernandes VC, Coitinho JB, Veloso JM, Araújo SA, Pedroso EP, Goes AM.</emphasis> 2011. Combined use of <citetitle><emphasis>Paracoccidioides brasiliensis</emphasis></citetitle> recombinant rPb27 and rPb40 antigens in an enzyme-linked immunosorbent assay for immunodiagnosis of paracoccidioidomycosis. <citetitle><emphasis>J Immunol Methods</emphasis></citetitle> <emphasis role="strong">367:</emphasis>78–84.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0160" role="bibliographyEntry">
            <para>160.<emphasis role="strong">Gegembauer G, Araujo LM, Pereira EF, Rodrigues AM, Paniago AM, Hahn RC, de Camargo ZP.</emphasis> 2014. Serology of paracoccidioidomycosis due to <citetitle><emphasis>Paracoccidioides lutzii. PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e2986.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0161" role="bibliographyEntry">
            <para>161.<emphasis role="strong">Vidal MS, Del Negro GM, Vicentini AP, Svidzinski TI, Mendes-Giannini MJ, Almeida AM, Martinez R, de Camargo ZP, Taborda CP, Benard G.</emphasis> 2014. Serological diagnosis of paracoccidioidomycosis: high rate of inter-laboratorial variability among medical mycology reference centers. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e3174.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0162" role="bibliographyEntry">
            <para>162.<emphasis role="strong">da Silva JF, de Oliveira HC, Marcos CM, Assato PA, Fusco-Almeida AM, Mendes-Giannini MJS.</emphasis> 2016. Advances and challenges in paracoccidioidomycosis serology caused by <citetitle><emphasis>Paracoccidioides</emphasis></citetitle> species complex: an update. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">84:</emphasis>87–94.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0163" role="bibliographyEntry">
            <para>163.<emphasis role="strong">Rodrigues AM, Kubitschek-Barreira PH, Pinheiro BG, Teixeira-Ferreira A, Hahn RC, de Camargo ZP.</emphasis> 2020. Immunoproteomic analysis reveals novel candidate antigens for the diagnosis of paracoccidioidomycosis due to <citetitle><emphasis>Paracoccidioides lutzii. J Fungi (Basel)</emphasis></citetitle> <emphasis role="strong">6:</emphasis>E357.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0164" role="bibliographyEntry">
            <para>164.<emphasis role="strong">Lima EO, Navarro LC, Morishita KN, Kamikawa CM, Rodrigues RGM, Dabaja MZ, de Oliveira DN, Delafiori J, Dias-Audibert FL, Ribeiro MDS, Vicentini AP, Rocha A, Catharino RR.</emphasis> 2020. Metabolomics and machine learning approaches combined in pursuit for more accurate paracoccidioidomycosis diagnoses. <citetitle><emphasis>mSystems</emphasis></citetitle> <emphasis role="strong">5:</emphasis>e00258-20.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0165" role="bibliographyEntry">
            <para>165.<emphasis role="strong">Thompson GR III, Rendon A, Ribeiro Dos Santos R, Queiroz-Telles F, Ostrosky-Zeichner L, Azie N, Maher R, Lee M, Kovanda L, Engelhardt M, Vazquez JA, Cornely OA, Perfect JR.</emphasis> 2016. Isavuconazole treatment of cryptococcosis and dimorphic mycoses. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">63:</emphasis>356–362.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0166" role="bibliographyEntry">
            <para>166.<emphasis role="strong">Duan N, Yang S.</emphasis> 2022. Research progress on multifunctional fluorescent probes for biological imaging, food and environmental detection. <citetitle><emphasis>Crit Rev Anal Chem</emphasis></citetitle> <emphasis role="strong">18:</emphasis>1–43.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0167" role="bibliographyEntry">
            <para>167.<emphasis role="strong">Song F, Li T, Hur J, Wu F, Meng X.</emphasis> 2022. Eco-colloidal layer of micro/nanoplastics increases complexity and uncertainty of their biotoxicity in aquatic environments. <citetitle><emphasis>Environ Sci Technol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>10547–10549.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0168" role="bibliographyEntry">
            <para>168.<emphasis role="strong">Wheat LJ, Connolly P, Smedema M, Durkin M, Brizendine E, Mann P, Patel R, McNicholas PM, Goldman M.</emphasis> 2006. Activity of newer triazoles against <citetitle><emphasis>Histoplasma capsulatum</emphasis></citetitle> from patients with AIDS who failed fluconazole. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">57:</emphasis>1235–1239.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0169" role="bibliographyEntry">
            <para>169.<emphasis role="strong">Kriesel JD, Sutton DA, Schulman S, Fothergill AW, Rinaldi MG.</emphasis> 2008. Persistent pulmonary infection with an azole-resistant <citetitle><emphasis>Coccidioides</emphasis></citetitle> species. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>607–610.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0170" role="bibliographyEntry">
            <para>170.<emphasis role="strong">Gintjee TJ, Donnelley MA, Thompson GR III.</emphasis> 2020. Aspiring antifungals: review of current antifungal pipeline developments. <citetitle><emphasis>J Fungi (Basel)</emphasis></citetitle> <emphasis role="strong">6:</emphasis>E28.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0171" role="bibliographyEntry">
            <para>171.<emphasis role="strong">Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R, Lass-Flörl C, Prattes J, Spec A, Thompson GR III, Wiederhold N, Jenks JD.</emphasis> 2021. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. <citetitle><emphasis>Drugs</emphasis></citetitle> <emphasis role="strong">81:</emphasis>1703–1729.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0172" role="bibliographyEntry">
            <para>172.<emphasis role="strong">Hage CA, Ribes JA, Wengenack NL, Baddour LM, Assi M, McKinsey DS, Hammoud K, Alapat D, Babady NE, Parker M, Fuller D, Noor A, Davis TE, Rodgers M, Connolly PA, El Haddad B, Wheat LJ.</emphasis> 2011. A multicenter evaluation of tests for diagnosis of histoplasmosis. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">53:</emphasis>448–454.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0173" role="bibliographyEntry">
            <para>173.<emphasis role="strong">Stockman L, Clark KA, Hunt JM, Roberts GD.</emphasis> 1993. Evaluation of commercially available acridinium ester-labeled chemiluminescent DNA probes for culture identification of <citetitle><emphasis>Blastomyces dermatitidis</emphasis></citetitle>, <citetitle><emphasis>Coccidioides immitis</emphasis></citetitle>, <citetitle><emphasis>Cryptococcus neoformans</emphasis></citetitle>, and <citetitle><emphasis>Histoplasma capsulatum. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">31:</emphasis>845–850.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0174" role="bibliographyEntry">
            <para>174.<emphasis role="strong">Castillo CG, Kauffman CA, Miceli MH.</emphasis> 2016. Blastomycosis. <citetitle><emphasis>Infect Dis Clin North Am</emphasis></citetitle> <emphasis role="strong">30:</emphasis>247–264.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0175" role="bibliographyEntry">
            <para>175.<emphasis role="strong">McHardy IH, Dinh BN, Waldman S, Stewart E, Bays D, Pappagianis D, Thompson GR III.</emphasis> 2018. Coccidioidomycosis complement fixation titer trends in the age of antifungals. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>e01318-18.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0176" role="bibliographyEntry">
            <para>176.<emphasis role="strong">Stockamp NW, Thompson GR III.</emphasis> 2016. Coccidioidomycosis. <citetitle><emphasis>Infect Dis Clin North Am</emphasis></citetitle> <emphasis role="strong">30:</emphasis>229–246.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0177" role="bibliographyEntry">
            <para>177.<emphasis role="strong">Thompson G III, Wang S, Bercovitch R, Bolaris M, Van Den Akker D, Taylor S, Lopez R, Catanzaro A, Cadena J, Chin-Hong P, Spellberg B.</emphasis> 2013. Routine CSF analysis in coccidioidomycosis is not required. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e64249.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0178" role="bibliographyEntry">
            <para>178.<emphasis role="strong">Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Geertsma F, Hoover SE, Johnson RH, Kusne S, Lisse J, MacDonald JD, Meyerson SL, Raksin PB, Siever J, Stevens DA, Sunenshine R, Theodore N.</emphasis> 2016. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">63:</emphasis>e112–e146.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0179" role="bibliographyEntry">
            <para>179.<emphasis role="strong">Thompson GR III, Boulware DR, Bahr NC, Clancy CJ, Harrison TS, Kauffman CA, Le T, Miceli MH, Mylonakis E, Nguyen MH, Ostrosky-Zeichner L, Patterson TF, Perfect JR, Spec A, Kontoyiannis DP, Pappas PG.</emphasis> 2022. Noninvasive testing and surrogate markers in invasive fungal diseases. Open Forum Infect Dis <emphasis role="strong">9:</emphasis>ofac112.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0180" role="bibliographyEntry">
            <para>180.<emphasis role="strong">McKinsey DS, McKinsey JP, Northcutt N, Sarria JC.</emphasis> 2009. Interlaboratory discrepancy of antigenuria results in 2 patients with AIDS and histoplasmosis. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">63:</emphasis>111–114.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0181" role="bibliographyEntry">
            <para>181.<emphasis role="strong">Verghese S, Arjundas D, Krishnakumar KC, Padmaja P, Elizabeth D, Padhye AA, Warnock DW.</emphasis> 2002. Coccidioidomycosis in India: report of a second imported case. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>307–309.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0182" role="bibliographyEntry">
            <para>182.<emphasis role="strong">Espinel-Ingroff A.</emphasis> 1998. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>198–202.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0183" role="bibliographyEntry">
            <para>183.<emphasis role="strong">Li RK, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR.</emphasis> 2000. In vitro activities of voriconazole, itraconazole, and amphotericin B against <citetitle><emphasis>Blastomyces dermatitidis</emphasis></citetitle>, <citetitle><emphasis>Coccidioides immitis</emphasis></citetitle>, and <citetitle><emphasis>Histoplasma capsulatum. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">44:</emphasis>1734–1736.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0184" role="bibliographyEntry">
            <anchor id="ch0147s0055s0001a0008"/>
            <para>184.<emphasis role="strong">McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper CR Jr, Rinaldi MG.</emphasis> 1997. In vitro evaluation of voriconazole against some clinically important fungi. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">41:</emphasis>1832–1834.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0185" role="bibliographyEntry">
            <para>185.<emphasis role="strong">Thompson GR III, Wiederhold NP.</emphasis> 2010. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. <citetitle><emphasis>Mycopathologia</emphasis></citetitle> <emphasis role="strong">170:</emphasis>291–313.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0186" role="bibliographyEntry">
            <para>186.<emphasis role="strong">Espinel-Ingroff A.</emphasis> 1998. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>2950–2956.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0187" role="bibliographyEntry">
            <para>187.<emphasis role="strong">González GM, Tijerina R, Najvar LK, Bocanegra R, Luther M, Rinaldi MG, Graybill JR.</emphasis> 2001. Correlation between antifungal susceptibilities of <citetitle><emphasis>Coccidioides immitis</emphasis></citetitle> in vitro and antifungal treatment with caspofungin in a mouse model. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">45:</emphasis>1854–1859.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0188" role="bibliographyEntry">
            <para>188.<emphasis role="strong">Thompson GR III, Barker BM, Wiederhold NP.</emphasis> 2017. Large-scale evaluation of <citetitle><emphasis>in vitro</emphasis></citetitle> amphotericin B, triazole, and echinocandin activity against <citetitle><emphasis>Coccidioides</emphasis></citetitle> species from U.S. institutions. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">61:</emphasis>e02634-16.</para>
          </listitem>
          <listitem id="ch0147s0055s0001li0189" role="bibliographyEntry">
            <para>189.<emphasis role="strong">González GM, Tijerina R, Najvar LK, Bocanegra R, Rinaldi M, Loebenberg D, Graybill JR.</emphasis> 2002. In vitro and in vivo activities of posaconazole against <citetitle><emphasis>Coccidioides immitis. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">46:</emphasis>1352–1356.</para>
          </listitem>
        </itemizedlist>
      </sect2>
    </sect1>
  </chapter>
